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Daniel F. Levey 
Towards Personalized Medicine in Psychiatry: Focus on Suicide 
 Psychiatric disorders cost an estimated $273 billion annually.  This cost 
comes largely in the form of lost income and the chronic disability that often strikes 
people when they are young and can last decades.  While the monetary costs are 
quantifiable, the suffering of each individual patient is no less vital.  As many as 1 
in 5 persons diagnosed with mental illness will commit suicide, a contributing factor 
in suicide being the second leading cause of death of people age 15-34.  There is 
a critical need to find better ways to identify and help those who are at risk. 
 Understanding mental illness and improving treatment has been difficult 
due to the heterogeneous and complex etiology of these illnesses.  A significant 
challenge for the field is integrating findings from diverse laboratories all over the 
world contributing to the ever expanding literature and translating them into 
actionable treatment.  Our lab employs a convergent functional genomics 
approach which incorporates multiple independent lines of evidence provided by 
genetic and functional genomic data published in the primary literature as a 
Bayesian strategy to prioritize experimental findings.   
Heritability and genetics clearly play an important role in psychiatric 
disorders.  We looked at schizophrenia and alcoholism in separate case-control 
analyses in order to identify and prioritize genes related to these disorders.  We 
were able to reproduce these findings in additional independent cohorts using 
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polygenic risk scores.  We found overlap in these disorders, and identified possible 
underlying biological processes. 
Genetics play an important role in identifying clinical risk, particularly at the 
population level.  At the level of the individual, gene expression may provide more 
proximal association to disease state, assimilating environmental, genetic, as well 
as epigenetic influence.  We undertook N of 1 analyses in a longitudinally followed 
cohort of psychiatric participants, identifying genes which change in expression 
tracking an individual’s change in suicidal ideation.   These genes were able to 
predict suicidal behavior in independent cohorts.  When combined with simple 
clinical instruments these predictions were improved.  This work shows how multi-
level integration of genetic, gene expression, and clinical data could be used to 
enable precision medicine in psychiatry.  
           
Andrew J. Saykin, Psy. D. - Chair 
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Introduction: Precision Medicine 
 Psychiatric disorders are the manifestation of a synthesis of underlying 
genetics, biology, and psychology interacting with environmental stressors.  Some 
individuals may be more or less predisposed to illness.  Some find themselves in 
privileged idyllic environments while others are deprived of nutrition, 
entertainment, education, stability, etc.  It is in this complex interplay that an 
individual is forged.  There is a growing understanding that none of these factors 
appear single-handedly sufficient for the development of psychopathology.  It may 
therefore be necessary to take a personalized medicine approach, embracing the 
complexity of each individual patient and taking full advantage of developing tools 
from genetics, neuroscience, and psychology to improve nosology, diagnosis, and 
treatment.  
The American Heart Association (AHA) defines heart failure as “a complex 
clinical syndrome that can result from any structural cardiac disorder that impairs 
the ability of the ventricle to fill or eject blood.”  This definition seems to embrace 
the pluropotentiality for distinctly different underlying structural dysfunction, in 
combination and interactions, arriving at a similar outcome.  Diabetes mellitus, 
coronary heart disease, and hypertension are known risk factors of mechanistically 
dissimilar etiology. 1    If complex and interacting risk factors influence the 
pathology and predictability of heart failure, might brain disorders also be 
influenced by a confluence of interacting risk factors? 
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Not everyone responds the same way to treatments and interventions.   
Numerous studies indicate clozapine may be an effective alternative medication 
for schizophrenia patients who are ‘treatment-resistant’ to other typical and 
atypical anti-psychotics2.  But the term itself, ‘treatment-resistant’, seems to imply 
that some patients with the same underlying disease pathology fail to see relief 
from the same drug.  It is possible, however, that while patients appear to have 
similar symptoms the totality of underlying pathology that yields the symptoms 
may not be identical.  Indeed, while it was thought that the benefits of clozapine 
in treatment resistant patients might be shared by other atypical antipsychotic 
medications, this may not be the case.  3 
The environment of an individual plays an important role in the 
development of psychopathology.  Childhood trauma appears to be associated with 
psychopathology.  This may be related to increased hypothalamic pituitary adrenal 
(HPA) axis activity and cortisol secretion in patients with a history of trauma. 
Rhesus monkeys exposed to social separation at 6 months of age they showed 
increased plasma cortisol.  Those subjects who showed increased plasma cortisol 
also voluntarily consumed significantly more alcohol.4  This system has been widely 
implicated as a risk factor in psychiatric disorders5 and for suicide.  The 
dexamethasone suppression test (DST) is a quantitative assessment of adrenal 
gland function, classically used to aid in the diagnosis of Cushing’s syndrome6 and 
still used today7.  It consists of an IV injection of dexamethasone into the patient 
and measurement of cortisol levels in response on the following day.  A patient 
3 
 
 
with normative HPA function should show reduced cortisol levels in response to 
dexamethasone through suppression of the adrenocorticotropic hormone (ACTH) 
secretion from the anterior pituitary.  A failure to suppress cortisol levels suggests 
hyperactivity in the system.  It has been used as a measure for diagnosis and for 
suicide risk assessment8, though it has not proven to be sufficiently sensitive or 
specific to be clinically useful9.  It does appear to have at least population level 
utility as a risk factor.  Limitations at the level of individual patients could be due 
to heterogeneity in the clinical populations, and certain subtypes of individual may 
be better served with this kind of test. 
Monozygotic twins of patients with psychiatric disorders tend to have a 
higher risk for psychopathology but the outcome is far from certain, though genetic 
predisposition as measured by singular markers or mutations are often neither 
necessary nor sufficient alone.  Multiple common and de novo mutations probably 
interact to yield an observable disease phenotype, which might explain the reduced 
or incomplete penetrance often used to describe false positive or false negative 
findings from genetic risk factors.  Additionally, development of disease may 
require additional environmental or acute pathological insult.  This is why many 
modern theories posit that multiple ‘hits’ lead to illness.  10 
Some of the strongest common heritable findings in genetics, such as the 
APOE E4 allele as a risk factor for Alzheimer’s disease (AD), represent significant 
increases (as much as 11x) of relative risk to develop the disorder.  APOE E4 can 
be defined by two SNPs, the T allele of rs429358 and the C allele of rs7412, and 
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can be assessed in individuals by personal genomics companies such as 23andMe.  
But even those with the allele are not certain to develop AD, and disease risk is 
modified by factors such as gender.  Additionally, ~40% of AD patients do not 
carry an E4 allele, showing that mutations in this gene have a powerful but perhaps 
not necessary role in the disease. 11  While the evidence is convincing that APOE 
E4 modifies risk in a dose dependent fashion and modifies population level average 
age of onset, it also displays incomplete penetrance and is likely influenced by 
genetic background and environmental context, and is therefore not sufficient in 
the development of AD.12  Studies which embrace the complexity of interactions 
of a gene of large influence such as APOE with additional genetic risk modifiers 
such as CR1 and tie them to related amyloid pathology phenotype may point to 
future ways to better chart the disease risk and progression in individuals.  13 
Personalized medicine studies, sometimes called N-of-1 trials where a single 
individual is followed with significantly greater clinical and multi-omic depth, are 
beginning to gain traction.  A landmark paper published in Cell by Michael Snyder 
and his lab at Stanford University follow a single individual over a period of 14 
months.  14  The participant in this study was followed very closely with multiple 
high throughput methods and integrations of genomic, transcriptomic, proteomic, 
and metabolomic data.  Various genetic markers, known to influence disease risk 
at the population level, were identified in the individual and used to prioritize 
biomarkers associated with diseases identified as highest risk were monitored, 
notably for elevated risk for diabetes.  Over the course of the study the participants 
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blood glucose became elevated following an acute viral infection, and lifestyle 
changes were made along with beginning a low dose acetylsalicylic acid treatment.  
Risk factors were identified and This is an example of how personalized medicine 
can help inform choices made in treatment.  
Personalized medicine offers the possibility of using established risk factors 
from epidemiological, molecular neuroscience, and psychological studies, which 
have population or sample level significance to disease, and integrate these factors 
at the level of the pathology of an individual patient.  To that end we have worked 
to develop genetic and peripheral blood biomarkers.  Initial work focused on 
identifying population level genetic risk factors using genome wide association 
studies (GWAS).  These risk factors were identified in independent GWAS at a 
single nucleotide polymorphism level (SNP), converted into nearest associated 
genes, and then validated by multiple independent lines of evidence using a 
convergent functional genomics (CFG) approach, and top findings were finally 
integrated into a polygenic genetic risk prediction score (GRPS) and tested in 
multiple independent GWAS.  Later work focused on longitudinal within subject 
designs for gene expression tracking the phenotype of individual study 
participants.  Deep databases of quantitative phenotypes allowed for the 
integration of multiple different psychological and environmental modalities. 
 In this way we were able to begin to embrace the complexity of the 
individual and develop multi-dimensional genetic and phenomic biomarkers for 
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more personalized and accurate risk assessment of suicidal behavior in psychiatric 
patients. 
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Convergent Functional Genomics 
 Convergent functional genomics is an algorithmic approach that leverages 
large genomic datasets with the relevant peer reviewed primary literature to find 
reproducible disease relevant genes and biomarkers.  Initially, high throughput 
technologies behind GWAS studies, microarray, RNA-Seq etc. produce a potentially 
large list of genes which are differentially associated with a target disease or 
phenotype.  Nominally significant findings are then prioritized by integrating with 
an exhaustive database of all disease relevant primary literature to create a 
polyevidence CFG score.  The primary literature is produced by a number of 
different labs utilizing a wide array of different approaches.  Human studies of 
genetics and peripheral blood provide specificity to human disease, while human 
brain studies provide additional specificity to the likely target tissue, the brain.  
Animal studies provide sensitivity of in vivo analysis of implicated pathology and 
pathways.   
It is essential to note that only those genes initially identified in the 
discovery analyses or experiments are made available for prioritization by CFG.  
This is crucial to the CFG process.  What makes the CFG so effective is that it, by 
default, requires that prioritized genes from primary work done in the discovery 
analysis replicate peer reviewed research by multiple independent studies, often 
in multiple tissues and animal models.  It prioritizes and cross-validates primary 
findings, which still means a great deal of importance and care must be invested 
in the quality and precision of the initial discovery analysis. 
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 CFG has prior success in the identification of blood biomarkers for mood 
state in bipolar patients.15  The resulting panel of 10 biomarkers showed sensitivity 
and specificity for predicting high and low mood states in 2 bipolar cohorts and 1 
cohort with psychotic disorders (schizophrenia and schizoaffective).  More 
importantly, this panel (which was previously shown to track elevated mood state) 
has been shown to increase following cognitive behavioral therapy treatment for 
depressed patients (an increased score indicates an elevated mood state) and to 
track changes in Hamilton Depression Rating Scale scores.16  This highlights one 
of the key advantages of CFG: built in reproducibility.  There is a wealth of excellent 
peer-reviewed literature available.  Unlike a simple literature search, CFG cross-
validates and enriches primary analyses by utilizing the literature in an a priori 
empirical and unbiased fashion to prioritize the most relevant findings.    
Universal Materials and Methods 
GWAS Studies 
GWAS methodology is particular to the individual study, and will be 
discussed in greater detail in the appropriate chapter. 
Gene Expression Studies 
Human participants 
Live psychiatric participants are part of a larger ongoing longitudinal cohort 
that is continuously collected.  Participants are recruited from the patient 
population at the Richard L. Roudebush Veteran Affairs Medical Center (VAMC) 
and Indiana University School of Medicine (IUSM) in Indianapolis through referrals 
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from care providers, brochures left in plain sight in public areas, and mental health 
clinics through word of mouth.  All participants understood and signed informed 
consent forms detailing research goals, procedure, caveats, and safeguards, per 
institutional review board approved protocol.  Participants completed a Diagnostic 
Interview for Genetic Studies (DIGS) at the initial baseline visit, followed by up to 
6 testing visits, generally 3-6 months apart or whenever a new psychiatric 
hospitalization occurred.  At each testing visit they received a series of 
psychiatric rating scales and blood was drawn.  Whole blood (10 ml) was collected 
in two RNA-stabilizing PAXgene tubes, labeled with deidentified ID number and 
stored at -80ᵒ C in a locked freezer until the time of future processing.  Whole-
blood RNA was extracted for microarray gene expression studies from the PAXgene 
tubes, as described below. 
Postmortem subjects of suicide completers were used to validate findings 
from live participants, and were obtained through the Marion County coroner’s 
office.  We required a last observed alive postmortem interval of 24 hours or less, 
and cases selected had completed suicide by means other than overdose, which 
could affect gene expression.  See the demographic tables for cause of death and 
age at time of death. 
Medications 
 Live participants were all diagnosed with various psychiatric disorders.  
Their psychiatric medications were listed in their electronic medical records and 
documented at the time of each testing visit.  Participants were on a variety of 
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different psychiatric medications.  Medications can have a strong influence on gene 
expression.  Because we focused our discovery of differentially expressed genes 
on within-participant analyses, and therefore relative within-participant gene 
expression changes, this influence is of negligible effect on our results.  There was 
no consistent pattern in any particular type of medication or between type of 
medication and change in phenotype on the rare occasions where there was a 
medication change between visits. 
Human blood gene expression experiments and analyses 
Whole blood (2.5 – 5 ml) was collected into each PAXGene tube by routine 
venipuncture.  PAXGene tubes contain proprietary reagents for the stabilization of 
RNA.  The cells from whole blood were concentrated by centrifugation, the pellet 
washed, resuspended and incubated in buffers containing Proteinase K for protein 
digestion.  A second centrifugation step was done to remove residual cell debris. 
After the addition of ethanol for an optimal binding condition, the lysate was 
applied to a silica-gel membrane/column.  The RNA bound to the membrane as 
the column was centrifuged and contaminants were removed in three wash steps.  
The RNA was then eluted using diethlypyrocarbonate-treated water.  The protocol 
for RNA extraction is carried out on a QIAgen QIAcube. 
Sample labeling   
Sample labeling was performed using the Ambion MessageAmp II-
BiotinEnhanced antisense RNA (aRNA) amplification kit.  The procedure is briefly 
outlined below: 
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1. Reverse transcription to synthesize first-strand cDNA was primed with T7 
oligo(dT) primer to synthesize cDNA containing a T7 promoter sequence. 
2. Second-strand cDNA synthesis converted the single-stranded cDNA into a 
double-stranded DNA template for transcription.  The reaction employed 
DNA polymerase and RNase H to simultaneously degrade the RNA and 
synthesize the second-strand cDNA. 
3. cDNA purification removed RNA, primers, enzymes, and salts that would 
have inhibited in vitro transcription. 
4. In vitro transcription to synthesize aRNA with biotin-NTP Mix generated 
multiple copies of biotin-modified aRNA from the double-stranded cDNA 
templates; this is the amplification step. 
5. aRNA purification removed unincorporated NTPs, salts, enzymes and 
inorganic phosphate to improve the stability of the biotin-modified aRNA. 
6. aRNA fragmentation: the amplified RNA is fragmented in a reaction the 
employs a metal-induced hydrolysis to fragment the aRNA.   The 
fragmented labeled aRNA is now ready for hybridization to the Affymetrix 
microarray chip (Affymetrix, Santa Clara, CA, USA). 
Microarrays 
Biotin-labeled aRNAs were hybridized to Affymetrix HG-U133 Plus 2.0 
GeneChips (Affymetrix; with over 40,000 genes and expressed sequence tags), 
according to manufacturer’s protocols 
http://media.affymetrix.com/support/downloads/manuals/expression_analysis_te
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chnical_manual.pdf.  Arrays were stained using standard Affymetrix protocols for 
antibody signal amplification and scanned on an Affymetrix GeneArray 2500 
scanner with a target intensity set at 250.  Quality-control measures, including 
30/50 ratios for glyceraldehyde 3-phosphate dehydrogenase and β-actin, scale 
factors, background and Q-values, were within acceptable limits. 
Convergent Functional Genomics 
Databases  
  The Niculescu Lab of Neurophenomics has created a manually curated 
database of all of the primary literature for human and nonhuman gene expression 
(post-mortem brain, blood and cell cultures), genetic, (association, copy number 
variants, linkage, and transgenic) published to date on psychiatric disorders.  We 
added only those findings which were described as significant by the authors, using 
their particular methodology.  This database only contains primary literature and 
not reviews, meta-analyses, or other secondary analyses.  This was done to avoid 
circularity with results already found in the primary literature.  These databases 
are constantly updated as new research is published. 
Human post-mortem brain, blood and other peripheral tissue gene 
expression 
 Literature search was performed in PubMed 
(http://www.ncbi.nlm.nih.gov/pubmed), searching the primary literature with 
various keyword combinations, human, brain, postmortem, lymphocytes, blood, 
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cells, gene expression, along with specific keywords for the disease or phenotype 
of interest.   
Human genetic evidence (association, linkage) 
 We took special care to omit studies where subjects in our discovery cohorts 
overlapped with published studies scored for CFG.  For linkage the location of each 
gene was obtained through GeneCards (http://www.genecards.org/).  We input 
the chromosome location and start position into the Rutgers Map Interpolator17 
http://compgen.rutgers.edu/mapinterpolator to receive a sex-averaged 
centimorgan position.  To be scored for linkage a gene had to map to within 5 
centimorgans of a marker for linkage.  Only published markers with a LOD score 
of >=2 were scored for convergence. 
 Animal model brain and blood gene expression 
 We used animal model evidence reported in the literature to score 
convergence.  Where applicable we used data generated by our own lab, as 
described in the relevant chapters below.  
 Animal model genetic evidence 
 PubMed searches were performed, using project specific keywords, for 
relevant animal models for the disease or phenotype of interest.  In addition we 
searched the Mouse Genome Informatics database 
(http://www.informatics.jax.org/) for transgenic studies using project specific 
categories. 
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 CFG scoring 
 Internal score: Genes which were significantly associated with the disease 
of interest were first identified.  The methods for identifying these genes are 
discussed in detail in the relevant chapters for schizophrenia, alcoholism, and 
suicide.  Following the internal scoring of genes, external scoring was carried out 
on the same genes, 
 External score:  There were a maximum possible of 6 lines of evidence 
which could be used to calculate a CFG score.  Each line of evidence was capped 
in such a way that a positive hit within a line of evidence in the database would 
result in maximum points, no matter how many positive hits were present.  This 
was done to avoid popularity biases.  In the schizophrenia work, each line of 
evidence could contribute 1 single point, for a maximum possible CFG score of 6.  
All other work weighted the lines of evidence such that human evidence received 
twice as much as nonhuman evidence, and brain evidence received twice as many 
points as evidence from genetics or peripheral tissue.  In this way, human brain 
evidence was given 4 points, human peripheral or genetic evidence would be given 
2 points each, nonhuman brain evidence was given 2 points, and nonhuman 
peripheral, genetic, or transgenic evidence received 1 point each.  In this weighting 
the maximum possible score was 12 (4 human brain, 2 human genetic, 2 human 
peripheral, 2 nonhuman brain, 1 nonhuman genetic, 1 nonhuman peripheral = 
12). 
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Workflow  
 A vital part of our methodology is the work flow that we use.  All of our 
projects have maintained an evolution of the basic framework of discovering 
markers in an initial independent cohort, prioritizing these findings with a 
polyevidence CFG score, and using top prioritized findings to predict in additional 
independent cohorts.  Once we have demonstrated a consistency and 
reproducibility across cohorts we dig deeper into the biology and pathology of our 
findings, identifying overlap with other psychiatric disorders and treatments. 
Discovery 
Discovery is always performed in an independent cohort.  In the case of 
GWAS, findings came from analyzing data in a standard case control design.  All 
SNPs with a p < 0.05 were deemed to be nominally significant.  For the initial 
suicide gene expression study a similar methodology was employed, with 
nominally significance required to proceed to the next step of analysis.  Later gene 
expression studies applied a newer and different approach, and are defined in 
greater detail in the appropriate chapters. 
Prioritization 
Prioritization was applied to all genes deemed to be nominally significant in 
the first step.  All nominally significant were prioritized with a CFG score as 
described above.  
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Validation 
This step was not employed yet in the schizophrenia work.  In all other 
studies validation was performed as an additional step to show reproducibility in 
other cohorts or approaches.  This is discussed in greater detail in the following 
chapters, but briefly, an in house stress reactive alcohol consuming animal model 
was used to validate findings from the alcohol study.  In the suicide study cohorts 
of gender and age matched suicide completers collected in collaboration with the 
Marion County Coroner’s office were used to validate peripheral blood gene 
expression findings. 
Prediction 
In all studies outside independent cohorts were used to replicate findings.   
Understanding 
All work is completed naïve and blind to the actual nature of the biological 
processes and implications of findings.  Only once findings have been 
independently discovered, prioritized, validated, and predicted do we dig deeper 
into the possible underlying biology.  In this way work proceeds unbiased by 
favored genes or popularity effects.  Once findings were verified we dug deeper 
into the biological implications, canonical pathways, overlap with other disorders, 
and treatment possibilities. 
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Chapter 1:  Schizophrenia 
Schizophrenia is a heterogeneous syndrome of serious and chronic cognitive 
dysfunction effecting as many as 51 million people worldwide.  It is generally 
diagnosed by a co-occurrence of at least two positive and negative symptoms with 
the presence of delusions, hallucinations, or disorganized speech.   
Disorganized speech could be thought of as an outwardly observable 
manifestation of fragmented thinking.  This commonly may come in the form of 
tangential and hard to follow loose associations in conversation.   
Hallucinations are the illusion of sensation in the absence of sensory stimuli.  
It commonly occurs in the form of hearing voices (auditory hallucination) or seeing 
things that do not exist (visual hallucination).     
Firmly held but clearly false ideas make up the third major symptom of 
schizophrenia, delusions.  Delusions may be particularly difficult to identify in 
screening as it requires identifying false ideas that a patient may not voluntarily 
express to a caregiver and may be difficult to distinguish from simply overvalued 
ideas without further probing.  
Although environmental influences are important, genetics and heritability 
may play a significantly greater role.  Schizophrenia has a high rate of heritability 
as evidenced by countless studies over the last 60 years (Nuechterlein and 
Dawson, 1984).  Recent advances in the field of genetics have led to the 
hypothesis that schizophrenia heritability is probably not the result of the influence 
of any one gene but rather through the interaction of several different genes.  
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Genetics offer the potential of identifying individuals with a predisposition towards 
schizophrenia and intervening early in life to minimize additional environmental 
risks. 
We sought to identify and prioritize a set of genes involved in schizophrenia.  
We began by using an independent GWAS study from the International 
Schizophrenia Consortium (ISC) for the discovery of genes, integrating all single 
nucleotide polymorphisms (SNPs) with a nominally significant p-value of <0.05 
into the nearest gene.  We then used CFG to prioritize these findings with a 
polyevidence score, resulting in a panel of 42 genes containing 542 SNPs.   
We next validated these prioritized findings by creating a polygenic risk 
score derived entirely from the top SNPs identified in the discovery cohort and 
tested it in 4 independent cohorts provided by the Genetic Association Information 
Network (GAIN) and Molecular Genetics of Schizophrenia (MGS) non-GAIN studies.  
A polygenic panel of all 542 nominally significant SNPs was able to successfully 
separate schizophrenia cases from controls in all independent cohorts while a panel 
consisting of only the top SNP from each of the 42 genes failed to do so.  This may 
be due to the small effect size of each individual SNP. 
In post hoc analysis examining reproducibility across independent GWAS, 
we carried out discovery analysis in the GAIN cohorts, taking all nominally 
significant SNPs, integrating them at the nearest gene, and prioritizing with CFG.  
What we found was that there was very little overlap at the level of individual SNPs 
(0.4%), but we found increasing reproducibility between GWAS as we integrated 
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SNPs with the nearest gene (54.2%), with increasing CFG evidence (83.3%), and 
integrating genes at the level of canonical pathways (97.1%).  This may reveal the 
importance of moving beyond simple statistical relevance of a SNP and shows the 
added value examining the impact of SNPs at the level of genes and the pathways 
in which they interact. 
Along these lines we also sought to understand the biological roles of our 
top genes and how they interact in pathways by using our top findings from each 
independent GWAS with a CFG polyevidence score ≥3.  As mentioned above, we 
found a striking consistency of findings across GWAS when results were integrated 
at the pathway level, with glutamate signaling in particular implicated as the top 
enriched pathway in 2 independent cohorts (ISC and GAIN EA) and the second 
highest enrichment in a third (GAIN AA).  The danger in broadly implicating a 
neurotransmitter system such as glutamate is that they have been so widely study 
by so many labs and so many different approaches that the potential exists for 
popularity bias in the algorithm.  With that said, many of the promising novel 
therapeutics in the literature are targeting this system.  18   
Given the heterogeneous nature of symptoms associated with 
schizophrenia, it has been an understandably difficult to understand and treat.  
Indeed, its definition has been evolving since early psychiatrists labeled the disease 
dementia praecox, through each iteration of the Diagnostic and Statistical Manual 
of Mental Disorders (DSM), currently on its fifth edition, through today.  As method 
and technique continue to be refined, this work points to the possibility of 
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quantitative genetic risk assessment for predisposition to schizophrenia, and opens 
the door to early preventative interventions. 
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Convergent functional genomics of schizophrenia: from comprehensive 
understanding to genetic risk prediction 
Introduction 
Schizophrenia is a devastating disorder affecting ~1% of the population. 
While there is clear evidence for roles for both genes and environment, a 
comprehensive biological understanding of the disorder has been elusive so far. 
Most notably, there has been until recently a lack of concerted integration across 
functional and genetic studies, and across human and animal model studies, 
resulting in missed opportunities to see the whole picture. 
As part of a translational convergent functional genomics (CFG) approach, 
developed by us over the last decade,19,20,21,22,15 and expanding upon our earlier 
work on identifying genes for schizophrenia23 and biomarkers for psychosis,24 we 
set out to comprehensively identify candidate genes, pathways and mechanisms 
for schizophrenia, integrating the available evidence in the field to date. We have 
used data from published genome-wide association studies (GWAS) data sets for 
schizophrenia.25,26 We integrated those data with gene expression data---human 
postmortem brain gene expression data, human induced pluripotent stem cell-
derived neuronal cells27 and human blood gene expression data24 published by 
others and us, as well as with relevant animal model brain and blood gene 
expression data generated by our group28 and others. In addition, we have 
integrated as part of this comprehensive approach other genetic data---human 
genetic data (linkage, copy number variant (CNV) or association) for 
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schizophrenia, as well as relevant mouse model genetic evidence (Figure 1-1, 
Table 1-1 and Figure 1-2). Animal model data provide sensitivity of detection, and 
human data provide specificity for the illness. Together, they help to identify and 
prioritize candidate genes for the illness, using a polyevidence CFG score, resulting 
in essence in a de facto field-wide integration putting together the best available 
evidence to date.  Once that is done, biological pathway analyses can be conducted 
and mechanistic models can be constructed (Figure 1-3). 
 
  
Figure 1-1. Convergent Functional Genomics. 
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An obvious next step is developing a way of applying that knowledge to 
genetic testing of individuals to determine risk for the disorder. On the basis of our 
comprehensive identification of top candidate genes described in this paper, we 
have chosen the nominally significant single-nucleotide polymorphisms (SNPs) 
inside those genes in the GWAS data set used for discovery (International 
Schizophrenia Consortium, ISC), and assembled a genetic risk prediction (GRP) 
panel out of those SNPs. We then developed a genetic risk prediction score (GRPS) 
for schizophrenia based on the presence or absence of the alleles of the SNPs 
associated with the illness in ISC, and tested the GRPS in independent cohorts 
(GAIN European Americans (EA), GAIN African Americans (AA), nonGAIN EA, 
nonGAIN AA) 26 for which we had both genotypic and clinical data available, 
comparing the schizophrenia subjects to normal controls. Our results show that a 
panel of SNPs in top genes identified and prioritized by CFG analysis can 
differentiate between schizophrenia subjects and controls at a population level, 
although at an individual level the margin is minimal. The latter point suggests 
that, like for bipolar disorder,29 the contextual cumulative combinatorics of 
common variants and environment30 plays a major role in risk for illness. Moreover, 
the genetic risk component identified by us seems to be stronger for classic age 
at onset schizophrenia than for early onset and late-onset schizophrenia, 
suggesting that those subtypes may be different, either in having a larger 
environmental component or having a different genetic component. 
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We have also looked at genetic heterogeneity, overlap and reproducibility 
between independent GWAS for schizophrenia. We show that the overlap is 
minimal at a nominal P-value SNP level, but increases dramatically at a gene level, 
then at a CFG-prioritized gene level and finally at a pathway level. CFG provides a 
fit-to disease prioritization of genes that leads to generalizability in independent 
cohorts, and counterbalances the fit-to-cohort prioritization inherent in classic SNP 
level genetic-only approaches, which have been plagued by poor reproducibility 
across cohorts. Finally, we have looked at overlap with candidate genes for other 
psychiatric disorders (bipolar disorder, anxiety disorders), as well as with other 
disorders affecting cognition (autism, Alzheimer disease (AD)), and provide 
evidence for shared genes.  
Overall, this work sheds comprehensive light on the genetic architecture 
and pathophysiology of schizophrenia, provides mechanistic targets for therapeutic 
intervention and has implications for genetic testing to assess risk for illness before 
the illness manifests itself clinically. 
Materials and Methods 
Genome-wide association studies data for schizophrenia 
The GWAS data from the ISC was used for the discovery CFG work. 25 This 
cohort consists of EA subjects (3322 schizophrenics and 3587 controls).  SNPs with 
a nominal allelic P-value <0.05 were selected for our analysis.  No Bonferroni 
correction was performed. 
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Four independent cohorts, 26 two EA (GAIN EA 1170 schizophrenics and 
1378 controls; nonGAIN EA 1149 schizophrenics and 1347 controls) and two AA 
(GAIN AA 915 schizophrenics and 949 controls; nonGAIN AA 78 schizophrenics 
and 20 controls), were used for testing the results of the discovery analyses. The 
GWAS GAIN and nonGAIN data used for analyses described in this paper were 
obtained from the database of Genotype and Phenotype (dbGaP) found at 
www.ncbi.nlm.nih.gov. 
The software package PLINK (http://pngu.mgh.harvard.edu/~purcell) was 
used to extract individual genotype information for each subject from the GAIN 
GWAS data files. We analyzed EA, and separately, AA, schizophrenia subjects and 
controls. 
Gene identification 
To identify the genes that correspond to the selected SNPs, the lists of SNPs 
from the GWAS were uploaded to NetAFFX (Affymetrix, Santa Clara, CA, USA; 
http://www.affymetrix.com/analysis/index.affx). We used the Netaffx na32 
Genotyping Annotation build. In the cases where a SNP mapped to multiple genes, 
we selected all the genes. SNPs for which no gene was identified were not included 
in our subsequent analyses. 
Keywords for Convergent Functional Genomics 
Methods were as described above in the introduction, except that keywords 
used for scoring convergence were schizophrenia and psychosis.  Additionally, in 
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this work all converging lines of evidence were weighted equally, with a maximum 
possible score of 6. 
Pathway analyses 
IPA 9.0. (Ingenuity Systems, Redwood City, CA, USA) was used to analyze 
the biological roles, including top canonical pathways, of the candidate genes 
resulting from our work (Table 1-2 and Supplementary Table S1-5), as well as 
used to identify genes in our data sets that are the target of existing drugs 
(Supplementary Table S1-2). 
Intra-pathway epistasis testing 
As an example, 29 the ISC GWAS data were used to test for epistatic 
interactions among the best P-value SNPs in genes from our data set present in a 
top canonical biological pathway identified by Ingenuity pathway analysis 
(Supplementary Table S1-4). SNPxSNP allelic epistasis was tested for each distinct 
pair of SNPs between genes, using the PLINK software package. 
 Genetic risk prediction panel and scoring 
As we had previously done for bipolar disorder, 29 we developed a polygenic 
GRPS for schizophrenia based on the presence or absence of the alleles of the 
SNPs associated with illness, and tested the GRPS in independent cohorts for which 
we had both genotypic and clinical data available, comparing the schizophrenia 
subjects to normal controls. We tested two panels: a smaller one (GRPS-42) 
containing the single best P-value SNP in ISC in each of the top CFG prioritized 
genes (n = 42), and a larger one (GRPS-542), containing all the nominally 
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significant SNPs (n = 542) in ISC in the top CFG prioritized genes (n = 42; Tables 
1-3, 1-4, Supplementary Table S1-3, and Figure 1-4).  
Of note, our SNP panels and choice of affected alleles were based solely on 
analysis of the ISC GWAS, which is our discovery cohort, completely independently 
from the test cohorts. Each SNP has two alleles (represented by base letters at 
that position). One of them is associated with the illness (affected), the other not 
(non-affected), based on the odds ratios from the discovery ISC GWAS. We 
assigned the affected allele a score of 1 and the non-affected allele a score of 0. 
A two-dimensional matrix of subjects by GRP panel alleles is generated, with the 
cells populated by 0 or 1. A SNP in a particular individual subject can have any 
permutation of 1 and 0 (1 and 1, 0 and 1, 0 and 0). By adding these numbers, the 
minimum score for a SNP in an individual subject is 0, and the maximum score is 
2. By adding the scores for all the alleles in the panel, averaging that, and 
multiplying by 100, we generate for each subject an average score corresponding 
to a genetic loading for disease, which we call Genetic Risk Predictive Score 
(GRPS). 
The software package PLINK (http://pngu.mgh.harvard.edu/~purcell) was 
used to extract individual genotype information for each subject from the GAIN 
and nonGAIN GWAS data files.  We analyzed separately EA and AA schizophrenia 
subjects and controls, to examine any potential ethnicity variability (Tables 1-3 
and 1-4, and Supplementary Table S1-3). To test for significance, a one-tailed t-
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test was performed between the schizophrenia subjects and the control subjects, 
looking at differences in GRPS.   
Figures 
Each figure in this chapter was completed by Mikias Ayalew, Helen Le-
Niculescu, and Daniel Levey.  This work has been published.  31 
Results 
Top candidate genes 
To minimize false negatives, we initially cast a wide net, using as a filter a 
minimal requirement for a gene to have both some GWAS evidence and some 
additional independent evidence. We thus generated an initial list of 3194 unique 
genes with at least a SNP at P<0.05 in the discovery GWAS analyzed (ISC), 25 that 
also had some additional evidence (human or animal model data), implicating 
them in schizophrenia (CFG score >1; Table 1-5). This suggests, using these 
minimal thresholds and requirements, that the repertoire of genes potentially 
involved directly or indirectly in cognitive processes and schizophrenia may be 
quite large, similar to what we have previously seen for bipolar disorder. 29 
To minimize false positives, we then used the CFG analysis integrating 
multiple lines of evidence to further prioritize this list of genes, and focused our 
subsequent analyses on only the top CFG scoring candidate genes. Overall, 186 
genes had a CFG score of 3 and above (≥50% of maximum possible score of 6), 
and 42 had a CFG score of 4 and above (Tables 1-1 and 1-5, and Figure 1-2).  Our 
top findings from ISC (Table 1-1) were over-represented in two independent 
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schizophrenia GWAS cohorts, the GAIN EA and GAIN AA. In total, 37 of the top 42 
genes identified by our approach (88.1%) had at least a SNP with a P-value of 
<0.05 in those independent cohorts, an estimated twofold enrichment over what 
would be expected by chance alone at a genetic level (as there were 9002 genes 
at P<0.05 in the GAIN-EA GWAS, and the number of genes in the human genome 
is estimated at 20,500,32 the enrichment factor provided by our approach is 
(37/42)/(9002/20 500) ≈ 2). Of note, there was no correlation between CFG 
prioritization and gene size, thus excluding a gene-size effect for the observed 
enrichment (Supplementary Figure S1-1). 
 
  Figure 1-2. Top Candidate Genes for Schizophrenia 
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derive
d 
neurot
rophic 
factor 
0.00
1666 
rs10
7421
78 
 
(I) 
SZ 
(Grotti
ck, 
Bagnol 
et al. 
2005, 
Pillai 
and 
Mahad
ik 
2008, 
Somm
 
11p1
4.1  
(Ass
oc) 
SZ 
(Gratac
os, 
Gonzale
z et al. 
2007, 
Chao, 
Kao et 
al. 
(D) 
SZ(Torr
ey, Barci 
et al. 
2005, 
Pillai 
2008) 
(Weicker
t, Hyde 
et al. 
2003) 
 (D) 
SZ 
Seru
m 
(Grillo, 
Ottoni 
et al. 
2007, 
Miodow
nik, 
Maayan 
et al. 
2011, 
4.0  
0.0055
07 
rs21310
60 
47 
 
 
er, 
Schmit
t et al. 
2010) 
(I) 
 PCP 
in 
rats 
(Kaise
r, Foltz 
et al. 
2004) 
(I) 
 
MK-
801 
in 
rats(
Guo, 
Yang 
et al. 
2010) 
2008) 
(Decost
er, van 
Os et al. 
2011, 
Suchan
ek, 
Owczar
ek et al. 
2011) 
 
Rizos, 
Papatha
nasiou 
et al. 
2011, 
Schwar
z, Guest 
et al. 
2011) 
(D) 
Leuk
ocyte
s 
Psyc
hosis
(Mondel
li, 
Cattane
o et al. 
2011) 
48 
 
 
CD9 
CD9 
molec
ule 
0.04
55 
rs31
8129
1 
 
(I)  
PCP  
AMY
; 
(D)  
PCP  
PFC
; 
(I) 
PCP  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 (I) 
PC
P 
and 
CLZ 
 
 
(D) 
SZ(Kats
el, Davis 
et al. 
2005) 
(D)  
SZ 
IPS 
deriv
ed 
neur
ons 
(Brenna
nd, 
Simone 
et al. 
2011) 
4.0 
0.01
167 
rs22
680
14 
0.0473
9 
rs73423
06 
CNR1 
canna
binoid 
recept
0.00
2567 
rs13
SZ(H
aller, 
Szirmai 
 (D)  
PCP 
and 
CLZ  
 
6q15
  (As
soc) 
SZ 
(D) 
SZ(Egg
an, 
Hashimo
 4.0 
0.00
154
2 
rs94
0.0021
28 
rs87341
3 
49 
 
 
or 1 
(brain) 
2407
3 
et al. 
2005) 
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
resp
ons
e to 
anti
psyc
hoti
cs(Ta
kahas
hi, 
Kuma
nishi 
et al. 
(Ujike, 
Takaki 
et al. 
2002, 
Xu, 
Woodro
ffe et al. 
2009) 
 
 
to et al. 
2008) 
 
510
23 
50 
 
 
2004) 
 
COMT 
catech
ol-O-
methyl
transfe
rase 
0.04
098 
rs15
4432
5 
SZ(H
uotari, 
Garcia-
Horsm
an et 
al. 
2004, 
Babovi
c, 
O'Tuat
haigh 
et al. 
2008) 
(I) 
CLZ  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
SZ(Ju
rata, 
Gallag
her et 
al. 
2006) 
 
22q1
1.21 
   (As
soc) 
SZ(Shi
fman, 
Bronste
in et al. 
2002) 
(I) 
SZ(Abd
olmaleky
, Cheng 
et al. 
2006) 
 
 4.0  
0.0145
7 
rs15443
25 
CPLX2 
compl
exin 2 
0.04
338 
rs10
SZ(Ya
mauchi
, Qin et 
 (D) 
PCP 
and 
 
5q35
.2 
 
(D)  
 4.0 
0.01
658 
rs68
 
51 
 
 
2139
27 
al. 
2005) 
CLZ 
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
SZ 
(Som
mer, 
Schmit
t et al. 
2010) 
(Ass
oc) 
SZ 
(Lee, 
Song et 
al. 
2005) 
SZ(East
wood 
and 
Harrison 
2005, 
Torrey, 
Barci et 
al. 2005, 
Weidenh
ofer, 
Bowden 
et al. 
2006) 
 
 
876
20 
DRD2 
dopam
ine 
recept
or D2 
0.01
151 
rs12
7919
90 
 
 (D)  
PCP 
and 
CLZ 
PFC 
(Le-
 
11q2
3.2   
(Ass
oc) 
SZ 
(Liu, 
 
 
(D)  
SZ 
(Dean, 
Pavey et 
(D)  
SZ 
Delu
sions 
(Kurian, 
Le-
4.0 
0.00
726
5 
rs49
380
21 
0.0109
6 
rs17529
477 
52 
 
 
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
SZ(O
rtega-
Alvaro
, 
Aracil-
Ferna
ndez 
et al. 
2011) 
Downin
g et al. 
2010, 
McClay, 
Adkins 
et al. 
2011) 
 
al. 2004, 
Torrey, 
Barci et 
al. 2005, 
Zhan, 
Kerr et 
al. 2011) 
Niculesc
u et al. 
2011) 
DTNBP
1 
dystro
brevin 
bindin
g 
0.00
2634 
rs12
2099
43 
SZ 
(Chen, 
Feng 
et al. 
2008, 
Feng, 
  
6p22
.3   (
Asso
c) 
SZ(Sc
hwab, 
(D) 
SZ(Wei
ckert, 
Straub et 
al. 2004) 
(Talbot, 
(D) 
Lym
phoc
ytes(
Chagno
n, Roy 
4.0 
0.00
914
6 
rs94
770
21 
0.0001
501 
rs1687
6575 
53 
 
 
protein 
1 
 
 
Zhou 
et al. 
2008, 
Hattori
, 
Murota
ni et al. 
2008, 
Takao, 
Toyam
a et al. 
2008) 
Knapp 
et al. 
2003, 
Kirov, 
Ivanov 
et al. 
2004, 
Fallin, 
Lassete
r et al. 
2005, 
Rethelyi
, Bakker 
et al. 
2010, 
Voisey, 
Swagell 
et al. 
2010, 
Fatjo-
Vilas, 
Papiol 
Eidem et 
al. 2004, 
Weickert, 
Rothmon
d et al. 
2008, 
Talbot, 
Louneva 
et al. 
2011) 
et al. 
2008) 
54 
 
 
et al. 
2011) 
FABP7 
fatty 
acid 
bindin
g 
protein 
7, 
brain 
0.01
053 
rs94
9054
6 
SZ 
(Wata
nabe, 
Toyota 
et al. 
2007) 
 (I) 
CLZ  
NAC
; (I)  
PCP 
and 
CLZ  
PFC 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 
6q22
.31   
(Ass
oc) 
SZ 
(Watan
abe, 
Toyota 
et al. 
2007) 
(I)  
SZ 
(Watana
be, 
Toyota et 
al. 2007) 
 4.0   
GABRB
3 
gamm
a-
amino
0.00
4635 
rs80
3746
1 
 
 (I)  
PCP  
AMY
;  
(D)  
 
15q1
2  (A
ssoc) 
SZ 
(Bergen
(I) 
SZ 
(Bullock, 
Cardon 
(I) 
SZ 
Seru
m 
(Silver, 
4.0 
0.01
579 
rs12
904
865 
0.0009
769 
rs4906
835 
55 
 
 
butyric 
acid 
(GABA
) A 
recept
or, 
beta 3 
PCP  
HIP; 
(D)  
PCP  
PFC  
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 
, 
Fanous 
et al. 
2009) 
et al. 
2008) 
(D)  
SZ(Has
himoto, 
Arion et 
al. 2008) 
Susser 
et al. 
2011) 
GAD1 
glutam
ate 
decarb
oxylas
e 1 
(brain, 
67kDa
) 
0.03
907 
rs16
8590
26 
 
 (I) 
PCP  
AMY 
(Le-
Nicule
scu, 
Balara
man et 
al. 
 
(I)  
CLZ 
2q31
.1   (
Asso
c) 
SZ 
(Straub, 
Lipska 
et al. 
 
 
(D) 
SZ 
(Impagn
atiello, 
Guidotti 
et al. 
1998, 
 4.0 
0.00
844
7 
rs10
191
129 
0.0177
6 
rs28838
88 
56 
 
 
2007) 
 
(D) 
SZ(S
omme
r, 
Schmit
t et al. 
2010);
(Pillai 
and 
Mahad
ik 
2008) 
 
(I) 
SZ(B
ullock, 
Cardo
n et al. 
2008) 
2007) 
 
Guidotti, 
Auta et 
al. 2000, 
Mirnics, 
Middleto
n et al. 
2000, 
Costa, 
Davis et 
al. 2001, 
Heckers, 
Stone et 
al. 2002, 
Hashimo
to, Volk 
et al. 
2003, 
Veldic, 
Carunch
o et al. 
2004, 
Woo, 
57 
 
 
Walsh et 
al. 2004, 
Torrey, 
Barci et 
al. 2005, 
Veldic, 
Guidotti 
et al. 
2005, 
Akbarian 
and 
Huang 
2006, 
Straub, 
Lipska et 
al. 2007, 
Benes, 
Lim et al. 
2008, 
Bullock, 
Cardon 
et al. 
58 
 
 
2008, 
Hashimo
to, Arion 
et al. 
2008, 
Hashimo
to, Bazmi 
et al. 
2008) 
(I) 
 
SZ(Hak
ak, 
Walker et 
al. 2001) 
GNB1L 
guanin
e 
nucleo
tide 
bindin
g 
0.03
659 
rs17
7453
02 
Imp
aire
d 
PPI 
(Paylor
, 
Glaser 
(I)  
Chr
onic 
halo
peri
dol 
(Ishig
 
22q1
1.21 
(Ass
oc) 
SZ 
(William
s, 
(D) 
SZ 
(Ishiguro
, Koga et 
al. 2010) 
 4.0   
59 
 
 
protein 
(G 
protein
), beta 
polype
ptide 
1-like 
et al. 
2006) 
uro, 
Koga 
et al. 
2010) 
(D)  
SZ(Ju
rata, 
Gallag
her et 
al. 
2006); 
 
Glaser 
et al. 
2008) 
GRIA1 
glutam
ate 
recept
or, 
ionotro
pic, 
AMPA 
1 
0.00
080
31 
rs29
628
16 
SZ 
(Wiedh
olz, 
Owens 
et al. 
2008) 
 (D) 
PCP 
and 
CLZ  
AMY 
(Le-
Nicule
scu, 
Balara
man et 
 
5q33
.2 
(Ass
oc) 
SZ 
(Magri, 
Gardell
a et al. 
2006, 
Leon, 
(D) 
SZ(Sok
olov 
1998, 
Ibrahim, 
Hogg et 
al. 2000) 
(I) 
SZ(Drac
heva, 
 4.0 
0.00
659 
rs10
044
974 
0.0060
37 
rs49866
0 
60 
 
 
al. 
2007) 
(I) 
Res
pon
se 
to 
anti
psyc
hoti
cs 
(Taka
hashi, 
Kuma
nishi 
et al. 
2004) 
(D) 
Res
pon
se 
to 
Schuma
cher et 
al. 
2011) 
 
 
McGurk 
et al. 
2005, 
Stadler, 
Kolb et 
al. 2005, 
Benes, 
Lim et al. 
2008) 
61 
 
 
PCP 
(Toyo
oka, 
Usui et 
al. 
2002) 
GRIA4 
glutam
ate 
recept
or, 
ionotro
phic, 
AMPA 
4 
0.02
792 
rs64
9098 
Cog
nitio
n(I
mpa
ired 
PPI)(
Sagata
, Iwaki 
et al. 
2010) 
(I)  
PCP 
and 
CLZ  
AMY  
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
SZ(C
hong, 
Young 
 
11q2
2.3 
(Ass
oc) 
SZ(Ma
kino, 
Fujii et 
al. 
2003) 
 
(D) 
SZ 
(Beneyto 
and 
Meador-
Woodruff 
2008, 
Chu, Liu 
et al. 
2009) 
(I) 
SZ(Drac
heva, 
McGurk 
et al. 
2005) 
 4.0 
0.00
152
6 
rs71
161
18 
0.0034
3 
rs22772
80 
62 
 
 
et al. 
2002) 
GRIN2
B 
glutam
ate 
recept
or, 
ionotro
pic, N-
methyl 
D-
aspart
ate 2B 
0.00
1569 
rs43
6370
3 
SZ 
(Kochl
amaza
shvili, 
Senkov 
et al. 
2010) 
 (D) 
CLZ  
AMY
; 
(I) 
CLZ  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 
 
MK-
801 
trea
ted 
 
12p1
3.1 
(Ass
oc) 
SZ(Fall
in, 
Lassete
r et al. 
2005, 
Liu, 
Downin
g et al. 
2010) 
 
(D) 
SZ(Ibra
him, 
Hogg et 
al. 2000) 
(I) 
SZ(Bow
den, 
Scott et 
al. 2008) 
 
 4.0 
0.00
142
7 
rs10
723
88 
0.0031
02 
rs12826
365 
63 
 
 
rats(
Marva
nova, 
Lakso 
et al. 
2004) 
 
(D) 
Res
pon
se 
to 
anti
psyc
hoti
cs 
(Taka
hashi, 
Kuma
nishi 
et al. 
2004) 
64 
 
 
(D) 
SZ 
(Bulloc
k, 
Cardo
n et al. 
2008) 
GRM5 
glutam
ate 
recept
or, 
metab
otropic 
5 
0.00
2559 
rs99
2259 
SZ 
(Kinne
y, 
Burno 
et al. 
2003) 
 (D) 
PCP  
AMY
; 
(D) 
PCP  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(D) 
 
11q1
4.3 
(Ass
oc) 
SZ 
(Devon, 
Anders
on et al. 
2001) 
 
(D) 
SZ(Ben
es, Lim 
et al. 
2008) 
 
 4.0 
0.01
842 
rs17
011
0 
0.0012
63 
rs18464
75 
65 
 
 
SZ(G
rottick
, 
Bagnol 
et al. 
2005) 
GSN 
gelsoli
n 
0.04
739 
rs12
3760
78 
 
 
 (I) 
PCP  
AMY
; 
(D) 
CLZ  
CP 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 (I) 
PC
P 
and 
CLZ 
33.2 
(Ass
oc) 
SZ(Xi, 
Qin et 
al. 
2004) 
 
(D) 
SZ(Hak
ak, 
Walker et 
al. 2001, 
Prabakar
an, 
Swatton 
et al. 
2004) 
(Davis 
and 
Haroutun
ian 2003, 
Katsel, 
 4.0 
0.00
231
3 
rs76
777
0 
0.0001
564 
rs4837
835 
66 
 
 
Davis et 
al. 2005) 
HINT1 
histidin
e triad 
nucleo
tide 
bindin
g 
protein 
1 
0.00
008
672 
rs11
242
025 
SZ 
(Barbie
r, 
Zapata 
et al. 
2007) 
  
5q23
.3 
(Ass
oc) 
SZ 
(Chen, 
Wang 
et al. 
2008, 
Kurotak
i, Tasaki 
et al. 
2011) 
(D) 
SZ 
(Vawter, 
Crook et 
al. 2002) 
 
(I) 
SZ 
Whol
e 
Bloo
d 
(Kuzma
n, 
Medved 
et al. 
2009) 
4.0 
0.00
863
7 
rs77
341
77 
 
HTR2A 
5-
hydrox
ytrypta
mine 
(seroto
nin) 
0.02
014 
rs79
8515
5 
 
(I) 
Res
pon
se 
to 
anti
psyc
 
13q1
4.2 
(Ass
oc) 
SZ 
(Liu, 
Downin
(D) 
SZ 
(Polessk
aya and 
Sokolov 
2002, 
Torrey, 
 (D) 
SZ 
Lym
phoc
ytes 
(Fukud
a, Koga 
4.0 
0.00
346
1 
rs17
070
879 
0.0025
29 
rs18864
39 
67 
 
 
recept
or 2A 
hoti
cs 
(Taka
hashi, 
Kuma
nishi 
et al. 
2004) 
 
(D) 
SZ(St
eward, 
Kenne
dy et 
al. 
2004) 
(I) 
SZ(O
rtega-
Alvaro
, 
Aracil-
g et al. 
2010, 
McClay, 
Adkins 
et al. 
2011) 
 
 
Barci et 
al. 2005, 
Garbett, 
Gal-Chis 
et al. 
2008) 
et al. 
2006) 
68 
 
 
Ferna
ndez 
et al. 
2011) 
KALRN 
kalirin, 
RhoGE
F 
kinase 
0.00
6285 
rs37
7275
6 
 
 (I) 
CLZ  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
 
3q21
.1 
(Ass
oc) 
SZ(Ku
shima, 
Nakam
ura et 
al. 
2010) 
 
(D) 
SZ(Hill, 
Hashimo
to et al. 
2006) 
(D)  
SZ 
IPS 
deriv
ed 
neur
ons 
(Brenna
nd, 
Simone 
et al. 
2011) 
4.0 
0.01
015 
rs98
324
19 
0.0090
74 
rs18227
91 
KIF2A 
kinesin 
heavy 
chain 
memb
er 2A 
0.00
5374 
rs68
6479
3 
 
 
(D) 
CLZ  
VT 
(Le-
Nicule
 
(I) 
PC
P 
and 
5q12
.1 
(Ass
oc) 
SZ(Li, 
Zheng 
(D) 
SZ 
(Chu, Liu 
et al. 
2009) 
 4.0 
0.00
339
6 
rs15
386
4 
0.0052
07 
rs10069
830 
69 
 
 
scu, 
Balara
man et 
al. 
2007) 
CLZ 
 
et al. 
2006) 
NR4A2 
nuclea
r 
recept
or 
subfa
mily 4, 
group 
A, 
memb
er 2 
0.00
068
87 
rs12
465
886 
SZ 
(Rojas, 
Joodm
ardi et 
al. 
2007) 
 (I)  
PCP 
and 
CLZ  
HIP; 
(I)  
PCP 
and 
CLZ  
NAC
; 
(D) 
PCP  
PFC
; 
(I) 
 
2q24
.1 
(Ass
oc) 
SZ(Hu
ang, 
Perlis et 
al. 
2010) 
 
 
(I)  
SZ 
IPS 
deriv
ed 
neur
ons 
(Brenna
nd, 
Simone 
et al. 
2011) 
4.0 
0.00
162
4 
rs67
438
34 
0.0040
81 
rs16840
214 
70 
 
 
PCP 
and 
CLZ  
VT 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
NRG1 
neureg
ulin 1 
0.00
1731 
rs11
5800
1 
SZ 
(Stefan
sson, 
Sigurd
sson et 
al. 
2002, 
O'Tuat
haigh, 
Babovi
c et al. 
  
8p12 
(Ass
oc) 
SZ 
(van 
Schijnd
el, van 
Loo et 
al. 
2009, 
Walker, 
(D) 
SZ 
(Tkachev
, 
Mimmac
k et al. 
2003, 
Law, 
Shannon 
Weickert 
et al. 
(I)  
SZ 
IPS 
deriv
ed 
neur
ons 
(Brenna
nd, 
Simone 
4.0 
0.00
104 
rs27
169
60 
0.0000
06564 
rs6989
777 
71 
 
 
2007, 
Chen, 
Johnso
n et al. 
2008) 
 
Christof
orou et 
al. 
2010, 
Greenw
ood, 
Lazzero
ni et al. 
2011, 
McClay, 
Adkins 
et al. 
2011) 
(Stefan
sson, 
Sargins
on et al. 
2003, 
Mozhui 
2011) 
 
2004, 
Colantuo
ni, Hyde 
et al. 
2008, 
Harris, 
Lockston
e et al. 
2009) 
(I) 
SZ(Has
himoto, 
Straub et 
al. 2004, 
Hahn, 
Wang et 
al. 2006, 
Law, 
Lipska et 
al. 2006) 
et al. 
2011) 
(I) 
SZ 
Leuc
ocyte
s(Petry
shen, 
Middlet
on et al. 
2005) 
(I) 
SZ 
Lym
phoc
yte 
(Middlet
on, 
Pato et 
al. 
2005) 
(I)  
72 
 
 
SZ 
Delu
sions 
(Kurian, 
Le-
Niculesc
u et al. 
2011)  
PDE4B 
phosp
hodies
terase 
4B, 
cAMP-
specifi
c 
0.00
3042 
rs65
8819
3 
SZ 
(Siucia
k, 
McCart
hy et 
al. 
2008) 
(D) 
PCP 
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(I) 
Psyc
hosi
s(Dlab
oga, 
 
1p31
.3 
(Ass
oc) 
SZ 
 
(Pickard
, 
Thomso
n et al. 
2007, 
Fatemi, 
King et 
al. 
(D) 
SZ(Fate
mi, King 
et al. 
2008) 
 
 4.0 
0.02
102 
rs11
805
090 
0.0001
03 
rs1741
7507 
73 
 
 
Hajjhu
ssein 
et al. 
2008) 
(D) 
Res
pon
se 
to 
anti
psyc
hoti
cs(Fa
temi, 
Folso
m et 
al. 
2010) 
2008, 
Tompp
o, 
Hennah 
et al. 
2009, 
Kahler, 
Otnaess 
et al. 
2010, 
Mozhui 
2011) 
 
 
PRKCA 
protein 
kinase 
0.00
7991 
rs65
 
(I)  
CLZ  
PFC
 
17q2
4.2 
(Ass
oc) 
(D) 
SZ(Torr
ey, Barci 
(D)  
SZ 
IPS 
deriv
4.0 
0.01
166 
rs99
0.0004
001 
rs1695
9057 
74 
 
 
C, 
alpha 
0442
8 
; 
(D) 
CLZ  
VT  
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007) 
(I) 
Res
pon
se 
to 
anti
psyc
hoti
cs 
(Chen 
and 
SZ(Car
roll, 
William
s et al. 
2010, 
Jablens
ky, 
Morar 
et al. 
2011) 
 
et al. 
2005) 
ed 
neur
ons 
(Brenna
nd, 
Simone 
et al. 
2011) 
088
14 
75 
 
 
Chen 
2005) 
RELN 
reelin 
0.01
368 
rs27
1186
5 
SZ 
(Ballm
aier, 
Zoli et 
al. 
2002) 
(I)  
CLZ  
PFC
; 
(D)  
PCP 
and 
CLZ  
VT  
(Le-
Nicule
scu, 
Balara
man et 
al. 
2007)
; 
(D) 
SZ(Pi
llai 
 
7q22
.1 
(Ass
oc) 
SZ 
(Kahler, 
Djurovi
c et al. 
2008, 
Shifma
n, 
Johann
esson 
et al. 
2008, 
van 
Schijnd
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Candidate blood biomarkers 
Of the top candidate genes from Table 1-1 (see also Figure 1-2), 15 out of 
42 have prior human blood evidence for change in schizophrenia, implicating them 
as potential blood biomarkers. The additional evidence provided by GWAS data 
suggests a genetic rather than purely environmental (medications, stress) basis 
for their alteration in disease, and their potential utility as trait rather than purely 
state markers.  
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Biological pathways 
Pathway analyses were carried out on the top genes (Table 1-2), and on all the 
candidate genes (Supplementary Table S1-5). Notably, glutamate receptor 
signaling, G-protein--coupled receptor signaling and cAMP-mediated signaling 
were the top canonical pathways over-represented in schizophrenia, which may 
be informative for new drug discovery efforts by pharmaceutical companies. 
Genetic risk prediction 
Once the genes involved in a disorder are identified, and prioritized for 
likelihood of involvement, then an obvious next step is developing a way of 
applying that knowledge to genetic testing of individuals to determine risk for the 
disorder. Based on our identification of top candidate genes described above using 
CFG, we pursued a polygenic panel approach, with digitized binary scoring for 
presence or absence, similar to the one we have devised and used in the past for 
biomarkers testing15 and for genetic testing in bipolar disorder. 29 Somewhat 
similar approaches but without CFG prioritization, attempted by other groups, have 
been either unsuccessful33 or have required very large panels of markers. 9,34  
We first chose the single best P-value SNPs in each of our top CFG prioritized 
genes (n = 42) in the ISC GWAS data set used for discovery, and assembled a 
GRP  
Table 1-2. Ingenuity Pathway analyses of top candidate genes.  
Discovery in ISC and reproducibility in two independent cohorts, GAIN EA and 
GAIN AA. 
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Top Canonical Pathways CFG ≥ 3 P-Value Ratio 
    
ISC (n=186 genes) 
  
 
Glutamate Receptor Signaling  9.25E-13 12/69 (0.174) 
 
G-Protein Coupled Receptor Signaling 9.33E-13 
27/530 
(0.051) 
 
CREB Signaling in Neurons 1.76E-12 
17/202 
(0.084) 
 
cAMP-mediated signaling 3.55E-11 
17/219 
(0.078) 
 
Neuropathic Pain Signaling In Dorsal Horn 
Neurons 
3.64E-11 
13/112 
(0.116) 
 
----------------------------------------------------------
----------------- 
-----------
---- 
-----------------
----- 
GAIN EA (n=173 genes) 
  
 
Glutamate Receptor Signaling 4.57E-16 14/69 (0.203) 
 
CREB Signaling in Neurons  4.72E-14 
18/202 
(0.089) 
 
G-Protein Coupled Receptor Signaling 2E-13 
27/530(0.051
) 
 
cAMP-mediated signaling 1.2E-12 
18/219 
(0.082) 
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Synaptic Long Term Potentiation 1.58E-12 
14/114 
(0.123) 
    
GAIN AA (n= 201 genes) 
  
 
cAMP-mediated signaling 7.6E-17 
23/219 
(0.105) 
 
Glutamate Receptor Signaling 1.09E-16 15/69 (0.217) 
 
Synaptic Long Term Potentiation  2.24E-15 
17/114(0.149
) 
 
G-Protein Coupled Receptor Signaling 2.43E-14 
30/530 
(0.057) 
  CREB Signaling in Neurons 4.52E-14 
19/202 
(0.094) 
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Figure 1-3. Schizophrenia as a Disease of Disconnection.  
A. Biology of Schizophrenia B. Gene-Environment Interplay 
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panel out of those SNPs (Table 1-3). We then developed a GRPS for schizophrenia 
based on the presence or absence of the alleles of the SNPs associated with the 
illness, and tested the GRPS in independent cohorts (GAIN EA and GAIN AA), 
comparing the schizophrenia subjects to normal controls (Table 1-3). The results 
were not significant. We concluded that genetic heterogeneity at a SNP level is a 
possible explanation for these negative results. We then sought to see if we get 
better separation with a larger panel, containing all the nominally significant SNPs 
(n = 542) in the top CFG prioritized genes in ISC (n = 42), on the premise that a 
larger panel may reduce the heterogeneity effects, as different SNPs might be 
more strongly associated with illness in  different cohorts. We found that our larger 
panel of SNPs was indeed able to significantly distinguish schizophrenics from 
controls in both GAIN EA and GAIN AA, two independent cohorts of different 
ethnicities. To verify this unexpectedly strong result, we further tested our panel 
in two other independent cohorts, nonGAIN EA and nonGAIN AA, and obtained 
similarly significant results (Table 1-4 and Figure 1-4).  
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We also looked at whether our GRPS score distinguishes classic age of onset 
schizophrenia (defined by us as ages 15 to 30 years) from early onset (before 15 
years) and late-onset (after 30 years) illness. Our results show that classic age of 
onset schizophrenia has a significantly higher GRPS than early or late-onset 
schizophrenia, in three out of the four independent cohorts of two different 
ethnicities (Figure 1-5).  
Figure 1-4. Genetic Risk Prediction of Schizophrenia in four 
independent cohorts 
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Figure 1-5.  Genetic Risk Score and Age at Onset of Schizophrenia.  AA, 
African American; AAO, age at onset; EA, European American; GRPS, genetic 
risk prediction score. 
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Finally, as we had done previously for bipolar disorder, 29 we developed a 
prototype of how the GRPS score could be used in testing individuals to establish 
their category of risk for schizophrenia (Figure 1-6). The current iteration of the 
test, using the panel of 542 SNPs, seems to be able to distinguish in independent 
cohorts who is at lower risk for classic age of onset schizophrenia in two out of 
three EA subjects, and who is at higher risk for classic age of onset schizophrenia 
in three out of four AA subjects. 
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Table 1-3. GRPS-42: non- differentiation between schizophrenics and 
controls in independent cohorts using a panel composed of the single 
best SNP from ISC in each of the top candidate genes (42 SNPs, in 42 
genes).  
 
                                                             
 
 
 
Description of panel 
 
GAIN-EA 
 
GAIN-AA 
Single Best p-value SNPS 
in each of the top 42 candidate 
genes from ISC GWAS 
 
n=42 
p= 0.10308 
 
39 
out of the 42 ISC 
SNPs were present in 
GAIN-EA 
 
 
p= 0.13567 
 
37 
out of the 42 ISC 
SNPs were present  
in GAIN-AA 
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Table 1-4.  GRPS-542: differentiation between schizophrenics and 
controls in four independent cohorts using a panel composed of all the 
nominally significant  SNPs from  ISC in the top candidate genes  (542 
SNPs in 42 genes).  
GAIN EA 
 
GAIN AA 
 
p= 0.03213 
 
527 SNPs in 41 genes 
were present in GAIN-EA 
p= 0.00847 
516 SNPs in 42 genes 
were present  in GAIN-AA 
nonGAIN EA 
 
 
 
nonGAIN AA 
 
p= 0.00664 
 
537 SNPs in 42 genes 
were present  in nonGAIN EA 
 
p= 0.03829 
 
537 SNPs in 42 genes 
were present  in nonGAIN AA 
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Figure 1-6. Prototype of how GRPS testing could be used at an individual rather 
than population level, to aid diagnostic and personalized medicine approaches. We 
used the average values and standard deviation values for GRPS from the GAIN 
samples from each ethnicity (EA and AA) as thresholds for predictive testing in the 
independent nonGAIN EA and nonGAIN AA cohorts. The average GRPS score for 
schizophrenics in the GAIN cohort is used as a cut-off for schizophrenics in the test 
cohort (i.e., being above that threshold), and the average GRPS score for controls 
in the GAIN  cohort is used as a cutoff for controls in the test nonGAIN cohort (i.e., 
being below that threshold). The subjects who are in between these two 
thresholds are called undetermined. Furthermore, to stratify risk, we categorized 
subjects into risk categories (in red increased risk, in blue decreased risk): 
95 
 
 
Category 1 if they fall within one standard deviation above the schizophrenics’ 
threshold, and Category -1 if they fall within one standard deviation below the 
controls threshold.  Category 2 and -2 subjects are between one and two standard 
deviations from the thresholds, Category 3 and -3 between two and three standard 
deviations, and Category 4 and -4 are those who fall beyond three standard 
deviations of the thresholds. The positive predictive value (PPV) of the tests 
increases in the higher categories, and the test is somewhat better at 
distinguishing controls in EA (i.e., in a practical application, individuals that are 
lower risk of developing the illness), and schizophrenics in AA (i.e., in a practical 
application, individuals that are higher risk of developing the illness).  
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Overlap among studies 
We examined the overlap at a nominally significant (P<0.05) SNP level 
between ISC, GAIN EA and GAIN AA, and found that a minority of these SNPs 
(0.4%) overlap (Table 1-5 and Figure 1-7). We then examined the overlap at a 
gene level, then CFG prioritized genes level and finally biological pathways level, 
and found increasing evidence of commonality and reproducibility of findings 
across studies. 
  
Figure 1-7. Overlap Between Independent GWAS.   AA, African American; 
EA, European American; CFG, convergent functional genomics; ISC, International 
Schizophrenia Consortium; SNP, single-nucleotide polymorphism. 
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Table 1-5.  Reproducibility between independent GWAS.  
Increasing consistency and overlap observed from nominally significant SNPs 
(0.4%) to genes, then to CFG prioritized genes , and finally to pathways of CFG 
prioritized genes (97.1%). 
 
Numbers 
and 
overlap 
across 
studies 
ISC 
GAIN-
EA 
GAIN-
AA 
ISC vs. 
GAIN-
EA 
ISC vs. 
GAIN-
AA 
GAIN-
EA vs. 
GAIN-
AA 
ISC  
vs.  
GAIN-EA 
vs.  
GAIN-AA 
(% of 
ISC) 
SNPs 
P≤0.05 
45,972 42,336 57,118 2,649 2,986 2,839 
163 
(0.4%) 
Genes 10,180 9,002 11,260 6,470 7,583 6,807 
5,518 
(54.2%) 
Genes 
 CFG ≥1 
3,194 2,913 3,524 2,243 2,564 2,384 
2,012 
(63.0%) 
Genes  
CFG ≥3 
186 173 201 147 160 153 
134 
(72.0%) 
Genes  
CFG ≥4 
42 41 45 37 37 38 
35 
(83.3%) 
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Pathways 
for genes 
with CFG 
≥1 
217 210 205 194 188 180 
176 
(81.1%) 
Pathways 
for genes 
with CFG 
≥3 
79 85 108 72 76 81 
72 
(91.1%) 
Pathways 
for genes 
with CFG 
≥4 
34 50 75 33 34 48 
33 
(97.1%) 
 
 
 
Discussion 
Our CFG approach helped prioritize genes, such as DISC1 and MBP, with 
weaker evidence in the GWAS data but with strong independent evidence in terms 
of gene expression studies and other prior human or animal genetic work. 
Conversely, some of the top findings from GWAS, such as ZNF804A, have fewer 
different independent lines of evidence, and thus received a lower CFG 
prioritization score in our analysis (Supplementary Information Table S1-1), 
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although ZNF804A is clearly involved in schizophrenia-related cognitive 
processes.35 While we cannot exclude that more recently discovered genes have 
had less hypothesis driven work done and thus might score lower on CFG, it is to 
be noted that the CFG approach integrates predominantly non-hypothesis driven, 
discovery-type data sets, such as gene expression, GWAS, CNV, linkage and 
quantitative traits loci. We also cap each line of evidence from an experimental 
approach (Figure 1-1) at a maximum score of 1, to minimize any ‘popularity’ bias, 
whereas multiple studies of the same kind are conducted on better-established 
genes. In the end, it is gene-level reproducibility across multiple approaches and 
platforms that is built into the approach and gets prioritized most by CFG scoring 
during the discovery process. Our top results subsequently show good 
reproducibility and predictive ability in independent cohort testing, the litmus test 
for any such work. 
At the very top of our list of candidate genes for schizophrenia, with a CFG 
score of 5, we have four genes: DISC1, TCF4, MBP and HSPA1B. An additional five 
genes have a CFG score of 4.5: MOBP, NRCAM, NCAM1, NDUFV2 and RAB18.  
DISC1 (Disrupted-in Schizophrenia 1), encodes a scaffold protein that has 
an impact on neuronal development and function,36, 37, 38 including neuronal 
connectivity.39 DISC1 has been identified as a susceptibility gene for major mental 
disorders by multiple studies.40,41,42 DISC1 isoforms are upregulated in expression 
in blood cells in schizophrenia, thus serving as a potential peripheral biomarker as 
well.43,44 Developmental stress interacts with DISC1 expression to produce 
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neuropsychiatric phenotypes in mice.45 Notably, its interacting partners PDE4B,46 
TNIK,47 FEZ148 and DIXDC149 are also present on our list of prioritized candidate 
genes, with CFG scores of 4, 4, 3.5 and 2.5, respectively (Table 1-1 and 
Supplementary Table S1-1). 
TCF4 (transcription factor 4) encodes a basic helix-turn-helix transcription 
factor, expressed in immune system as well as neuronal cells. It is required for the 
differentiation of subsets of neurons in the developing brain. There are multiple 
alternatively spliced transcripts that encode different proteins, providing for 
biological diversity and heterogeneity. Defects in this gene are a cause of Pitt-
Hopkins syndrome, characterized by mental retardation with or without associated 
facial dimorphisms and intermittent hyperventilation. TCF4 has additional genetic 
evidence for association with schizophrenia-relevant phenotypes.50,51,52,53 It is 
changed in expression in postmortem brain,54 induced pluripotent stem cell-
derived neurons27 and blood from schizophrenia patients. 24 Notably, it is a 
candidate blood biomarker for level of delusional symptoms (decreased in high 
delusional states) based on our previous work. 24 
MBP (myelin basic protein) is a major constituent of the myelin sheath of 
oligodendrocytes and Schwann cells in the nervous system. MBP-related 
transcripts are also present in the bone marrow and the immune system. MBP has 
additional genetic evidence for association with schizophrenia.55 It is decreased in 
expression in postmortem brain56 and blood57 from schizophrenia patients. MBP is 
also changed in expression in the brain and blood of a pharmacogenomics mouse 
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model of schizophrenia, based on our previous work. 23 It was also decreased in 
expression in a stress-reactive genetic mouse model of bipolar disorder, 58 and 
treatment with the omega-3 fatty acid docosahexaenoic acid led to an increase in 
expression. Notably, MBP is a candidate blood biomarker for level of mood 
symptoms (increased in high mood states in bipolar subjects), based on our 
previous work. 15 Overall, the data indicate that MBP and other myelin-related 
genes59,60 may be involved in the effects of stress on psychosis and mood. 
Demyelinating disorders such as multiple sclerosis tend to be precipitated and 
exacerbated by stress, and have co-morbid psychiatric symptoms.61 Of note, other 
myelin-related genes are also present on our list of prioritized candidate genes: 
MOBP and MOG, with CFG scores of 4.5 and 3, respectively (Table 1-1 and 
Supplementary Table S1-1). 
HSPA1B (heat-shock 70-kDa protein 1B), a chaperone involved in stress 
response, stabilizes existing proteins against aggregation and mediates the folding 
of newly translated proteins. HSPA1B has additional genetic evidence for 
association with schizophrenia.62 It is changed in expression in postmortem brain63 
and induced pluripotent stem cell-derived neurons27 from schizophrenia patients. 
HSPA1B is also increased in expression in the brain and blood of a 
pharmacogenomics mouse model of schizophrenia, based on our previous work. 
23 It was also codirectionally changed in the brain and blood in a 
pharmacogenomics mouse model of anxiety disorders, we have recently 
described,64 as well as in a stress-reactive genetic mouse model.40 Treatment with 
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the omega-3 fatty acid docosahexaenoic acid reversed the increase in expression 
of HSPA1B in this stress reactive genetic mouse model.65 Another closely related 
molecule, HSPA1A (heat-shock 70-kDa protein 1A), is also present on our list of 
prioritized candidate genes, with a CFG score of 3.5 (Supplementary Table S1-1). 
Heat-shock proteins may be involved in the biological and clinical overlap and 
interdependence between response to stress, anxiety and psychosis. 
NRCAM (neuronal cell adhesion molecule) encodes a neuronal cell adhesion 
molecule. This ankyrin-binding protein is involved in neuron--neuron adhesion and 
promotes directional signaling during axonal cone growth. NRCAM is also 
expressed in non-neural tissues and may have a general role in cell--cell 
communication via signaling from its intracellular domain to the actin cytoskeleton 
during directional cell migration. It is decreased in expression in postmortem 
brain66 and peripherally in serum67 from schizophrenia patients. NRCAM is also 
changed in expression in the brain of a pharmacogenomics mouse model of 
schizophrenia, based on our previous work. 23 It was also increased in the 
amygdala in a stress-reactive genetic mouse model studied by our group.40 
Another closely related molecule, NCAM1 (neural cell adhesion molecule 1), is 
among our top candidate genes as well. These data support a central role for cell 
connectivity and cell adhesion in schizophrenia.  
Another top candidate gene is CNR1 (cannabinoid receptor 1, brain). CNR1 
is a member of the guanine-nucleotide-binding protein (G-protein) coupled 
receptor family, which inhibits adenylate cyclase activity in a dose-dependent 
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manner. CNR1 has additional genetic evidence for association with 
schizophrenia.68,69  It is decreased in expression in postmortem brain from 
schizophrenics.70  The other main cannabinoid receptor, CNR2 (cannabinoid 
receptor 2), is among our top candidate genes too (Supplementary Table S1-1), 
and is decreased in expression in postmortem brain from schizophrenics as well. 
These data support a role for the cannabinoid system in schizophrenia, perhaps 
through a deficiency of the endogenous cannabinoid signaling that leads to 
vulnerability to psychotogenic stress,71 and is accompanied by increased 
compensatory exogenous cannabinoid consumption that may have additional 
deleterious consequences.72 
A number of glutamate receptor genes are present among our top 
candidate genes for schizophrenia (GRIA1, GRIA4, GRIN2B and GRM5), as well as 
GAD1, an enzyme involved in glutamate metabolism, and SLC1A2, a glutamate 
transporter (Table 1-1).  Other genes involved in glutamate signaling present in 
our data, with a lower scores, are GRIN2A, SLC1A3, GRIA3, GRIK4, GRM1, GRM4 
and GRM7 (Supplementary Table S1-1). Glutamate receptor signaling is one of the 
top canonical pathways over-represented in our analyses (Table 1-2), and that 
finding is reproduced in independent GWA data sets (Table 1-2). One has to be 
circumspect with interpreting such results, as glutamate signaling is quasi-
ubiquitous in the brain, and a lot of prior hypothesis-driven work has focused on 
this area, potentially biasing the available evidence. Nevertheless, our results are 
striking, and contribute to the growing body of evidence that has emerged over 
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the last few years implicating glutamate signaling as a point of convergence for 
findings in schizophrenia,73 as well as for autism74 and AD.75 Glutamate signaling 
is the target of active drug development efforts,76 which may be informed and 
encouraged by our current findings. 
Our analysis also provides evidence for other genes that have long been of 
interest in schizophrenia, but have had previous variable evidence from genetic-
only studies: BDNF, COMT, DRD2, DTNBP1 (dystrobrevin binding 
protein1/dysbindin; Table 1-1). In addition, our analysis provides evidence for 
genes that had previously not been widely implicated in schizophrenia, but do have 
relevant biological roles, demonstrating the value of empirical discovery-based 
approaches such as CFG (Table 1-1): ANK3, 66 ALDH1A1 and ADCYAP1, which is 
a ligand for schizophrenia candidate gene VIPR2,77,78 also present in our data set, 
albeit with a lower CFG score of 2. Other genes of interest in our full data set 
(Supplementary Table S1-1) include ADRBK2 (GRK3), first described by us as a 
candidate gene for psychosis, 19 CHRNA7,79 and PDE10A,80 which are targets for 
drug development efforts. 
Pathways and mechanisms 
Our pathway analyses results are consistent with the accumulating evidence 
about the role of synaptic connections and glutamate signaling in schizophrenia, 
most recently from CNV studies81 (Table 1-2, Supplementary Table S1-5, Figure 1-
3). Very importantly, the same top pathways were consistent across independent 
GWA studies we analyzed (Tables 1-2, 1-5, and Supplementary Table S1-5). We 
105 
 
 
also did a manual curation of the top candidate genes and their grouping into 
biological roles examining them one by one using PubMed and GeneCards, to come 
up with a heuristic model of schizophrenia (Figure 1-3).  Overall, while multiple 
mechanistic entry points may contribute to schizophrenia pathogenesis (Figure 3a-
1), it is likely at its core a disease of decreased cellular connectivity precipitated 
by environmental stress during brain development, on a background of genetic 
vulnerability (Figure 1-3b). 
Genetic risk prediction 
Of note, our SNP panels and choice of affected alleles were based solely on 
analysis of the discovery ISC GWAS, completely independently from the test GAIN 
EA, GAIN AA, nonGAIN EA and nonGAIN AA GWAS. Our results show that a 
relatively limited and well-defined panel of SNPs identified based on our CFG 
analysis could differentiate between schizophrenia subjects and controls in four 
independent cohorts of two different ethnicities, EA and AA. Moreover, the genetic 
risk component identified by us seems to be stronger for classic age of onset 
schizophrenia than for early or late-onset illness, suggesting that the latter two 
may be more environmentally driven or have a somewhat different genetic 
architecture. It is likely that such genetic testing will have to be optimized for 
different cohorts if done at a SNP level. Interestingly, at a gene and pathway level, 
the differences between studies seem much less pronounced than at a SNP level, 
if at all present (Table 1-5), suggesting that gene-level and pathway-level tests 
may have more universal applicability. In the end, such genetic data, combined 
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with family history and other clinical information (phenomics),82 as well as with 
blood biomarker testing, 15 may provide a comprehensive picture of risk of 
illness.83,84 
Reproducibility among studies 
Our work provides striking evidence for the advantages, reproducibility and 
consistency of gene-level analyses of data, as opposed to SNP level analyses, 
pointing to the fundamental issue of genetic heterogeneity at a SNP level (Table 
1-5 and Figure 1-7). In fact, it may be that the more biologically important a gene 
is for higher mental functions, the more heterogeneity it has at a SNP level85 and 
the more evolutionary divergence,86 for adaptive reasons. On top of that, CFG 
provides a way to prioritize genes based on disease relevance, not study-specific 
effects (that is, fit-to-disease as opposed to fit-to-cohort). Reproducibility of 
findings across different studies, experimental paradigms and technical platforms 
is deemed more important (and scored as such by CFG) than the strength of 
finding in an individual study (for example, P-value in a GWAS). The CFG prioritized 
genes show even more reproducibility among independent GWAS cohorts (ISC, 
GAIN EA, GAIN AA) than the full list of unprioritized genes with nominal significant 
SNPs. The increasing overlap and reproducibility between studies of genes with a 
higher average CFG score points out to their biological relevance to disease 
architecture. Finally, at a pathway level, there is even more consistency across 
studies. Again, the pathways derived from the top CFG scoring genes show more 
consistency than the pathways derived from the lower CFG scoring genes. Overall, 
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using our approach, we go from reproducibility between independent studies of 
0.4% at the level of nominally significant SNPs to a reproducibility of 97.1% at the 
level of pathways derived from top CFG scoring genes. 
Overlap with other psychiatric disorders 
Despite using lines of evidence for our CFG approach that have to do only 
with schizophrenia, the list of genes identified has a notable overlap with other 
psychiatric disorders (Figure 1-8, Supplementary Table S1-1). This is a topic of 
major interest and debate in the field.30,87 We demonstrate an overlap between 
top candidate genes for schizophrenia and candidate genes for anxiety and bipolar 
disorder, previously identified by us through CFG (Figure 1-8), thus providing a 
possible molecular basis for the frequently observed clinical co-morbidity and 
interdependence between schizophrenia and those other major psychiatric 
disorders, as well as cross-utility of pharmacological agents. In particular, PDE10A 
is at the overlap of all three major psychiatric domains, and may be of major 
interest for drug development.80  The overlap between schizophrenia and bipolar 
may have to do primarily with neurotrophicity and brain infrastructure (underlined 
by genes such as DISC1, NRG1, BDNF, MBP, NCAM1, NRCAM, PTPRM). The 
overlap between schizophrenia and anxiety may have to do primarily to do with 
reactivity and stress response (underlined by genes such as NR4A2, QKI, RGS4, 
HSPA1B, SNCA, STMN1, LPL). Notably, the overlap between schizophrenia and 
anxiety is of the same magnitude as the previously better appreciated overlap 
between schizophrenia and bipolar disorder, 23,88 supporting the consideration of 
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a nosological domain of schizoanxiety disorder,64 by analogy to schizoaffective 
disorder.  Clinically, while there are some reports of co-morbidity between 
schizophrenia and anxiety,89 it is an area that has possibly been under-appreciated 
and understudied. ‘Schizoanxiety disorder’ may have heuristic value and pragmatic 
clinical utility.  
  
Figure 1-8. Genetic Overlap Among Psychiatric Disorders. 
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We also looked at the overlap with candidate genes for autism and AD from 
the literature (Supplementary Table S1-1), to elucidate whether schizophrenia, 
autism and AD might be on a spectrum, that is, whether autism might be a form 
of ‘schizophrenia praecox’, similar to schizophrenia being referred to as ‘dementia 
praecox’ (Kraepelin). We see significant overlap between the three disorders 
among the top genes with a CFG score of 4: a third of the genes overlap between 
schizophrenia and autism, and a quarter between schizophrenia and AD. Additional 
key genes of interest are lower on the list as well, with a CFG score of 3: CNTNAP2 
for autism, MAPT and SNCA for AD (Supplementary Table S1-1). 
Conclusions and future directions 
First, in spite of its limitations, our analysis is arguably the most 
comprehensive integration of genetics and functional genomics to date in the field 
of schizophrenia, yielding a comprehensive view of genes, blood biomarkers, 
pathways and mechanisms that may underlie the disorder. From a pragmatic 
standpoint, we would like to suggest that our work provides new and/or more 
comprehensive insights on genes and biological pathways to target for new drug 
development by pharmaceutical companies, as well as potential new uses in 
schizophrenia for existing drugs, including omega-3 fatty acids (Supplementary 
Table S1-2). 
Second, our current work and body of work over the years provides proof 
how a combined approach, integrating functional and genotypic data, can be used 
for complex disorders-psychiatric and non-psychiatric, as has been attempted by 
110 
 
 
others as well.90,91 What we are seeing across GWAS of complex disorders are not 
necessarily the same SNPs showing the strongest signal, but rather consistency at 
the level of genes and biological pathways.  The distance from genotype to 
phenotype may be a bridge too far for genetic-only approaches, given genetic 
heterogeneity and the intervening complex layers of epigenetics and gene 
expression regulation.92 Consistency is much higher at a gene expression level 
(Table 1-5),93 and then at a biological pathway level. Using GWAS data in 
conjunction with gene expression data as part of CFG or integrative genomics94 
approaches, followed by pathway-level analysis of the prioritized candidate genes, 
can lead to the unraveling of the genetic code of complex disorders such as 
schizophrenia.  
Third, our work provides additional integrated evidence focusing attention 
and prioritizing a number of genes as candidate blood biomarkers for 
schizophrenia, with an inherited genetic basis (Table 1-1 and Figure 1-2). While 
prior evidence existed as to alterations in gene expression levels of those genes in 
whole-blood samples or lymphoblastoid cell lines from schizophrenia patients, it 
was unclear prior to our analysis whether those alterations were truly related to 
the disorder or were instead related only to medication effects and environmental 
factors. 
Fourth, we have put together a panel of SNPs, based on the top candidate 
genes we identified. We developed a GRPS based on our panel, and demonstrate 
how in four independent cohorts of two different ethnicities, the GRPS 
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differentiates between subjects with schizophrenia and normal controls. From a 
personalized medicine standpoint, genetic testing with highly prioritized panels of 
best SNP markers may have, upon further development (Figure 1-6) and 
calibration by ethnicity and gender, a role in informing decisions regarding early 
intervention and prevention efforts; for example, for classic age of onset 
schizophrenia before the illness fully manifests itself clinically, in young offspring 
from high-risk families. After the illness manifests itself, gene expression 
biomarkers and phenomic testing approaches, including clinical data, may have 
higher yield than genetic testing. A multi-modal integration of testing modalities 
would be the best approach to assess and track patients, as individual markers are 
likely to not be specific for a single disorder. The continuing re-evaluation in 
psychiatric nosology84,95 brought about by recent advances will have to be taken 
into account as well for final interpretation of any such testing. The complexity, 
heterogeneity, overlap and interdependence of major psychiatric disorders as 
currently defined by DSM suggests that the development of tests for dimensional 
disease manifestations (psychosis, mood and anxiety)84 will ultimately be more 
useful and precise than developing tests for existing DSM diagnostic categories. 
Finally, while we cannot exclude that rare genetic variants with major 
effects may exist in some individuals and families, we suggest a contextual 
cumulative combinatorics of common variants genetic model best explains our 
findings, and accounts for the thin genetic load margin between clinically ill 
subjects and normal controls, which leaves a major role to be played by gene 
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expression (including epigenetic changes) and the environment.  This is similar to 
our conclusions when studying bipolar disorder,29 and may hold true in general for 
complex medical disorders, psychiatric and non-psychiatric. Full-blown illness 
occurs when genetic and environmental factors converge, usually in young 
adulthood for schizophrenia. When they diverge, a stressful/hostile environment 
may lead to mild or transient illness even in normal genetic load individuals, 
whereas a favorable environment may lead to supra-normative functioning in 
certain life areas (such as creative endeavors) for individuals who carry a higher 
genetic load. The flexible interplay between genetic load, environment and 
phenotype may permit evolution to engender diversity, select and conserve alleles, 
and ultimately shape populations. Our emerging mechanistic understanding of 
psychosis as disconnectivity, mood as activity29 and anxiety as reactivity64 may 
guide such testing and understanding of population distribution as being on a 
multi-dimensional spectrum, from supra-normative to normal to clinical illness. 
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Chapter 2:  Alcoholism 
Alcohol is one of the most widely used recreational drugs in the U.S., with 
82.1 percent of people over the age of 12 having drank alcohol at some point in 
their lifetime.  There has been mixed data over potential health benefits of drinking 
alcohol.  Light to moderate consumption has been associated in epidemiological 
investigations with reduced relative mortality risk96, while heavy drinking is 
associated with increased risk, forming a distinctive and often replicated U or J-
shaped curve when relative risk is plotted against average alcohol intake.  97 98  
While drinking itself can be socially normative and part of a healthy lifestyle, many 
people struggle with alcohol use disorders (AUD), and this can have a profoundly 
negative impact on both quality99 and quantity of life100.   
This study sought to identify genes involved in alcohol use disorders in a 
similar fashion to prior work on schizophrenia.  We began with an independent 
GWAS provided by collaborators in Germany.  We again identified SNPs which were 
nominally significant with a p < 0.05, which were then converted into nearest 
gene.  In this analysis we implemented an internal score based on purely on the 
data from the discovery cohort.  This was calculated using the ratio of nominally 
significant SNPs associated with a gene to total SNPs tested for a gene.   Genes in 
the top 0.1% of the distribution scored 4 points, genes in the top 5% received 3 
points, and the remaining genes received 2 points.  This provides additional weight 
to the primary analysis, and this internal score was added to the external score as 
described below. 
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Converted genes were then prioritized with a polyevidence CFG score.  
Keywords used to determine convergence for this project were alcohol and 
alcoholism, in addition to tissue or species relevant search terms.  We used the 
Jackson Laboratory Mouse Phenome Database to find relevant transgenic animal 
models by searching the relevant phenotype categories as described below.  This 
analysis used the variation as described previously by weighting the lines of 
evidence such that human evidence received twice as much as nonhuman 
evidence, and brain evidence received twice as many points as evidence from 
genetics or peripheral tissue.  In this way, human brain evidence was given 4 
points, human peripheral or genetic evidence would be given 2 points each, 
nonhuman brain evidence was given 2 points, and nonhuman peripheral, genetic, 
or transgenic evidence received 1 point each.  In this weighting the maximum 
possible score from CFG was 12 (4 human brain, 2 human genetic, 2 human 
peripheral, 2 nonhuman brain, 1 nonhuman genetic, 1 nonhuman peripheral = 
12).  This was added to the internal score derived from the primary GWAS so that 
the maximum possible score overall could be 16 (4 from internal score, 12 from 
CFG). 
Using the exact same methodology as the schizophrenia paper, we set the 
prioritization cutoff as being half the possible max score, in this case ≥8.  135 
genes and 713 SNPs met this criterion, and were used to generate a polygenic 
GRPS.  This showed a trend towards significance (p=0.053) in separating cases 
from controls in an additional independent German GWAS test cohort.   
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Prior work by the Niculescu lab had identified the D-Box binding protein 
(DBP) as a potential candidate gene for bipolar disorder19.  D-box elements are 
important factors in circadian regulation.  DBP is a transcription factor that binds 
to these elements, and plays a role in activating downstream circadian output 
genes.  In previous studies of transgenic mice with a homozygous deletion of the 
DBP gene found that animals increased ethanol consumption in response to stress 
when compared to wild type animals.  58  Koob and many others have implicated 
stress systems in driving drug seeking behavior.  101  We sought to validate our 
top GWAS genes by finding the overlap with top candidate genes from the stress-
reactive DBP knockout (KO) mouse model.  Validation in the animal model 
produced 11 genes with 66 SNPs. 
We used this smaller panel of genes and SNPs to create polygenic GRPS 
scores which were tested in the independent German GWAS as well as 2 additional 
independent GWAS from the United States.  This smaller panel validated by the 
animal model showed nominally significant separation between cases and controls 
in the German GWAS (p=0.041) as well as in United States cohorts of alcohol 
dependence (p=1.3E-5) and alcohol abusers (p=1.2E-4). 
We used a combination of three pathway enrichment tools (Ingenuity, 
KEGG, and GeneGO) to help further our understanding of the biology of our top 
genes.  Pathway analysis explicitly identified addiction (cocaine) as well as 
implicating signaling pathways and neurogenesis.   
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Alcohol can be part of a healthy lifestyle. But for the many people who are 
susceptible to AUDs, alcohol can have a highly deleterious effect on health and 
mortality.  It is important to recognize that while this study attempts to identify 
genetic predisposition, context and environmental stress plays a large role as 
evidenced by the enrichment by the stress reactive animal model.  Reinforcing 
prior findings in schizophrenia, this study points to how we can begin to use 
genetic predisposition to inform the choices of an individual.   
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Genetic Risk Prediction and Neurobiological Understanding of 
Alcoholism 
Introduction 
Alcohol use and overuse (alcoholism) have deep historical and cultural 
roots, as well as important medical and societal consequences102. While there is 
evidence for roles for both genes and environment in alcoholism, a comprehensive 
biological understanding of the disorder has been elusive so far, despite extensive 
work in the field.  Most notably, there has been until recently insufficient 
translational integration across functional and genetic studies, and across human 
and animal model studies, resulting in missed opportunities for a comprehensive 
understanding. 
As part of a translational Convergent Functional Genomics (CFG) approach, 
developed by us over the last 15 years 30, and expanding upon our earlier work on 
identifying genes for alcoholism 22 58 65 ,  we set out to comprehensively identify 
candidate genes, pathways and mechanisms for alcoholism, integrating the 
available evidence in the field to date. We have used data from a published German 
genome-wide association study for alcoholism 103. We integrated those data in a 
Bayesian-like fashion with other human genetic data (association or linkage) for 
alcoholism, as well as human gene expression data - postmortem brain gene 
expression data, and peripheral (blood, cell culture) gene expression data. We also 
used relevant animal model genetic data (transgenic, QTL), as well as animal 
model gene expression data (brain and blood) generated by our group and others 
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(Figures 2-1 and 2-2). Human data provides specificity for the illness, and animal 
model data provides sensitivity of detection. Together, they helped identify and 
prioritize candidate genes for the illness using a polyevidence CFG score, resulting 
in essence in a de facto field-wide integration putting together all the available 
evidence to date. Once that is done, biological pathway analyses can be conducted 
and mechanistic models can be constructed.  
An obvious next step is developing a way of applying that knowledge to 
genetic testing of individuals to determine risk for the disorder. Based on our 
comprehensive identification of top candidate genes described in this paper, we 
have chosen all the nominally significant p-value SNPs corresponding to each of 
those 135 genes from the GWAS dataset used for discovery (top candidate genes 
prioritized by CFG with score of 8 and above (>=50% max. possible CFG score of 
16), and assembled a Genetic Risk Prediction (GRP) panel out of those 713 SNPs.  
We then developed a Genetic Risk Prediction Score (GRPS) for alcoholism based 
on the presence or absence of the alleles of the SNPs associated with the illness 
from the discovery GWAS, and tested the GRPS in an independent German cohort 
104, to see if it can differentiate alcohol dependent subjects from controls, 
observing a trend towards significance.  
In order to validate and prioritize genes in this panel using a behavioral 
prism, we then looked at the overlap between our panel of 135 top candidate 
genes and genes changed in expression in a stress-reactive  animal model for 
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alcoholism developed by our group, the DBP knock-out mouse58,65. We used this 
overlap to reduce our panel to 11 genes (66 SNPs).  
This small panel of 11 genes was subsequently  tested and shown to be 
able to differentiate between alcoholics and controls in the three independent test 
cohorts, one German 104 and two US based105, suggesting that the animal model  
served in essence  as a filter to identify from the larger list of CFG-prioritized genes 
the key behaviorally relevant genes. Our results indicate that  panels of SNPs in 
top genes identified and prioritized by CFG analysis and by a behaviorally-relevant 
animal model can differentiate between alcoholics and controls at a population 
level (Figure 2-5), although at an individual level the margin may be small (Figure 
S2). The latter point suggests that, like for bipolar disorder 29 and schizophrenia 
31, the contextual cumulative combinatorics of common gene variants and 
environment 106 plays a major role in risk for illness.       
Lastly, we have looked at overlap with candidate genes for other major 
psychiatric disorders domains (bipolar disorders, anxiety disorders, schizophrenias) 
from our previous studies, and provide evidence for shared genes (Figures 2-3 and 
2-4) as well as shared genetic risk (Figure 2-6).      
Overall, this work sheds light on the genetic architecture and 
pathophysiology of alcoholism, provides mechanistic targets for therapeutic 
intervention, and has implications for genetic testing to assess risk for illness 
before the illness manifests itself clinically, opening the door for enhanced 
prevention strategies at a young age. As alcoholism is a disease that does not exist 
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if the exogenous agent (alcohol) is not consumed, the use of genetic information 
to inform lifestyle choices could be quite powerful. 
Materials and Methods 
Human subject cohorts 
Discovery cohort (cohort 1): Data for the discovery CFG work (Cohort 1) 
were obtained from a GWAS of self-reported German descent subjects, consisting 
of 411 alcohol dependent male subjects and 1307 population-based controls (663 
male and 644 female subjects). 103  Individuals were genotyped using HumanHap 
550 BeadChips (Illumina Inc, San Diego, CA, USA). SNPs with a nominal allelic P-
value <0.05 were selected for analysis. No Bonferroni correction was performed. 
Test cohort 2 (alcohol dependence, Germany):  An independent test cohort 
of German descent 104 consisting of 740 alcohol-dependent male subjects and 861 
controls (276 male and 585 female subjects) was used for testing the results of 
the discovery analyses. Individuals were genotyped using Illumina Human 610 
Quad or Illumina Human660w Quad BeadChips (Illumina Inc). The controls were 
genotyped using Illumina HumanHap550 Bead Chips. 
Test cohort 3 (alcohol dependence, United States) and test cohort 4 (alcohol 
abuse, United States):  The sample consisted of small nuclear families originally 
collected for linkage studies, and unrelated individuals, Caucasians and African-
American, male and female subjects. The subjects were recruited at five US clinical 
sites: Yale University School of Medicine (APT Foundation; New Haven, CT, USA), 
the University of Connecticut Health Center (Farmington, CT, USA), the University 
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of Pennsylvania Perelman School of Medicine (Philadelphia, PA, USA), the Medical 
University of South Carolina (Charleston, SC, USA) and McLean Hospital (Belmont, 
MA, USA). All subjects were interviewed using the Semi-Structured Assessment for 
Drug Dependence and Alcoholism to derive diagnoses for lifetime alcohol 
dependence, alcohol abuse and other major psychiatric traits according to the 
DSM-IV criteria. There were 1687 male subjects with alcohol dependence, 366 
male subjects with alcohol abuse and 475 male controls. There were 1081 female 
subjects with alcohol dependence, 234 female subjects with alcohol abuse and 786 
female controls (Table 2-1).  Individuals were genotyped on the Illumina 
HumanOmni1-Quad v1.0 microarray (988,306 autosomal SNPs). GWAS 
genotyping was conducted at the Yale Center for Genome Analysis and the Center 
for Inherited Disease Research. Genotypes were called using the GenomeStudio 
software V2011.1 and genotyping module version 1.8.4 (Illumina Inc). 105 
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Table 2-1. Discovery and Test Cohorts 
Test  
Cohort 2 
Germany 
Alcohol Dependence Control 
Male 740 276 
Female 0 585 
Ethnicity All Caucasians 
All 
Caucasians 
 
Test  
Cohorts 3 and 4 
Alcohol 
Dependence 
Alcohol 
Abuse 
Control 
Discovery  
Cohort 1 
GWAS  
Germany 
Alcohol Dependence Control 
Male 411 663 
Female 0 644 
Ethnicity All Caucasians 
All 
Caucasians 
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United States 
Male 1687 366 475 
Female 1081 234 786 
Male Ethnicity 
(Caucasian/African-
American) 
802/885 201/165 168/307 
Female Ethnicity 
(Caucasian/African-
American) 
471/610 123/111 220/566 
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Gene identification in discovery cohort 1 
Quality control:  Genotype data had been filtered using stringent quality- 
control criteria as described earlier104 and accounted for call rate, population 
substructure, cryptic relatedness, minor allele frequency and batch effects. 
Association test in discovery sample:  Association testing was performed 
using  PLINK  1.07  (http://pngu.mgh.harvard.edu/ ~ purcell) 107 software 
package. A logistic regression modelling approach was applied to correct for 
population stratification. Therefore, principal component analysis was conducted 
considering only independent autosomal SNPs with minor allele frequency >0.05 
and pairwise R2 <0.05 within a 200-SNP window. LD filtering resulted in a set of 
28,505 SNPs used for principal component analysis, which was carried out using 
GCTA 1.04 (http://www.complex-traitgenomics.com/software/gcta/). 108 The first 
two principal components resulting from this analysis were included as covariates 
in the logistic regression model. 
Assignment of SNPs to genes:  Genes corresponding to SNPs were identified 
initially using the annotation file from the Illumina website 
(http://www.illumina.com,  HumanHAP550v3_Gene_Annotation).  Next, genes 
were cross-checked with GeneCards (http://www.genecards.org) to ensure that 
each gene symbol was current. Any gene symbol that matched to a different gene 
symbol in Gene Cards was checked to verify chromosome number and location 
match with the original gene, and was replaced with the current GeneCards gene 
symbol. SNPs from the original annotation files that had no gene matches in the 
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annotation file and UCSC Genome Browser (that is, not falling within an exon or 
intron of a known gene) were assumed to regulate and thus implicate the gene 
closest to the SNP location, using the refSNP database from NCBI 
(http://www.ncbi.nlm.nih.gov/snp/?SITE= NcbiHome&submit = Go). 
Convergent functional genomic analyses 
Databases and scoring were as previously described.   
Prioritizing top alcoholism candidate genes that overlap with a  
stress-reactive animal model of alcoholism 
      Stress has been proposed as a driver of alcoholism, notably by Koob and 
colleagues109 110, as well as by Heilig and colleagues111. We have previously 
identified the circadian clock gene D-box Binding Protein (DBP) as a candidate 
gene for bipolar disorder 19, as well as for alcoholism 22, using a Convergent 
Functional Genomics (CFG) approach. In follow-up work, we established mice with 
a homozygous deletion of DBP (DBP KO) as a stress-reactive genetic animal model 
of bipolar disorder and alcoholism58. We reported that DBP KO mice have lower 
locomotor activity, blunted responses to stimulants, and gain less weight over 
time. In response to a stress paradigm that translationally mimics what can happen 
in humans (chronic stress-isolation housing for 4 weeks, with acute stress on top 
of that- experimental handling in week 3), the mice exhibit a diametric switch in 
these phenotypes. DBP KO mice are also activated by sleep deprivation, similar to 
bipolar patients, and that activation is prevented by treatment with the mood 
stabilizer drug valproate. Moreover, these mice show increased alcohol intake 
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following exposure to stress. Microarray studies of brain and blood revealed a 
pattern of gene expression changes that may explain the observed phenotypes. 
CFG analysis of the gene expression changes identified a series of candidate genes 
and blood biomarkers for bipolar disorder, alcoholism and stress reactivity. 
Subsequent studies by us showed that treatment with the omega-3 fatty acid 
docosahexaenoic acid (DHA) normalized the gene expression (brain, blood) and 
behavioral phenotypes of this mouse model, including reducing alcohol 
consumption65. 
       We examined the overlap between the top candidate genes for alcoholism 
from the current analysis and the top candidate genes from the DBP KO stress 
mice, thus reducing the list from 135 to 11 (Figure 2-3). 
Pathway Analyses  
IPA 9.0 (Ingenuity Systems, www.ingenuity.com , Redwood City, CA) was used to 
analyze the biological roles, including top canonical pathways and diseases, of the 
candidate genes resulting from our work (Tables 2-3 and S2-2), as well as used to 
identify genes in our datasets that are the targets of existing drugs (Table S2-3). 
Pathways were identified from the IPA library of canonical pathways that were 
most significantly associated with genes in our data set.  The significance of the 
association between the data set and the canonical pathway was measured in 2 
ways: 1) a ratio of the number of molecules from the data set that map to the 
pathway divided by the total number of molecules that map to the canonical 
pathway is displayed; 2) Fisher’s exact test was used to calculate a p‐value 
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determining the probability that the association between the genes in the dataset 
and the canonical pathway is explained by chance alone. We also conducted a 
KEGG pathway analysis through the Partek Genomic Suites 6.6 software package, 
Partek Inc., Saint Louis, MO), and GeneGo MetaCore from Thomson Reuters, New 
York, NY) pathway analyses (https://portal.genego.com/). 
Epistasis testing   
The test cohort 2 data were used to test for epistatic interactions among 
the best p-value SNPs in the 11 top candidate genes from our work.  SNP-SNP 
allelic epistasis was tested for each distinct pair of SNPs between genes, using the 
PLINK software package (Table S2-5). 
Genetic Risk Prediction  
      The software package PLINK 1.07 (http://pngu.mgh.harvard.edu/~purcell) 
107 was used to extract individual genotype information for each subject from the 
test cohorts 2, 3 and 4 data files.  As we had previously done for bipolar disorder 
and schizophrenia, we developed a polygenic Genetic Risk Prediction Score (GRPS) 
for alcoholism based on the presence or absence of the alleles of the SNPs 
associated with illness in the discovery GWAS cohort 1, and tested the GRPS in 
three independent cohorts, from different geographic areas, ethnicities, and 
different types of alcoholism.  We tested two panels: a larger panel containing all 
the nominally significant SNPs in top CFG scoring candidate genes (n=135) from 
the discovery GWAS1 in the top CFG prioritized genes (Tables S2-1 and S2-4) and 
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a smaller one (n=11) containing genes out of the larger panel that were cross-
validated using an animal model of alcoholism. 
        Of note, our genes, SNP panels, and choice of affected alleles were based 
solely on analysis of the discovery GWAS1, which is our discovery cohort, 
completely independently from the test cohorts.   Each SNP has two alleles 
(represented by base letters at that position).  One of them is associated with the 
illness (affected), the other not (non-affected), based on the odds ratios from the 
discovery GWAS1. We assigned the affected allele a score of 1 and the non-
affected allele a score of 0. A two-dimensional matrix of subjects by GRP panel 
alleles is generated, with the cells populated by 0 or 1.  A SNP in a particular 
individual subject can have any permutation of 1 and 0 (1 and 1, 0 and 1, 0 and 
0).  By adding these numbers, the minimum score for a SNP in an individual subject 
is 0, and the maximum score is 2.  By adding the scores for all the alleles in the 
panel, averaging that, and multiplying by 100, we generated for each subject an 
average score corresponding to a genetic loading for disease, which we call 
Genetic Risk Predictive Score (GRPS)29,31.  To test for significance, a one-tailed t-
test with unequal variance was performed between the alcoholic subjects and the 
control subjects, looking at differences in GRPS.  
ROC Curves 
ROC curves were plotted using IBM SPSS Statistics 21.  Diagnosis was 
converted to a binary call of 0 (control) or 1(alcohol dependent or abuser) and 
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entered as the state variable, with calculated GRPS entered as the test variable 
(Figure S2-2).   
Figures 
Each figure in this chapter was completed by Daniel Levey and Helen Le-
Niculescu.  This work has been published.  112 
Results 
Top candidate genes  
To minimize false negatives, we initially cast a wide net, using as a filter a 
minimal requirement for a gene to have both some GWAS evidence and some 
additional independent evidence. Thus, out of the 6085 genes with at least a SNP 
at p<0.05 in the discovery GWAS cohort 1, we generated a list of 3142 genes that 
also had some additional evidence (human or animal model data), implicating 
them in alcoholism (CFG score >=2.5 (>=2 internal) + (>=0.5 external)). This 
suggests, using these minimal thresholds and requirements, that the repertoire of 
genes potentially involved directly or indirectly in alcohol consumption and 
alcoholism may be quite large, similar to what we have previously seen for bipolar 
disorder113 and schizophrenia31. To minimize false positives, we used an internal 
score based on percent of SNPs in a gene that were nominally significant, with 4 
points for those in the top 0.1% of the distribution (n=  77), 3   points for those 
in the top 5% of the distribution (n=561)   and 2 points for the rest of the 
nominally significant SNPs (n=5447). We then used the CFG analysis and scoring 
integrating multiple lines of evidence to prioritize this list of genes (Figure 2-1), 
130 
 
 
and focused our subsequent analyses on only the top CFG scoring candidate 
genes. Overall, 135 genes had a CFG score of 8 and above (>=50% of maximum 
possible score of 16).  
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Table 2-2. Top candidate genes for alcoholism. Top genes with a CFG score 
of 8 and above that overlapped with top genes from the stress-reactive animal 
model are shown (n=11) (Figure 2-3). Best p-value SNP within the gene or 
flanking regions is depicted.  A more complete list of genes with CFG score of 8 
and above (n= 135) is available in the Supplementary Information section (Table 
S1).   I - increased; D – decreased in expression; PFC - prefrontal cortex; AMY - 
amygdala; CP - caudate putamen; NAC - nucleus accumbens; VT - ventral 
tegmentum; TG- transgenic. P1- paradigm 1, P2- Paradigm 2, P3-paradigm 3 in 
the Rodd, Bertsch et al. 2007.   Association- association evidence; Linkage- 
linkage evidence. Underlined gene symbol represents means gene is a blood 
biomarker candidate. Bold p-values <0.001.  
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Of note, there was no correlation between CFG prioritization and gene size, thus 
excluding a gene-size effect for the observed enrichment (Supplementary Figure 
S2-1).  
  
Figure 2-1. Convergent Functional Genomics. Schematic for 
Alcoholism study. 
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Figure 2-2. Top candidate genes for alcoholism. 
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Biological pathways and drug targets 
Pathway analyses were carried out on the top candidate genes (Table 2-3). 
Notably, Gαi signaling, cocaine addiction, and transmission of nerve impulses, were 
the top biological pathways in alcoholism, which may be informative for treatments 
and drug discovery efforts by pharmaceutical companies. Of note, these top 
candidate genes were identified and prioritized only for evidence for alcoholism 
prior to pathway analyses, so the overlap with cocaine addiction is a completely 
independent result, suggesting a shared drive and neurobiology. Consistent with 
that, two of  our 135 top candidate genes for alcoholism (CPE and VWF) had SNPs 
with p<10-5 in a recent GWAS of cocaine addiction158. 
      Some of the top alcohol candidate genes have prior evidence of being 
modulated by the omega-3 fatty acid DHA in our DBP mouse animal model (Tables 
2-2 and S2-1). That is of particular interest, as we have previously shown that 
treatment with the omega-3 fatty acid docosahexaenoic acid (DHA) decreased 
alcohol consumption in that animal model, as well as in another independent 
animal model, the alcohol preferring P rats65. Omega-3 fatty acids, particularly 
DHA, have been described to have alcoholism, mood, psychosis, and suicide 
modulating properties, in preclinical models as well as some human clinical trials 
and epidemiological studies. For example, deficits in omega-3 fatty acids have 
been linked to increased depression and aggression in animal models 159,160  and 
humans 161,162. DHA prevents ethanol damage in vitro in rat hippocampal slices163. 
Omega-3 supplementation can prevent oxidative damage caused by prenatal 
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alcohol exposure in rats164.  Of note, deficits in DHA have been reported in 
erythrocytes165 and in the postmortem orbitofrontal cortex of patients with bipolar 
disorder, and were  
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Table 2-3. Pathway Analyses. Pathway Analyses of top candidate genes. 
A. Biological Pathways. B. Disease and Disorders.   
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B. Ingenuity GeneGO 
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greater in those that had high vs. those that had low alcohol abuse 166. Low DHA 
levels may be a risk factor for suicide 167,168. Omega-3 fatty acids have been 
reported to be clinically useful in the treatment of both mood169 170 171,172 and 
psychotic disorders 173 174 175. 
Other existing pharmacological drugs that modulate alcohol candidate 
genes identified by us include, besides benzodiazepines, dopaminergic agents, 
glutamatergic agents, serotonergic agents, as well as statins (Table S2-3). 
Genetic risk prediction score (GRPS) 
       Once the genes involved in a disorder are identified, and prioritized for 
likelihood of involvement, then an obvious next step is developing a way of 
applying that knowledge to genetic testing of individuals to determine risk for the 
disorder. Based on our identification of top candidate genes described above using 
CFG, we pursued a polygenic panel approach, with digitized binary scoring for 
presence or absence, similar to the one we have devised and used in the past for 
biomarkers testing 29,176 and for genetic testing in bipolar disorder 29 and 
schizophrenia 31 . Somewhat similar approaches but without CFG prioritization, 
attempted by other groups, have been either unsuccessful177 or have required very 
large panels of markers178. 
       We chose all the nominally significant p-value SNPs (p<0.05) in each of our 
top CFG prioritized genes (n=135 with CFG score>=8) (Table S2-1) in the GWAS1 
data set used for discovery, and assembled a GRPS-135 panel out of those SNPs 
(Table 2-4). We then tested the GRPS-135 in the independent German test cohort 
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2, based on the presence or absence of the alleles of the SNPs associated with the 
illness, comparing the alcoholic subjects to controls (Table 2-4), and showed that, 
while there was a trend, we were not able to distinguish alcoholics from controls 
in both independent test cohorts.   
       We then prioritized a smaller panel of 11 genes (Table 2-2) out of this larger 
panel, by using as a cross-validator the top genes from a stress-reactive mouse 
animal model for alcoholism, the DBP knock-out mouse58 (Figure 2-3). The small 
panel (GRPS-11) showed more robust results than the larger panel (Table 2-4), 
suggesting that it captures key behaviorally-relevant genes. 
 
  
Table 2-4. Genetic Risk Prediction Score (GRPS)- Panels from 
Discovery Cohort 1. Differentiation between alcoholics and controls in three 
independent test cohorts using : GRPS-135,  a panel composed of all the 
nominally significant SNPs from GWAS1 in the top candidate genes prioritized by 
Convergent Functional Genomics (CFG); GRPS-11,  a panel additionally 
prioritized by a stress-reactive  animal model for alcoholism, the DBP KO stressed 
mouse; and GRPS-SNCA, the top candidate gene from our analyses.  P-values 
depict one-tailed t-test results between alcoholics and controls. 
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Test  
in Cohort 2 
Alcohol Dependent vs. 
Control 
GRPS-135 
Genes with CFG  score of >=8   
all nominally significant SNPs in each 
gene (n=713) 
P=0.053 
(135 genes, 713 SNPs) 
GRPS-11 
Top  animal model (DBP mouse) prioritized 
genes 
out of genes with CFG score of >=8   
all nominally significant SNPs in each 
gene (n=66) 
  
P= 0.041 
(11 genes, 66 SNPs) 
  
  
Test  
in Cohort 3 
Alcohol Dependent vs. 
Control 
GRPS-11 
Top  animal model (DBP mouse) prioritized 
genes 
out of genes with CFG score of >=8   
P=0.00012 
(10 genes, 34 SNPs present)  
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all nominally significant SNPs in each gene 
(n=66) 
GRPS-SNCA 
Top CFG gene 
all nominally significant SNPs in it (n=4) 
P= 0.000013 
(1 gene, 1 SNP rs17015888 
present) 
  
Test  
in Cohort 4 
Alcohol Abuse vs. Control 
GRPS-11 
Top  animal model (DBP mouse) prioritized 
genes 
out of genes with CFG score of >=8   
all nominally significant SNPs in each gene 
(n=66) 
P=0.0094 
 (10 genes, 34 SNPs present)  
GRPS-SNCA 
Top CFG gene 
all nominally significant SNPs in it (n=4) 
P= 0.023 
(1 genes, 1 SNP rs17015888 
present) 
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Discussion 
       Our CFG approach helped prioritize a very rich in signal and biologically 
interesting set of genes (Tables 2-2 and S2-1). Some, such as SNCA, CPE, DRD2 
and GRM3, have weaker evidence based on the GWAS data but strong 
independent evidence in terms of gene expression studies and other prior human 
or animal genetic work. Conversely, some of the top previous genetic findings in 
the field 179, such as ADH1C 180 (CFG score of 9), GABRA2 181 (CFG score of 8), as 
well as AUTS2 (CFG score of 7), CHRM2 and KCNJ6 (CFG scores of 4) have fewer 
different independent lines of evidence, and thus received a lower CFG 
prioritization score in our analysis (Table S2-1), although they are clearly involved 
in alcoholism-related processes.  While we cannot exclude that more recently 
discovered genes have had less hypothesis driven work done and thus might score 
lower on CFG, it is to be noted that the CFG approach integrates predominantly 
non-hypothesis driven, discovery-type datasets, such as GWAS data, linkage, 
quantitative traits loci, and particularly, gene expression. We also cap each line of 
evidence from an experimental approach (Figure 2-1), to minimize any ‘popularity’ 
bias, whereas multiple studies of the same kind are conducted on better-
established genes. In the end, it is gene-level reproducibility across multiple 
approaches and platforms that is built into the approach and gets prioritized most 
by CFG scoring during the discovery process. Our top results subsequently show 
good reproducibility and predictive ability in independent cohort testing, the litmus 
test for any such work. 
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       At the very top of our list of candidate genes for alcoholism, with a CFG 
score of 13, we have SNCA (synuclein alpha),  a pre-synaptic chaperone that has 
been reported to be involved in modulating brain plasticity and neurogenesis, as 
well as neurotransmission, primarily as a brake 182, 183. On the pathological side, 
low levels of SNCA might offer less protection against oxidative stress 184, while 
high levels of SNCA may play a role in neurodegenerative diseases, including in 
Parkinson Disease (PD). SNCA has been identified as a susceptibility gene for 
alcohol cravings 114 and response to alcohol cues 185.  The evidence provided by 
our data and other previous human genetic association studies suggest a genetic 
rather than purely environmental (alcohol consumption, stress) basis for its 
alteration in disease, and its potential utility as trait rather than purely state 
marker.  
Alcoholics carry a genetic variant that leads to reduced baseline expression 
of SNCA (Janeczek et al. 2012). SNCA is also downregulated in expression in the 
frontal cortex and caudate-putamen of inbred alcohol preferring rats 124, as well 
as in the brain (amygdala) and blood of our stress-reactive DBP animal model of 
alcoholism, prior to exposure to any alcohol. SNCA is upregulated in expression in 
blood in human alcoholism 119,120, as well as in the blood of monkeys consuming 
alcohol, and in rats after alcohol administration (Rodd, Bertsch et al. 2007). Thus, 
it may serve as a blood biomarker. Overall, we may infer that, while low levels of 
SNCA may predispose to cravings for alcohol and consequent alcoholism, possibly 
mediated through increased neurobiological activity and drive (the SNCA deficit 
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hypothesis), excessive alcohol consumption then increases SNCA expression 
beyond that seen in non-alcohol consuming controls, potentially compounding risk 
for neurodegenerative diseases in individuals that have mutations that lead to its 
aggregation. This observation is also biologically consistent with the fact that 
dementia is often observed late in the course of alcohol dependence. 
       GFAP (glial fibrillary acidic protein), a top candidate gene with a CFG score 
of 9.5, is an astrocyte intermediate filament-type protein involved in neuron-
astrocyte interactions, cell adhesion, process formation and cell-cell 
communication. It is decreased in expression in postmortem brain of alcoholics, 
but increased in expression in brains of animal models of predisposition to 
alcoholism, prior to exposure to alcohol (Table 2-2). This is consistent with a model 
for increased physiological robustness in individuals predisposed to alcoholism 22, 
as well as with the neurodegenerative consequences of protracted alcohol use.   
       DRD2 (dopamine receptor D2), another top candidate gene with a CFG 
score of 9, has prior human genetic association evidence. It is reduced in 
expression in the frontal cortex in human brain from alcoholics, as well as in the 
DBP animal model prior to any exposure to alcohol. One possible interpretation 
would be that lower levels of dopamine receptors are associated with reduced 
dopaminergic signaling and anhedonia, leading individuals to overcompensate by 
alcohol and drug abuse. Another interpretation, consistent with the low SNCA and 
consequently higher neurotransmitter (including dopamine) levels, would be that 
these individuals are in fact in a compulsive, hyperdopaminergic state, which drives 
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them to hedonic activities and leads to compensatory homeostatic downregulation 
of their DRD2 receptors. Consistent with this later scenario, mice that have a 
constitutive knock-out of their DRD2 receptors, not due to a hyperdopaminergic 
state, in fact consume less alcohol136, unless they are exposed to stress186. 
       Another top candidate gene, GRM3, is also involved in neurotransmitter 
signaling. Prior evidence in the field had implicated another metabotropic 
glutamate receptor, GRM2 187. 
       Other top candidate genes in the panel (MOBP, MBP, MOG) are involved in 
myelination (Table 2-2). They are decreased in expression in the pre-frontal cortex 
of human alcoholics, as well as in our stress-reactive DBP animal model of 
alcoholism, prior to exposure to any alcohol. Decreased myelination may lead to 
decreased connectivity. Interestingly, MOBP and MBP are increased in expression 
in the amygdala in the DBP mice, opposite to the direction of change in the PFC, 
consistent with a frontal deactivation and a limbic hyperactivity, which could lead 
to impulsivity.       
Epistasis testing of top candidate genes for alcoholism.   
       For the top 11 candidate genes, best p-value SNPs from GWAS1 were used 
to test for gene-gene interactions in GWAS2 (Table S2-5).  Nominally significant 
interactions were found between SNPs in SNCA and RXRG, DRD2 and SYT1, MOBP 
and TIMP2. As a caveat, the p-value was not corrected for multiple comparisons. 
The corresponding genes merit future follow-up work to elucidate the biological 
and pathophysiological relevance of their interactions.   
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Pathways and mechanisms  
       Our pathway analyses (Tables 2-3 and S2-2) results are consistent with the 
accumulating evidence about the role of  neuronal excitability and signaling in 
alcoholism188,189 178. 
Overlap with other psychiatric disorders 
       Despite using lines of evidence for our CFG approach that have to do only 
with alcoholism, the list of genes identified has a notable overlap at a pathway 
analysis level ( Tables 2B-2   and S2B-2.) and at a gene level (Figures 2-4 and 2-
5) with other psychiatric disorders. This is a topic of major interest and debate in 
the field. We demonstrate an overlap between top candidate genes for alcoholism 
and top candidate genes for schizophrenia, anxiety and bipolar disorder, previously 
identified by us through CFG (Figure 2-4), thus providing a possible molecular basis 
for the frequently observed clinical co-morbidity and interdependence between 
alcoholism and those other major psychiatric disorders, as well as cross-utility of 
pharmacological agents.  Moreover, we tested in alcoholics genetic risk predictive 
panels for bipolar disorder 29 and for schizophrenia 31 generated in previous studies 
by us, and show that they are significantly different in alcoholics vs. controls 
(Figure 2-6), beyond the overlap in genes with alcohol. There seems to be an 
increased genetic load for bipolar disorder, consistent with increased drive, and a 
decreased genetic load for schizophrenia, consistent with increased connectivity 
prior to alcohol use. These results led us to develop a heuristic, testable model of 
alcoholism (Figure 2-5). Some people may drink to be calm- mitigating the effects 
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of stress and anxiety, some people may drink to be happy- the common drive with 
bipolar disorder,  
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and some people may drink to be drunk- to disconnect from reality and/or get 
unstuck from internal obsessions and ruminations. 
Genetic risk prediction 
Of note, our SNP panels and choice of affected alleles were based solely on 
analysis of the discovery GWAS, completely independently from the test cohorts. 
Our results show that a relatively limited and well-defined panel of SNPs identified 
based on our CFG analysis could differentiate between alcoholism subjects and 
controls in three independent cohorts. The fact that our genetic testing worked for 
Figure 2-3. Genetic Risk Prediction using a panel of top candidate 
genes for alcoholism (GRPS-11). Testing in independent cohorts 3 and 4. 
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both alcohol dependence and alcohol abuse suggests that these two diagnostic 
categories are actually overlapping, supporting the DSM-V reclassification of a 
single category of alcohol use disorders. 
Reproducibility among studies 
       Our work provides striking evidence for the advantages, reproducibility and 
consistency of gene-level analyses of data, as opposed to SNP level analyses, 
pointing to the fundamental issue of genetic heterogeneity at a SNP level. In fact, 
it may be that the more biologically important a gene is for higher mental 
functions, the more heterogeneity it has at a SNP level and the more evolutionary 
divergence, for adaptive reasons. On top of that, CFG provides a way to prioritize 
genes based on disease relevance, not study-specific effects (that is, fit-to-disease 
as opposed to fit-to-cohort). Reproducibility of findings across different studies, 
experimental paradigms and technical platforms is deemed more important (and 
scored as such by CFG) than the strength of finding in an individual study (for 
example, P-value in a GWAS).  
Potential limitations and confounds 
       The GWAS study (cohort 1) on which our discovery was based contained 
males as probands, but contained males and females as controls. This was the 
case for the German test cohort (cohort 2) as well. It is possible that some of the 
nominally significant SNPs identified in the discovery GWAS have to do with gender 
differences rather than to alcoholism per se, or at least may have to do with male 
alcoholism. Stratification across gender and ethnicities may also be a factor in our 
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test cohorts 3 and 4 (Table 2-1). The issue of possible ethnicity differences in 
alleles, genes, and the consequent neurobiology may need to be explored more in 
the future, with larger 
 
 
 
sample sizes, and with environmental and cultural factors taken into account.   
However, the use of a CFG approach using evidence from other studies of 
alcoholism, including animal model studies, to prioritize the findings decreases the 
likelihood that our final top results are ethnicity or gender related. Of note, our 
GRPS predictions separate alcoholics from controls in independent test cohorts, in 
both genders, and in fact work even better at separating female alcoholics from 
female controls (Figure 2-3). Moreover, a series of individual genes from the panel, 
Figure 2-4. Overlap of alcoholism versus other major psychiatric disorders. 
Top candidate genes for alcoholism identified by CFG (n=135) in the current 
study versus top candidate genes for other psychiatric disorders and a stress-
driven animal model of alcoholism (DBP knockout mouse) from our previous 
work. 
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not just SNCA, separate alcoholics from controls in independent cohorts (Table 2-
5).    
 
 
 
  
Figure 2-5. Mindscape (mental landscape)-dimensional view of genes 
that may be involved in alcoholism and other major psychiatric disorders. 
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Figure 2-6. Genetic load for bipolar disorder and schizophrenia in 
alcoholism. A total of 34 out of 66 SNPs in our alcohol GRPS-11 panel 
(current work; in n =10 genes), 42 out of 224 SNPs in our bipolar 
GRPS53 (in n =34 genes) and 151 out of 542 SNPs in our schizophrenia 
GRPS54 (in n =35 genes) were present and tested in the alcohol cohorts 
3 and 4. See also Supplementary Table S7. 
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A.  
Test  Cohort  2 
 Mean GRPS t-test  
Gene/ 
SNPs 
CFG 
Score 
Control 
(n=861) 
Alcohol 
Dependence 
Cohort 2 
(n=740) 
 
Panel of 11 top genes 66 snps >=8 53.98 54.61 0.041 
SNCA 
rs7668883 
rs17015888 
rs17015982 
rs6532183 
13 93.93 92.84 0.086 
GFAP 
rs3744473 
rs3169733 
rs736866 
rs744281 
9.5 63.99 64.69 0.303 
DRD2 9 13.07 15.51 0.024 
Table 2-5. Individual top genes and genetic risk prediction in 
independent cohorts.  A. Cohort 2. B. Cohorts 3 and 4. Italic- nominally 
significant, bold italic- survived Bonferroni correction. 
 
162 
 
 
rs4648317 
rs4938019 
GRM3 
rs17160519 
rs6944937 
rs13236080 
rs17315854 
rs12668989 
rs41440 
rs2373124 
rs13222675 
rs2708553 
rs12673599 
rs4236502 
rs1554888 
rs10499898 
rs1527769 
rs17161018) 
9 55.44 54.94 0.271 
MBP 
rs470131 
rs2282566 
rs736421 
8.5 44.92 47.07 0.002 
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rs1789094 
rs9951586 
rs1667952 
rs1789105 
rs1789103 
rs1812680 
rs1789139 
rs4890912 
rs9947485 
rs1562771 
rs1015820 
rs1124941 
rs11877526 
MOBP 
rs562545 
rs2233204 
8.5 49.88 49.93 0.487 
GNAI1 
rs4731111 
rs6466884 
rs7803811 
rs17802148 
rs7805663 
8 72.97 72.71 0.393 
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rs10486920 
rs2523189 
rs2886611 
rs2886609 
rs12706724 
rs4731302 
MOG 
rs3117292 
rs2747442 
rs3117294 
8 34.53 34.56 0.493 
RXRG 
rs10800098 
8 6.04 5.27 0.174 
SYT1 
rs1569033 
rs10735416 
rs1245810 
rs1245819 
rs1268463 
rs1245840 
rs10861755 
8 39.16 40.89 0.113 
TIMP2 
rs7502935 
8 67.65 70.61 0.038 
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B. Test 
cohorts  
         3 and 4 
 
Mean GRPS t-test  
Gene/ 
SNPs 
CFG 
Scor
e 
Control 
(n=126
1) 
Alcohol 
Dependen
ce Cohort 
3 
(n=2768) 
Alcoho
l 
Abuse 
Cohort 
4 
(n=60
0) 
Alcohol 
Dependen
ce Cohort 
3 
 
Alcoh
ol 
Abuse 
Cohor
t 4 
 
Panel of 10 
top genes 
34 snps 
>=8 47.58 48.51 48.49 0.00012 0.0094 
SNCA 
rs17015888 13 72.28 76.96 75.58 0.000013 0.023 
GFAP 
rs3169733 
rs736866 9.5 58.92 60.38 60.17 0.042 0.158 
DRD2 
rs4648317 9 15.38 14.92 15.61 0.293 0.429 
GRM3 9 35.13 37.38 35.55 0.000061 0.309 
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rs17160519 
rs6944937 
rs17315854 
rs4236502 
MBP 
rs470131 
rs2282566 
rs736421 
rs1789094 
rs9951586 
rs1789103 
rs4890912 
rs9947485 
rs1124941 8.5 47.23 48.01 48.31 0.0443 0.059 
MOBP 
rs562545 
rs2233204 8.5 50.28 50.80 50.75 0.233 0.337 
GNAI1 
rs4731111 
rs6466884 
rs17802148 
rs10486920 8 61.58 63.03 62.87 0.006435 0.072 
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rs2523189 
rs2886611 
rs2886609 
MOG 
rs3117292 
rs2747442 
rs3117294 8 48.78 46.44 46.08 0.020216 0.056 
RXRG 
rs10800098 8 2.62 3.42 3.33 0.024279 0.126 
SYT1 
rs1569033 
rs1245819 
rs1268463 
rs10861755 8 41.56 42.48 44.25 0.11474 0.0087 
       The conversion from SNPs to genes as part of our discovery assumed the 
rule of proximity, i.e. an intragenic SNP implicates the gene inside which it falls, or 
if it falls into an intergenic region, it implicates the most proximal gene to it. That 
may not be true in reality in all cases, generating potentially false positives and 
false negatives. However, the convergent approach and focus on the top CFG 
scoring genes reduces the likelihood of false positives. 
       The only SNP for SNCA that was present/tested for in cohorts 3 and 4 
(rs17015888) was relatively far away upstream (0.13 MB) from SNCA. However, 
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no other known genes are present in that region, SNCA is the closest gene, and 
the distance is well within range of known examples of regulatory regions 
(enhancers). Additionally, the risk allele for this SNP (G/G) seems to be the major 
variant in the population (Table S2-6), suggesting that this allele per se is 
evolutionarily advantageous, when not coupled with the exogenous ingestion of 
alcohol.   
       A relatively large list of genes (n= 6085) was implicated by nominally 
significant SNPs from the discovery GWAS. There is a risk that out of such a large 
list, CFG will find something to prioritize. We have tried to mitigate that by 
developing an internal score for each gene based on the proportion of SNPs tested 
in a gene that were nominally significant. Also, in the end, we tested the 
reproducibility and predictive ability of our top findings in multiple independent 
cohorts, which is the ultimate litmus test for any genetic or biomarker study.  
Conclusion 
       Overall, while multiple mechanistic entry points may contribute to 
alcoholism pathogenesis, it is likely at its core a disease of an exogenous agent 
(alcohol) modulating different mind domains/dimensions (anxiety, mood, 
cognition)84,  precipitated by environmental stress on a background of genetic 
vulnerability (Figure 2-4). The degree to which various mind domains/dimensions 
are affected in different individuals is a fertile area for future research into 
subtypes of alcoholism, and lends itself to personalization of diagnosis and 
treatment, by integrating genetic data, blood gene expression biomarker data, and 
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clinical data. Lastly, it is important to note that individuals with a predisposition to 
alcoholism but no exposure to alcohol may in fact have a robust physiology and 
strong neurobiological drive that can be harnessed for other, more productive 
endeavors.  
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Chapter 3:  Focus on Suicide 
Historically, suicidal behavior, defined as a self-initiated sequence of 
behaviors by an individual who, at the time of initiation, expected that the set of 
actions would lead to his or her own death, has been considered a symptom of 
various psychiatric disorders such as Major Depressive Disorder (MDD) and 
Borderline Personality Disorder (BPD), rather than a distinct diagnostic entity. 
However, in advance of the publication of DSM V in May 2013, many clinicians and 
researchers advocated for the inclusion of suicidal behavior as an independent 
diagnosis.  190   
These individuals argued that while suicidal behavior occurs in the context 
of psychiatric conditions, this is not invariably the case. 10% of those who 
complete suicide in the United States have no identifiable psychiatric disorder and 
this number is estimated to be as high as 37% of suicide completers in China. 
Furthermore, even among disorders associated with a high risk for suicide the 
majority of those affected do not commit suicide.  For example, only 29% of 
individuals with Bipolar Disorder (BD) report a lifetime history of suicidal behavior. 
Thus, the vast majority of those afflicted with disease do not engage in this 
behavior over the course of their lifespan.  Consequently, it has been postulated 
that suicidal behavior should be considered a co-morbid condition of MDD, BPD as 
opposed to diagnostic criteria of these conditions.  Finally, to include suicidal 
behavior as a symptom of MDD and BPD exclusively implies that this is not of 
central concern in the management of schizophrenia, post-traumatic stress 
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disorder (PTSD), and substance use disorders (SUD) which do not include suicidal 
behavior as diagnostic criteria, but nonetheless are associated with increased risk 
for suicide. 190  Ultimately, “Suicidal Behavior Disorder” was included in the 
“Conditions for Further Study” section of the DSM V as an independent diagnosis 
and for the purposes of this review will be considered as such while continuing to 
acknowledge the highly co-morbid nature of this behavioral phenotype. 
Epidemiology 
Per the most recent World Health Organization, suicide is the second 
leading cause of death amongst 18-29 year olds worldwide (tenth across all age 
groups) and results in 800,000 deaths yearly, the equivalent of one death every 
40 seconds191 .  The age adjusted suicide rate in 2014 was 13.0 people per 100,000 
in the general population, 192 while the suicide rate may be substantially higher in 
patients suffering from mental disorders.   193  The WHO estimates that global 
annual suicide fatalities could rise to 1.5 million by 2020. Suicide attempts are 
estimated to be approximately 20-25 times more frequent than completed 
suicides, which conservatively equates to 16 million attempts yearly.  
In addition to age and gender disparities in rate of suicide, ethnic 
differences also exist. The highest U.S. suicide rate was among Whites and the 
second highest rate was among American Indians and Alaska Natives. Lower and 
similar rates were found among Hispanics, Asians and Pacific Islanders, and Blacks. 
194 
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Suicide via firearm, poisoning, and suffocation account for over 90% of 
suicide deaths in the United States.  49.9% of deaths are due to self-inflicted 
gunshot wounds, while 26.7% and 15.9% of suicides are a result of suffocation 
and poisoning respectively.  194   
Clinical Risk Assessment Scales 
Columbia-Suicide Severity Rating Scale (C-SSRS)  
The C-SSRS is a current gold standard for assessment of suicidal ideation 
and behavior in clinical trials and was designed based on research into aspects of 
past suicidal ideation and behavior that predict the future risk of suicidal behavior.   
195  
Convergent Functional Information for Suicide (CFI-S) 
The CFI-S is new a 22 item scale and Android app containing known risk 
factors for suicidal behavior which, in a simple binary fashion (yes =1, no =1), 
integrates information about clinical history, mental and physical health, addictions 
and cultural factors without explicitly querying suicidal ideation.  Positive responses 
are summed and then divided by the number of responses, a simple average, 
yielding a risk score between 0 and 1.  This measure can be scored from a medical 
chart or an interview with a patient or family member.  The scale has shown 
predictive validity for suicidal ideation and future hospitalizations due to suicidal 
behavior.  196 197  The scale has been used posthumously in interviews of next of 
kin to evaluate suicide completers and is receiving ongoing validation in emergency 
room settings.   
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Hamilton Depression Rating Scale (HDRS) and Clinical Interview 
for Depression 
The HDRS has been a gold standard measure for depression, first developed 
in the late 50s to assess the effectiveness of early anti-depressants.  While 
depression itself can be considered a risk factor for suicide a plurality of those who 
experience it will not attempt suicide or experience suicidal ideation.  Though 
lacking in specificity, scales like the HDRS may provide clinically meaningful context 
to the identification of suicide risk.  In addition, where a scale like the HDRS may 
be particularly useful is in the pragmatic sense that it has widespread usage and 
contains an item that does specifically assess suicidal thoughts and behaviors.   
Treatment 
As discussed in the introduction, suicidal behavior has traditionally been 
considered a result of an underlying psychiatric condition that if treated 
appropriately will lead to reduced risk of suicide in the future.  However, the unique 
genetic, epidemiologic, molecular, and neurobiological data presented in this 
review and elsewhere suggest that the pathophysiology of this behavior is distinct 
from the conditions it presents most commonly with. Thus while treatment of any 
comorbid psychiatric disturbances should be initiated promptly, it is important to 
highlight the pharmacologic, biological, and psychotherapeutic treatment 
modalities that have been demonstrated to be the most effective in addressing the 
unique pathophysiology of suicidal behavior, independent of their effects on any 
co-morbid conditions.   
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Lithium 
Lithium was approved by FDA for treatment of manic episodes in bipolar 
disorder in 1974 and remains widely used for this indication. It is also used off 
label for treatment of bipolar depression and adjunctive treatment of unipolar 
depression. The anti-suicidal properties of lithium were first observed in the 1970’s, 
and several studies in 1980’s and 90’s demonstrated decreased risk for suicidality 
in those with affective disorders, including independent studies both showing a 6-
fold decrease in incidence of suicide attempts.  
 The first study to provide evidence that lithium’s anti-suicidal properties 
are independent of its mood stabilization effect was published in 2001 by Conell 
et al. 198  This group investigated 33 patients with affective disorders who went 
through periods of discontinuation with lithium. They observed that those who had 
discontinued had poorer response relative to mood stabilization upon resuming 
lithium but the antisuicidal effects were unchanged by periods of discontinuation. 
Similarly, Ahrens and Müller-Oerlinghausen et. al 199, found a reduction in suicide 
attempts not only in the excellent lithium responders but also among patients with 
a moderate to poor response to lithium. An investigation of 12,662 Medicaid 
patients and demonstrated that lithium-treated bipolar patients had the lowest 
number of suicide attempts compared to patients treated with other 
mood stabilizers.  200  These results suggest that lithium can reduce the incidence 
of suicidality independent of its mood stabilization effects  and that mood 
stabilization effects are not required for resolution of suicidality further suggesting 
175 
 
 
a unique neurobiology of suicidal behavior distinct from that of comorbid affective 
disorders. 201 
Clozapine  
Clozapine is an atypical antipsychotic for the treatment of schizophrenia 
available since the 1960’s. In December of 2002, based on data published from 
the International Suicide Prevention Trial, clozapine became the first medication 
FDA approved for the treatment of suicidality in schizophrenia.   In this study 
clozapine reduced risk of suicide attempts by 25% when compared to the second 
generation antipsychotic, olanzapine .  Similar to lithium, clozapine’s antisuicide 
effects have been demonstrated to be independent of its effect on any other 
psychiatric symptoms. In the case of clozapine, risk for suicidal behavior decreased 
independently of its antipsychotic action . Despite clozapine’s effect on suicidal 
behavior and potent antipsychotic action it remains under prescribed compared to 
other antipsychotic medications.  The risk for agranulocytosis, which requires 
weekly white blood cell monitoring for the first six months of treatment, as well as 
myocarditis and seizures likely contributes to its relative under prescribing.   Still, 
the potential benefits of reducing suicide risk may be worth this risk.  202   
Ketamine 
Ketamine, known by its street name of “Special K”, ketamine is an NMDA-
receptor antagonist with potential as a treatment for mood, anxiety, and suicidal 
behavior has received significant attention in recent years as a result of its potential 
to rapidly treat mood symptoms and suicidality. Trials have shown it to have 
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promising anxiolytic and antidepressant properties.  203  In a small 2016 study of 
14 subjects, repeated doses of open-label ketamine rapidly and robustly decreased 
suicidal ideation in pharmacologically treated outpatients with treatment-resistant 
depression with stable suicidal thoughts; this decrease was maintained for at least 
3 months following the final ketamine infusion in 2 patients.  Weaknesses to the 
existing literature include the small sample sizes of the studies and the exclusion 
of patients with significant suicidality at baseline from several of the studies. The 
evidence supporting the clinical use of ketamine for suicidality is certainly 
preliminary, but appears to be a promising therapeutic option worthy of further 
controlled trials to allow for meaningful clinical recommendations.  204     
Anti-depressants  
Association of anti-depressants with suicidal behavior has been 
controversial.  SSRI medications have been shown to increase experiences of 
suicidal ideation and behavior when compared to placebo.  In May 2003, British 
pharmaceutical company GlaxoSmithKline submitted an analysis demonstrating a 
statistically significant increase in suicide-related adverse events in pediatric trials 
of the anti-depressant paroxetine compared to placebo.  These findings prompted 
the FDA to review the risk for emergent suicidal behavior with administration of 
nine antidepressant medications used in pediatric populations.  The studied drugs 
included fluoxetine, sertraline, paroxetine, fluvoxamine, citalopram, bupropion, 
venlafaxine, nefazodone, and mirtazapine. 205  
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A meta-analyses of 372 randomized clinical trials of these antidepressants 
involving nearly 100,000 participants, demonstrated that the rate of suicidal 
thinking or suicidal behavior was 4% among patients assigned to receive an 
antidepressant, as compared with 2% among those assigned to receive placebo.  
Further analysis of this data demonstrated that this increased risk was only 
statistically significant among children and adolescents under the age of 18. 
Conversely, there was no evidence of increased suicidality in adults 24 years and 
older and a “clear protective effect” against the emergence of suicidal behavior in 
adults 65 years and older.   206  Thus while the appropriate treatment of any 
comorbid affective or anxiety disorders should include consideration of the 
initiation of SSRI’s, SNRI’s, or bupropion it is important to be aware the potential 
risk for exacerbation of suicidality in children and adolescents and that only in the 
geriatric population does antidepressant therapy appear to demonstrate a 
significant protective effect against future suicidality. 
Omega 3 Fatty Acids 
Low docosahexaenoic acid (DHA), has been shown to be associated with 
increased risk of suicide in the military. 207  DHA is the most abundant omega-3 
fatty acid found in the brain, making up 10-20% of total fatty acids.  The primary 
source of DHA is in the diet, with the largest quantity found in cold water fish.  
DHA supplementation promotes neurite outgrowth.  208  Prenatal DHA deficiencies 
increase learning and memory deficits in rodents, but this effect may be reversible 
with supplementation.  209  A small study has found that supplementation with 
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DHA along with additional essential omega-3 fatty acid eicosapentaenoic acid 
(EPA) was able to reduce surrogate markers of suicidal behavior.  210 
Psychotherapeutics 
Cognitive Behavioral therapy developed by Aaron Beck in the 1970’s is a 
therapeutic technique which focuses on the development of personal coping 
strategies to solve current problems and change unhelpful patterns in cognitions 
(e.g., thoughts, beliefs, and attitudes), behaviors, and emotional regulation .  211 
It was originally designed to treat depression, and is now used for a number of 
mental health conditions. A Cochrane review examining over 17,000 patients and 
55 trials demonstrated CBT’s efficacy in reducing the risk for future self-harm in 
individuals who had previously engaged in self-harm. 
 This review also examined the effect of Dialectical Behavior Therapy (DBT) 
on reduction of future self-harm in individuals with Borderline Personality Disorder. 
DBT works towards helping people increase their emotional and cognitive 
regulation by learning about the triggers that lead to reactive states and helping 
to assess which coping skills to apply in the sequence of events, thoughts, feelings, 
and behaviors to help avoid undesired reactions.  212 The authors of the Cochrane 
review concluded that DBT may lead to a reduction in frequency of self-harm in 
“people with multiple episodes of SH/probable personality disorder”. 213 
Biological Therapies 
Both Electroconvulsive therapy (ECT) and more recently Transmagnetic 
Cranial Stimulation (TMS) have been proposed as alternatives to rapidly and safely 
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reduce risk for suicidal behavior. A randomized clinical trial comparing ECT and 
TMS (n = 73) found that ECT reduced depressive symptoms and suicidal ideation 
scores more rapidly and effectively than rTMS. Both objective (Hamilton Rating 
Scale for Depression) and subjective (Beck Depression Inventory) ratings of 
suicidal ideation were dramatically reduced after ECT, but only slightly with rTMS. 
214  ECT may also be more effective than traditional antidepressant therapy in 
reducing suicidality. A 2003 study in which suicidal behavior was assessed in the 
6 months after the treatment of depression in 519 patients demonstrated 0.8% 
rate of suicide attempts  of the ECT-treated patients compared to 4.2% of those 
who had received “adequate” and 7% of those offered “inadequate” 
antidepressant medication treatment  215 
Etiology/genetics 
Suicidal behavior encompasses a range of thoughts and acts centered on 
the act of intentionally ending one’s own life.  The causes can be very diverse, 
from long lasting psychological or physical pain to sudden traumatic events.  It can 
be very difficult to detect.  A patient may not want to admit to suicidal thoughts 
or feelings for fear of how others will judge them.  They may not want to burden 
others with their problems.  Still others, with a strong desire to commit suicide, 
may fear being thwarted in their attempt.   
It is important to keep in mind that while we are talking about suicidal 
behaviors as singular outcome they may be the result of very distinctly different 
underlying and preceding pathology.  A patient suffering from severe physical or 
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psychological pain may come to a very well thought out plan of action in what 
might be considered a ‘cold’ premeditated suicide attempt.  Conversely, Impulsive 
rage or sudden grief could trigger could trigger a sudden and violent ‘hot’ suicide 
attempt.  Command hallucinations could precipitate an attempt.  An anecdotal 
feature found in a suicide note may imply a feeling of burden and guilt over causing 
hardship to others, which might be the more the result of delusion then a true 
assessment of the situation.  These concepts have overlapping features with 
psychiatric disorders and may reveal subtle yet essential underlying subtypes of 
suicidal behavior.  Many possible paths converge on a similar outcome, and 
addressing the path may forestall the outcome.  
Paths to Pathology 
A challenge in identifying suicide is the limitation to superficial observations 
that can be made of a patient. Internal and unobservable motivations often drive 
the observable suicidal behaviors we wish to prevent.  Clinicians need to be 
perceptive of outward signs of risk and judicious with the use of objective tools 
such as clinical risk assessment scales and the emerging field of biomarkers.   
Some of the known demographic factors (described above in epidemiology) 
that inform suicide risk, such a previous suicide attempts or presence of mental 
illness such as depression, are particularly informative.  Other phenotypes have 
been shown to be associated more frequently with suicide attempts by those who 
meant to die.  Assessment of feelings of emptiness or loneliness, hopelessness, 
and disconnection may indicate increased risk of suicide. 216  Visual analog scales 
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for mood and anxiety may also predict suicidal ideation or attempts.  217 196 197  
The use of a synthesis of emotional and environmental intermediate phenotypes 
may give further evidence of suicidal risk. 
The Biology of Suicide 
A controversial subject, suicide may be a uniquely human characteristic.  
There is presently no animal model for suicidal behavior, and reports of this 
behavior in nonhuman animals are anecdotal and inconclusive, often calling on 
urban myth (lemmings leaping off of cliffs en masse) or behaviors which may not 
accurately fit the definition of suicide.  For example, a honey bee must sacrifice 
itself to use its barbed stinger in defense of the hive, but the action of the bee is 
‘motivated’ by defending the hive, not the intentional act of ending its life.  Another 
example comes from various forms of parasite which makes the target organism 
engage in risky behavior.  A rat infected with toxoplasma gondii will lose its 
instinctual aversion to cat urine and instead be attracted to it.  This greatly 
increases the risk of being preyed upon by cats.  While the neurobiology of this 
induced elevation in risky behavior could be relevant and interesting in the study 
of human suicide, the actual ‘intent’ comes from the toxoplasma gondii to complete 
its life cycle in the cat, not a ‘desire’ of the rat to end its own life. 
On the other hand, a soldier throwing them self on a grenade, while an 
intentional act which may end the life of the soldier, may be more likely motivated 
by a desire to protect his unit rather than a desire to end his or herself.  Thus 
motive or intent may be the crux of what defines and seperates suicide, the specific 
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desire with intent to end ones own life.  An important challenge for the field of 
suicide then is finding endophenotypes which may explain neurobiological and 
neuropsychological underpinnings of suicidality.     
There have been genetic studies indicating a heritable component to 
suicidal behavior, particularly linkage disequilbrium blocks found on chromosomes 
2 and 6.  218  It remains to be clarified whether these associations represent direct 
links to suicidal behavior per se, or if these represent links to psychiatric conditions 
which indirectly influence or are positively correlated with suicidal behavior.  And 
while linkage peaks are suggestive of targets for future study of association at a 
population level it doesn’t provide clinical useful targets for individual patients. 
Biomarkers have been defined by the National Institutes of Health 
Biomarkers Definitions Working Group as “a characteristic that is objectively 
measured and evaluated as an indicator of normal biological processes, pathogenic 
processes, or pharmacologic responses to therapeutic intervention.”  Biomarkers 
as a means of identifying the pathogenic process underlying suicidal behavior are 
essential to the goal of understanding and preventing these tragedies.  Several 
groups over the last decade have been working on identifying genetic risk factors 
and peripheral biomarkers for suicide.  These findings begin to shed light on the 
underlying neuropathology involved in suicide.  While these markers are still being 
evaluated for clinical relevance and validity, in the near future they may provide a 
quantitative lab testing method for identifying suicide risk.   
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While the target tissue for much of the putative pathology of suicide (and 
psychiatry generally) is the brain, this is not a candidate for biopsy for obvious 
reasons.  This is why the studies of peripherally tissue that can be accessed 
peripherally such as blood or cerebral spinal fluid (CSF) have great potential utility 
due to relative ease of access.  Imaging studies, on the other hand, hold the 
potential for identifying tissue specific (brain) biomarkers in vivo.    
Hypothalamic-pituitary-adrenal (HPA) axis abnormalities 
The hypothalamic-pituitary-adrenal (HPA) axis describes the interactions 
between the hypothalamus, the pituitary, and adrenal glands.  The HPA axis is 
thought to play an important biological role in stress reactivity.  Abnormalities in 
the HPA axis have been associated with pathology of numerous psychiatric 
disorders and phenomena, including suicidal behaviors.   
Dexamethasone Suppression Test 
Dexamethasone is an exogenous steroid that is often prescribed for relief 
of inflammation.     The dexamethasone suppression test (DST) assesses adrenal 
gland function by measuring change of cortisol levels in response to acute injection 
of dexamethasone.  Dexamethasone can inhibit adrenocorticotropic hormone 
(ACTH) secretion by the pituitary, leading to drops in serum cortisol in a patient 
with normative HPA axis function.  In patients with HPA abnormalities this drop in 
cortisol may not be observed.  These abnormalities are sometimes seen in patients 
with depression, though DST is not used in the diagnosis of depression.  The DST 
has been proposed as a method to predict suicide risk.  In a long-term follow-up 
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study of 78 inpatients with major depressive disorder or schizoaffective disorder, 
32 of 78 patients were found to have abnormal DST results.  Estimated risk of 
eventual suicide was 26.8% in the group of patients with abnormal DST results as 
compared to only 2.9% with normal results.  8   Another follow-up study of 106 
depressed inpatients with a suicide attempt yielded an Area Under the Curve (AUC, 
a measure of the sensitivity and specificity of a test) of 0.636.  9 This is suggestive 
of a role for HPA axis abnormality in suicidal behavior, but may not rise to the level 
of clinical utility.   It could be that HPA dysfunction is important in only certain 
specific subtypes of suicidal behavior and application of DST might be more 
informative in those individuals.  Work is ongoing on identifying such 
subgroupings.  
SKA2.  Another gene and potential biomarker identified reproducibly 
associated with suicide is the spindle and kinetochore associated complex subunit 
2 (SKA2).  SKA2 has been implicated in HPA axis abnormalities associated with 
PTSD and with suicidal behavior.  219  Robust across gender groups and studies, 
SKA2 was first identified as a risk factor in genome-wide DNA methylation analysis 
of post-mortem brains.  SKA2 was found to be differentially methylated, a finding 
that was extended to peripheral blood samples of additional cohorts.  220  In 
addition to increased DNA methylation, other studies have found decreased SKA2 
expression in the blood to be associated with suicide.  196 197  SKA2 may functionally 
explain some of the pathology underlying HPA axis abnormalities as well as serve 
as a biomarker for suicide.  
185 
 
 
SLC4A4.  The solute carrier family member 4 (SLC4A4) gene codes for a 
sodium bicarbonate cotransporter. Mutations in this gene lead to proximal renal 
tubular acidosis, which is caused by the loss of the ability to reabsorb 
bicarbonate.221  It has been found to be increased in expression in the blood of 
living psychiatric patients with suicidal ideation, and may be predictive of future 
hospitalizations in male psychiatric patients.  196  This gene is expressed in many 
tissues in the body, including blood, brain, and the kidneys.  Functionally, abnormal 
expression in this gene may lead to pH dysregulation, which has been associated 
with the pathophysiology of acute panic attacks. Genome wide association studies 
have also provided evidence for the involvement common mutations in the gene 
for depressed suicide attempters. 222  
SAT1 and polyamines (SMOX).    Polyamines are ubiquitous organic 
cations of low molecular mass and found in all living organisms and implicated in 
many biological processes.  Specifically, putrescine, spermidine, and spermine are 
involved in apoptosis, cell growth and differentiation.  Several of the enzymes 
involved in the catabolism of spermine to putrescine have been implicated in 
suicide. Differential gene expression of the spermine/spermidine acetyltransferase 
1 (SAT1), the rate limiting step in the catabolism from spermine to spermidine and 
spermidine to putrescene, has been reproducibility associated with suicidal 
behavior.  223  Interestingly, there has been some discrepancy in the data regarding 
the direction of change.  This could be due to tissue specific effects, as SAT1 was 
found to be decreased in many (though not all) brain regions in postmortem 
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tissue224, while it was found to be increased in the peripheral blood of living bipolar 
male patients with suicidal ideation.  217    This difference could also be associated 
with the different suicidal subtypes, as decreased expression was associated with 
major depressive disorder while increased expression was found both in bipolar 
patients and non-depressed suicides.  217 224   
Serotonin.  The serotonergic system has been widely implicated in 
psychiatric disorders.  This is particularly well known in the case of depression 
where one of the more classes of medication, the SSRI, targets the system.  
Disruption to the serotonergic system has also been frequently implicated by 
neuroanatomical studies of suicide, with some of the earliest findings showing 
diminished 5-hydroxyindoleacetic acid (5-HIAA) in the cerebral spinal fluid (CSF).  
225 These findings have been replicated over the years with some consistency, with 
evidence centering around the raphae nucleus (RN).  It was shown recently with 
positron emission tomography (PET) that greater serotonin1A binding potential 
(more available serotonin receptor binding sites) predict higher suicidal behavior 
and thinking.  226 
Inflammatory markers.  Inflammatory markers have also been tied to 
suicide.  IL-6 is increased in the CSF of suicide attempters.  227 This finding has 
also been reproduced in the peripheral blood of patients with suicidal ideation.  196  
Pro-inflammatory cytokines like IL-6 may act by inducing enzymatic activity 
through the kynurenine pathway. Plasma kynurenine levels have been found to be 
elevated in suicide attempters with major depressive disorder, but not when 
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comparing patients with MDD to healthy volunteers.  228  A downstream outcome 
of this proinflammatory pathway could be the increased expression of quinolinic 
acid (QUIN), a potent neurotoxin with excitatory glutamatergic action through 
NMDA receptors.  This effect would be reversible by the NMDA receptor antagonist 
and putative treatment for suicidal ideation ketamine.  QUIN has indeed been 
found to be increased in the CSF of suicidal patients when compared to healthy 
controls.  229 
Identifying Biomarkers for Suicidal Behavior. 
While prior suicide attempts are one of the greatest risk factors for a future 
suicide attempt, the majority of prior attempters will not eventually commit suicide.  
Data from a large web-based sample taken in Brazil provides evidence that the 
majority (72%) of suicide attempters did not have a real intention to die.  216  With 
regards to suicide completion, it may be that a substantial number of those who 
died might not have endorsed a real intention to do so had they survived.  Early 
intervention and prevention of the first attempt may save a substantial number of 
lives.  We embarked on a series of studies aimed at identifying biomarkers that 
might begin to provide for objective means to do so.  The initial study was a pilot 
example of how a small male bipolar cohort of longitudinally followed individuals 
who showed a change in suicidal ideation over time. 
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Chapter 4: Discovery and Validation of Blood Biomarkers for Suicidality 
Introduction 
Whatever its evolutionary230, teleological and cultural reasons for existing, 
suicidal  behavior is in most cases pathological and leads to irreversible 
tragedies231. Paradoxically, given its importance, there are yet no reliable objective 
tools to assess and track changes in suicidal risk without asking the individuals 
directly. Such tools are desperately needed, as individuals at risk often choose not 
to share their ideation or intent with others, for fear of stigma, hospitalization, or 
that in fact their plans may be thwarted.  
       A convergence of methods assessing the persons’ internal subjective feelings 
and thoughts, along with external more objective ratings of actions and behaviors, 
are used de facto in clinical psychiatry. Such an approach is insufficient, and 
lagging behind those used in other medical specialties. It lacks precision, 
objectivity and predictive ability.  
      Our group has previously provided first proof of principle for the use of blood 
gene expression biomarkers to predict mood state232 and psychosis symptoms233. 
As the target organ in psychiatry- the brain- cannot be biopsied in live patients, it 
is essential to be able to identify and validate peripheral biomarkers for subsequent 
practical implementation in clinical settings. We now present a comprehensive and 
highly reductionist approach for discovering and validating blood biomarkers for 
suicidality.  
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      We used a Convergent Functional Genomics approach to identify and prioritize 
biomarkers of relevance to suicidality. CFG is a powerful combined approach for 
extracting signal from noise in genetic and gene expression studies.  The CFG 
methodology has already been applied to help identify and prioritize candidate 
genes, pathways and mechanisms for neuropsychiatric disorders such as bipolar 
disorder234-237,  alcoholism238, anxiety239, and schizophrenia240, showing 
reproducibility and predictive ability in independent cohorts. 
 
Methods 
Human subjects  
We present data from four cohorts: one live bipolar discovery cohort, one 
postmortem coroner’s office test cohort, and two prospective follow-up live 
cohorts- one bipolar and one psychosis (schizophrenia/schizoaffective).  Sample 
collection procedures are as described previously for subjects recruited through 
the Indianapolis VA Medical Center. 
            Our intra-subject discovery cohort, from which the biomarker data were 
derived, consisted of 9 male Caucasian subjects with bipolar disorder, with multiple 
visits, that had each had a diametric change in suicidal ideation scores from no 
suicidal ideation to high suicidal ideation from one testing visit to another testing 
visit. There were 6 subjects with 3 visits each, and 3 subjects with 2 visits each, 
resulting in a total of 24 blood samples for subsequent microarray studies (Table 
4-1 and Figure 4-1).        
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       Our postmortem cohort, in which the top biomarker findings were tested, 
consisted of an age-matched  cohort of 9 male suicide completers obtained 
through the Marion County Coroner’s Office (8 Caucasians, 1 African-American) 
(Table 4-1 and Table S4-2). We required a last observed alive post-mortem interval 
of 24 hours or less, and the cases selected had completed suicide by means other 
than overdose, which could affect gene expression. Next of kin signed informed 
consent at the coroner’s office for donation of tissues and fluids for research. The 
samples were collected as part of our INBRAIN initiative (Indiana Center for 
Biomarker Research in Neuropsychiatry). 
       The bipolar follow-up cohort (n=42)  (Table 4-1) consisted of male 
Caucasian subjects in which whole-genome blood gene expression data, including  
levels of SAT1, were obtained by us at testing visits over the years as part of our 
longitudinal study. If the subjects had multiple testing visits, the visit with the 
highest SAT1 level was selected for this analysis. The subjects’ subsequent number 
of hospitalizations with or without suicidality was tabulated from electronic medical 
records. The psychosis (schizophrenia/schizoaffective) follow-up cohort (n=46)  
(Table S4-9) similarly consisted of Caucasian subjects in which whole-genome 
blood gene expression data, including  levels of SAT1, were obtained by us at 
testing visits over the years as part of our longitudinal study. If the subjects had 
multiple testing visits, the visit with the highest SAT1 level was selected for this 
analysis. The subjects’ subsequent number of hospitalizations with or without 
suicidality was tabulated from electronic medical records. A hospitalization was 
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deemed to be without suicidality if suicidality was not listed as a reason for 
admission, and no suicidal ideation was described in the admission and discharge 
medical notes. Conversely, a hospitalization was deemed to be due to suicidality if 
suicidal acts or intent was listed as a reason for admission, and suicidal ideation 
was described in the admission and discharge medical notes. 
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Table 4-1.  Demographics A. Individual. B. Aggregate. Diagnosis established by 
comprehensive structured clinical interview (DIGS). NOS- not otherwise specified. 
Suicidal Ideation question is from the Hamilton Rating Scale for Depression 
obtained at the time of the blood draw for each subject. GSW-Gun Shot Wound. 
A. 
Cohort 1: Live Bipolar Subjects  Discovery  
Cohort  (n=9) (24 chips) 
    
SubjectID-Visit Diagnosis 
A
ge 
Gen
der 
Ethni
city 
Suici
dal 
Ideat
ion 
phchp023v1 Bipolar Disorder NOS 52 M Cauca
sian 
0 
phchp023v2 Bipolar Disorder NOS 52 M Cauca
sian 
3 
phchp023v3 Bipolar Disorder NOS 52 M Cauca
sian 
0 
phchp093v1 Bipolar I Disorder  51 M Cauca
sian 
0 
phchp093v2 Bipolar I Disorder  51 M Cauca
sian 
0 
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phchp093v3 Bipolar I Disorder  52 M Cauca
sian 
3 
phchp095v1 Bipolar I Disorder  28 M Cauca
sian 
3 
phchp095v2 Bipolar I Disorder  29 M Cauca
sian 
0 
phchp095v3 Bipolar I Disorder  29 M Cauca
sian 
2 
phchp122v1 Bipolar Disorder NOS 51 M Cauca
sian 
0 
phchp122v2 Bipolar Disorder NOS 51 M Cauca
sian 
2 
phchp128v1 Bipolar I Disorder  45 M Cauca
sian 
2 
phchp128v2 Bipolar I Disorder  45 M Cauca
sian 
0 
phchp136v1 Bipolar I Disorder  41 M Cauca
sian 
0 
phchp136v2 Bipolar I Disorder  41 M Cauca
sian 
0 
phchp136v3 Bipolar I Disorder  41 M Cauca
sian 
3 
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Cohort 2: Coroner’s Office Test Cohort- Suicide Completers (n=9)  (9 
chips)     
SubjectID Psychiatric 
Diagnosis 
Age Gender Ethnicity Suicide by 
phchp153v1 Bipolar II Disorder  55 M Cauca
sian 
0 
phchp153v2 Bipolar II Disorder  55 M Cauca
sian 
2 
phchp153v3 Bipolar II Disorder  56 M Cauca
sian 
0 
phchp179v1 Bipolar Disorder NOS 36 M Cauca
sian 
0 
phchp179v2 Bipolar Disorder NOS 37 M Cauca
sian 
0 
phchp179v3 Bipolar Disorder NOS 37 M Cauca
sian 
3 
phchp183v1 Bipolar I Disorder  48 M Cauca
sian 
3 
phchp183v2 Bipolar I Disorder 48 M Cauca
sian 
0 
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INBR009 Bipolar/                                                                            
Schizophrenia 
59 M Caucasian Hanging 
 
INBR011 Depression/ADHD 26 M Caucasian GSW to chest 
INBR012 Unknown 39 M Caucasian GSW to head 
INBR013 Depression 68 M African-
American 
GSW to mouth 
INBR014 None 27 M Caucasian Hanging 
INBR015 None 40 M Caucasian Hanging 
INBR016 Anxiety/TBI 68 M Caucasian GSW to head 
INBR017 Depression 56 M Caucasian GSW to chest 
INBR018 None 65 M Caucasian Slit wrist 
 
Cohort 3: Live Bipolar Subjects Prospective Follow-up Cohort (n=42)      
Subje
ctID-
Visit 
Diag
nosi
s 
A
g
e 
Ge
nde
r 
Ethn
icity 
SA
T1 
Lev
els 
at 
tes
tin
g 
Ye
ars 
sin
ce 
tes
tin
g 
Futu
re 
Hosp
. w/o 
suici
dalit
y 
Futu
re 
Hosp
. due 
to 
suici
dalit
y 
Freq
uenc
y of 
Futur
e 
Hosp
. w/o 
suici
Freq
uenc
y of 
Futur
e 
Hosp
. due 
to 
suici
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dalit
y 
dalit
y 
phchp
234v1 
Bipol
ar II 
Disor
der 
4
4 
M 
Cauc
asian 
195
5.2
0 
0.8
3 
0 0 0.00 0.00 
phchp
053v2 
Bipol
ar I 
Disor
der 
5
8 
M 
Cauc
asian 
217
8.3
0 
5.6
7 
4 0 0.71 0.00 
phchp
152v1 
Bipol
ar I 
Disor
der 
4
5 
M 
Cauc
asian 
217
8.8
0 
2.3
3 
0 0 0.00 0.00 
phchp
122v1 
Bipol
ar 
Disor
der 
NOS 
5
1 
M 
Cauc
asian 
224
5.6
0 
0.5
8 
0 0 0.00 0.00 
phchp
190v3 
Bipol
ar 
Disor
5
0 
M 
Cauc
asian 
230
0.6
0 
1.2
5 
0 0 0.00 0.00 
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der 
NOS 
phchp
020v3 
Bipol
ar 
Disor
der 
NOS 
6
3 
M 
Cauc
asian 
234
2.6
0 
4.0
8 
0 0 0.00 0.00 
phchp
113v1 
Bipol
ar I 
Disor
der 
3
7 
M 
Cauc
asian 
243
7.4
0 
3.0
0 
0 0 0.00 0.00 
phchp
132v2 
Bipol
ar I 
Disor
der 
5
1 
M 
Cauc
asian 
255
8.9
0 
2.3
3 
0 0 0.00 0.00 
phchp
184v3 
Bipol
ar 
Disor
der 
NOS 
6
4 
M 
Cauc
asian 
257
5.4
0 
1.3
3 
0 0 0.00 0.00 
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phchp
039v3 
Bipol
ar I 
Disor
der 
5
2 
M 
Cauc
asian 
258
0.1
0 
5.7
5 
0 0 0.00 0.00 
phchp
147v1 
Bipol
ar II 
Disor
der 
3
8 
M 
Cauc
asian 
258
2.8
0 
2.2
5 
0 0 0.00 0.00 
phchp
178v1 
Bipol
ar I 
Disor
der 
4
9 
M 
Cauc
asian 
261
6.8
0 
1.0
0 
0 0 0.00 0.00 
phchp
136v3 
Bipol
ar I 
Disor
der 
4
1 
M 
Cauc
asian 
263
5.9
0 
2.0
0 
0 0 0.00 0.00 
phchp
045v3 
Bipol
ar I 
Disor
der 
3
6 
M 
Cauc
asian 
272
1.0
0 
5.4
2 
0 0 0.00 0.00 
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phchp
224v1 
Bipol
ar I 
Disor
der 
5
9 
M 
Cauc
asian 
274
8.1
0 
1.0
8 
1 1 0.92 0.92 
phchp
183v1 
Bipol
ar I 
Disor
der 
4
8 
M 
Cauc
asian 
275
0.9
0 
0.4
2 
2 1 4.80 2.40 
phchp
171v2 
Bipol
ar 
Disor
der 
NOS 
3
6 
M 
Cauc
asian 
279
5.7
0 
1.5
0 
0 0 0.00 0.00 
phchp
166v1 
Bipol
ar 
Disor
der 
NOS 
5
6 
M 
Cauc
asian 
282
9.6
0 
1.9
2 
0 0 0.00 0.00 
phchp
253v1 
Bipol
ar 
Disor
2
5 
M 
Cauc
asian 
288
8.5
0 
1.0
0 
0 0 0.00 0.00 
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der 
NOS 
phchp
186v1 
Bipol
ar II 
Disor
der 
4
3 
M 
Cauc
asian 
290
1.5
0 
1.6
7 
0 0 0.00 0.00 
phchp
079v2 
Bipol
ar 
Disor
der 
4
4 
M 
Cauc
asian 
305
3.2
0 
4.5
0 
0 0 0.00 0.00 
phchp
128v1 
Bipol
ar I 
Disor
der 
4
5 
M 
Cauc
asian 
311
8.6
0 
2.6
7 
0 0 0.00 0.00 
phchp
080v1 
Bipol
ar I 
Disor
der 
4
4 
M 
Cauc
asian 
315
3.6
0 
5.0
0 
0 0 0.00 0.00 
phchp
088v1 
Bipol
ar I 
Disor
der 
4
4 
M 
Cauc
asian 
319
4.1
0 
4.5
8 
0 10 0.00 2.18 
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phchp
109v1 
Bipol
ar I 
Disor
der 
2
2 
M 
Cauc
asian 
320
0.8
0 
3.0
0 
1 2 0.33 0.67 
phchp
134v3 
Bipol
ar II 
Disor
der 
5
9 
M 
Cauc
asian 
320
2.3
0 
1.9
2 
0 0 0.00 0.00 
phchp
153v1 
Bipol
ar II 
Disor
der 
5
5 
M 
Cauc
asian 
330
4.9
0 
2.0
0 
0 0 0.00 0.00 
phchp
274v2 
Bipol
ar  
Disor
der 
NOS 
4
8 
M 
Cauc
asian 
334
9.0
0 
0.5
0 
0 0 0.00 0.00 
phchp
140v3 
Bipol
ar II 
Disor
der 
3
8 
M 
Cauc
asian 
339
3.8
0 
1.9
2 
0 0 0.00 0.00 
202 
 
 
phchp
030v3 
Bipol
ar I 
Disor
der 
4
9 
M 
Cauc
asian 
339
5.2
0 
5.9
2 
0 3 0.00 0.51 
phchp
124v1 
Bipol
ar I 
Disor
der 
5
3 
M 
Cauc
asian 
366
0.9
0 
2.5
0 
0 6 0.00 2.40 
phchp
095v3 
Bipol
ar I 
Disor
der 
2
9 
M 
Cauc
asian 
369
5.4
0 
0.3
3 
0 1 0.00 3.00 
phchp
100v1 
Bipol
ar I 
Disor
der 
2
8 
M 
Cauc
asian 
376
7.8
0 
1.5
8 
0 0 0.00 0.00 
phchp
210v3 
Bipol
ar I 
Disor
der 
4
4 
M 
Cauc
asian 
384
4.6
0 
0.5
0 
0 0 0.00 0.00 
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phchp
219v1 
Bipol
ar 
Disor
der 
NOS 
6
1 
M 
Cauc
asian 
384
5.1
0 
1.1
7 
0 0 0.00 0.00 
phchp
031v3 
Bipol
ar I 
Disor
der 
5
2 
M 
Cauc
asian 
408
0.7
0 
4.0
8 
1 0 0.24 0.00 
phchp
093v3 
Bipol
ar I 
Disor
der 
5
2 
M 
Cauc
asian 
413
7.4
0 
2.6
7 
0 1 0.00 0.38 
phchp
067v1 
Bipol
ar II 
Disor
der 
3
9 
M 
Cauc
asian 
421
4.7
0 
5.5
8 
0 0 0.00 0.00 
phchp
142v3 
Bipol
ar I 
Disor
der 
5
5 
M 
Cauc
asian 
431
0.7
0 
1.9
2 
0 0 0.00 0.00 
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phchp
112v2 
Bipol
ar I 
Disor
der 
4
6 
M 
Cauc
asian 
441
0.4
0 
1.3
3 
0 0 0.00 0.00 
phchp
149v2 
Bipol
ar 
Disor
der 
NOS 
4
5 
M 
Cauc
asian 
458
6.9
0 
2.0
0 
1 0 0.50 0.00 
phchp
117v1 
Bipol
ar I 
Disor
der 
4
3 
M 
Cauc
asian 
653
1.1
0 
3.0
0 
0 0 0.00 0.00 
 
 
B. 
Live Bipolar Subjects 
Discovery Cohort (n=9) 
 
 
Suicidal Ideation (SI ) 
(score) 
No SI (0) 
High  SI (2-
4) 
Overall 
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Number of subjects 
(number of chips) 
9(14) 9(10) 9(24) 
Age  
mean   
(SD) 
range 
46.1 
(8.1) 
29-56 
43.8 
(9.7) 
28-55 
45.1 
(8.7) 
28-56 
Ethnicity (Caucasian/ 
African-American) 
(9/0) (9/0) (9/0) 
 
Coroner’s Office Test Cohort- Suicide 
Completers (n=9) 
 
Number of subjects (number of chips) 9(9) 
Age  
mean  
(SD) 
range 
49.8 
(17) 
26-68 
Ethnicity  (Caucasian/ African-
American) 
(8/1) 
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Live Bipolar Subjects  
Prospective Follow-up Cohort (n=42) 
 
SAT1 Levels 
Lower 
Tertile 
Upper 
Tertile 
Overall 
Number of subjects  14 14 42 
Age  
mean 
(SD) 
range 
48.5 
(9) 
36-64 
45.3 
(9.5) 
28-61 
46.2 
(9.9) 
22-64 
Ethnicity (Caucasian/ African-American) (14/0) (14/0) (42/0) 
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Medications 
       The subjects in the discovery cohort were all diagnosed with bipolar 
disorder (Table 4-1).  Their psychiatric medications are listed in Table S4-1.  The 
subjects were on a variety of different psychiatric medications: mood stabilizer, 
antidepressants, antipsychotics, benzodiazepines, and others.   Medications can 
have a strong influence on gene expression. However, our discovery of 
differentially expressed genes was based on intra-subject analyses, which factor 
out not only genetic background effects but also medication effects, as the 
subjects had no major medication changes between visits. Moreover, there was 
no consistent pattern in any particular type of medication, or between any change 
in medications and suicidal ideation, in the rare instances where there were 
changes in medications between visits. 
 
Human blood gene expression experiments and analyses 
 RNA extraction, sample labeling, and procedures for microarray are 
previously described. 
Analysis 
      We have used the subject’s suicidal ideation (SI) scores at the time of blood 
collection (0—no SI compared to 2 and above- high SI).  We looked at gene 
expression differences between the no SI and the high SI visits using both an 
intra-subject and an inter-subject design (Figure 4-1). 
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Differential Gene Expression Analyses in the Discovery Cohort 
      We imported all Affymetrix microarray data as .cel files into Partek Genomic 
Suites 6.6 software package (Partek Incorporated St.Louis, Missouri U.S.A).  Using 
only the Perfect Match (PM) values, we ran a robust multi-array analysis (RMA), 
background corrected with quantile normalization and a median polish probeset 
summarization of all 24 chips, to obtain the normalized expression levels of all 
probesets for each chip. Then, to establish a list of differentially expressed 
probesets, we ran two analyses.       
      An intra-subject analysis using a fold change in expression of at least 1.2 
between high and no SI visits within each subject was performed.  There were in 
total 15 comparisons.  Probesets that had a 1.2 fold change were then assigned 
either a 1 (increased in high SI) or a -1 (decreased in high SI) in each 
comparison.  These values were then summed for each probeset across the 15 
comparisons, yielding a range of scores between -11 and 12.  The probesets in 
the top 5% (1,269 probesets, <5% of 54,675 total probesets) had an absolute 
(without sign) score value of 7 and greater, and received an internal CFG score of 
1 point.  The probesets in the top .1% (24 probesets, <.1% of 54,675 total 
probesets) had an absolute score of 11 and greater, and received an internal CFG 
score of 3 points.  
      Additionally, an inter-subject analysis using  t-test (2-tailed, unequal variance) 
was performed to find probesets differential expressed between high SI and no SI 
chips (Figure 4-1), resulting in 648 probesets with P<.05.  Probesets with a P<.05 
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received an internal CFG score of 1 point, while probesets with P<.001 received 3 
points.   
      We further filtered results by only selecting probesets that overlapped 
between the intra-subject and the inter-subject analyses, resulting in 279 
probesets corresponding to 246 unique genes. Gene names for the probesets were 
identified using Partek as well as NetAffyx (Affymetrix) for Affymetrix HG-U133 
Plus 2.0 GeneChips, followed by  GeneCards to confirm the primary gene symbol.  
In addition, for those probesets that were not assigned a gene name by Partek or 
NetAffyx, we used the UCSC Genome Browser on Human Feb. 2009 
(GRCh37/hg19) to directly map them to known genes.   Genes were then scored 
using our manually curated CFG databases as described below (Figure 4-2). 
Validation Analyses 
      We imported the 9 Affymetrix microarray data files from the suicide completers 
cohort as .cel files into Partek Genomic Suites 6.6 software package (Partek 
Incorporated St.Louis,Missouri U.S.A).  We then ran a robust multi-array analysis 
(RMA), background corrected with quantile normalization and a median polish 
probeset summarization of all the chips from the discovery and validation cohort 
(24 +9=33 chips), to obtain the normalized expression levels of all probesets for 
each chip.    Partek normalizes expression data into a log base of 2 for visualization 
purposes.  We non-log transformed expression data by taking 2 to the power of 
the transformed expression value.     We then used the non-log transformed 
expression data to compare expression levels of biomarkers in the different groups 
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(Figure 4-3).   One-tail t-tests with unequal variance, one-way ANOVA, and 
Bonferonni corrections were used for statistical comparisons. 
      For live cohorts future hospitalization analyses in bipolar disorder and 
schizophrenia/schizoaffective, we similarly RMA normalized each cohort, prior to 
looking at biomarker levels in individual subjects. One-tail t-tests with equal 
variance were used for statistical comparisons. ROC curves were calculated using 
SPSS software for each of the 4 dimensional analyses, predicting the state variable 
of hospitalizations due to suicidality.   
Figures 
Each figure in this chapter was completed by Helen Le-Niculescu and Daniel 
Levey.  This work has been published.  217 
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Table 4-2. Top gene expression biomarkers for suicidality 
Gene Symbol/ Gene 
name 
Probe
sets 
Ch
an
ge 
Differe
ntial 
Expres
sion 
Score 
Prior 
Human 
Genetic 
Eviden
ce 
Prior 
Human 
Brain 
Expression 
Evidence 
Tot
al 
CFG 
Scor
e 
SAT1 
spermidine/spermine 
N1-acetyltransferase 1 
20345
5_s_at 
I 2 
(Assoc)  
Suicide 
attempt2
41; 
Suicide 
223 
Suicide in 
Depression  
(D) PFC 242 
 
Suicide 
(D) AMY, 
PFC, HIP, 
THAL243 
 
 
Suicide 
(D) PFC244 
 
 
Suicide 
(D) PFC245 
8 
212 
 
 
 
Suicide 
 (D) PFC246 
 
Suicide 
(D) PFC247 
 
 
Suicide 
(D) PFC224 
 
 
Suicide 
(D) PFC 223 
CD24 
CD24 molecule 
20977
2_s_at 
D 4  
Suicide  in 
mood 
disorders 
(D) NAC 248 
8 
FOXN3 
forkhead box N3 
23079
0_x_at 
I 2 
 
(Assoc) 
Suicide 
249  
Suicide 
(I) PFC 249  
 
8 
213 
 
 
 
GBP1 
guanylate binding 
protein 1, interferon-
inducible, 67kDa 
23157
7_s_at 
20226
9_x_at 
20227
0_at 
I 
4 
2 
2 
 
Suicide in 
mood 
disorders 
(D) NAC 248 
8 
6 
6 
PIK3R5 
Phosphoinositide-3-
kinase, regulatory 
subunit 5 
22755
3_at 
I 4  
Suicide  in 
mood  
disorders 
(D) PFC 248 
8 
APOL2 
Apolipoprotein L2 
22165
3_x_at 
I 2  
Suicide 
PFC (I)250  
6 
ATP13A2 
ATPase type 13A2 
21860
8_at 
D 2  
Suicide 
 (D)248 
6 
ATP6V0E1 
ATPase, H+ 
transporting, 
lysosomal 9kDa, V0 
subunit e1 
21414
9_s_at 
21424
4_s_at 
I 2  
Suicide 
(D) 
PFC 223 
6 
214 
 
 
EPHX1 
epoxide hydrolase 1, 
microsomal 
(xenobiotic) 
20201
7_at 
D 2  
Suicide in 
Schizophren
ia 
(D) PFC251 
6 
GCOM1 
GRINL1A complex 
locus 1 
23909
9_at 
I 2  
Suicide in 
Depression 
(D) PFC252 
6 
HTRA1 
HtrA serine peptidase 
1 
20118
5_at 
D 2  
Suicide 
 (I)248 
6 
IL1B 
interleukin 1, beta 
39402
_at 
I 2  
Suicide 
(I) PFC253 
6 
LEPR 
leptin receptor 
21135
4_s_at 
D 2  
Suicide 
(D) PFC252 
 
(D) PFC254 
 
(D) HIP255 
 
Suicide in 
Depression 
(I) PFC256  
6 
215 
 
 
LHFP 
lipoma HMGIC fusion 
partner 
21865
6_s_at 
I 2  
Suicide  in 
mood 
disorders 
(I) NAC 248 
6 
LIPA 
lipase A 
23615
6_at 
I 2  
Violent 
Suicide  
(I) PFC257 
6 
MARCKS 
myristoylated alanine-
rich protein kinase C 
substrate 
21300
2_at 
I 2  
 Suicide in 
Depression 
(I)258 
6 
PGLS 
6-
Phosphogluconolacton
ase 
23069
9_at 
I 2  
Suicide 
PFC (D)250 
6 
PTEN 
phosphatase and 
tensin homolog 
22217
6_at 
I 2  
 
Suicide 
PFC, HIP (I) 
259 
6 
RECK 
21615
3_x_at 
I 2  
Suicide  
(I) PFC248 
 
6 
216 
 
 
reversion-inducing-
cysteine-rich protein 
with kazal motifs 
SPTBN1 
spectrin, beta, non-
erythrocytic 1 
20067
1_s_at 
D 2  
Suicide  in 
mood 
disorders  
(I) NAC 248 
6 
TNFSF10 
tumor necrosis factor 
(ligand) superfamily, 
member 10 
20268
8_at 
20268
7_s_at 
21432
9_x_at 
I 2  
Suicide in 
Schizophren
ia 
(I)PFC 251 
 
Suicide in 
Depression 
(I) PFC256 
6 
ABCA1 
ATP-binding cassette, 
sub-family A (ABC1), 
member 1 
20350
4_s_at 
I 4   4 
ARHGEF40 
(FLJ10357) 
24163
1_at 
I 4   4 
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Rho guanine 
nucleotide exchange 
factor (GEF) 40 
CASC1 
cancer susceptibility 
candidate 1 
22016
8_at 
I 4   4 
DHRS9 
dehydrogenase/reduct
ase (SDR family) 
member 9 
21979
9_s_at 
I 4   4 
DISC1 
disrupted in 
schizophrenia 1 
24464
2_at 
I 2 
(Assoc) 
Suicide 
249 
 4 
EIF2AK2 
eukaryotic translation 
initiation factor 2-
alpha kinase 2 
20421
1_x_at 
I 4   4 
LOC727820 
uncharacterized 
LOC727820 
23124
7_s_at 
I 4   4 
MAP3K3 
24211
7_at 
I 4   4 
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mitogen-activated 
protein kinase kinase 
kinase 3 
MBNL2 
muscleblind-like 2 
(Drosophila) 
20501
7_s_at 
D 2 
(Assoc) 
Suicide 
249 
 4 
MT-ND6 (ND6) 
mitochondrially 
encoded NADH 
dehydrogenase 6 
15535
75_at 
I 4   4 
OR2J3 
olfactory receptor, 
family 2, subfamily J, 
member 3 
2173
34_at 
D 4   4 
RBM47 
RNA binding motif 
protein 47 
15655
97_at 
I 4   4 
RHEB 
Ras homolog enriched 
in brain 
22763
3_at 
D 2 
(Assoc) 
Suicide26
0 
 4 
RICTOR 
22824
8_at 
I 4   4 
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RPTOR independent 
companion of MTOR, 
complex 2 
SAMD9L 
sterile alpha motif 
domain containing 9-
like 
24327
1_at; 
23003
6_at 
I 4   4 
SCARF1 
scavenger receptor 
class F, member 1 
20699
5_x_at 
I 4   4 
SLC36A1 
solute carrier family 36 
(proton/amino acid 
symporter), member 1 
21311
9_at 
I 4   4 
STAT1 
signal transducer and 
activator of 
transcription 1, 91kDa 
23237
5_at 
I 4   4 
UBA6 
ubiquitin-like modifier 
activating enzyme 6 
23687
9_at 
I 4   4 
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ZC3HAV1 
zinc finger CCCH-type, 
antiviral 1 
15630
75_s_
at 
I 4   4 
COX5B 
cytochrome c oxidase 
subunit Vb 
21373
6_at 
I 2 
(Linkage
) 
2q11.226
1 
 3 
SMARCA1 
SWI/SNF related, 
matrix associated, 
actin dependent 
regulator of 
chromatin, subfamily 
a, member 1 
20387
4_s_at 
I 2 
(Linkage
) 
Xq25246 
 
 3 
DBP 
D-box binding protein 
20978
2_s_at 
 
D 2   2 
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Results 
Discovery 
      We conducted whole-genome gene expression profiling in blood samples from 
a longitudinally-followed homogeneous cohort of male subjects with a major mood 
disorder (bipolar disorder) that predisposes to suicidality. 1 in 3 individuals with 
bipolar disorder attempt suicide during their lifetime262. The samples were 
collected at repeated visits, 3 to 6 months apart. State information about suicidal 
ideation was collected from a questionnaire administered at the time of each blood 
draw (Table 4-1). Out of 75 bipolar subjects (with a total of 174 visits) followed 
longitudinally in our study, there were 9 subjects that switched from a no suicidal 
ideation (SI score of 0) to a high suicidal ideation state (SI score of 2 and above) 
at different visits, which was our intended study group. We used a powerful intra-
subject design to analyze data from these 9 subjects and their 24 visits. An intra-
subject design factors out genetic variability, as well as some medications, lifestyle 
and demographic effects on gene expression, permitting identification of relevant 
signal with Ns as small as 114. An ancillary benefit of an intra-subject design may 
be accuracy/consistency of self-report of psychiatric symptoms (“phene 
expression”), similar in rationale to the signal-detection benefits it provides in gene 
expression. We also used an overall inter-subject case-case analysis, to identify 
genes differentially expressed in the blood in no suicidal ideation states vs.  high 
suicidal ideation states (Figure 4-1). The number of subjects that met our criteria 
and were analyzed is small, but comparable to those in human postmortem brain 
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gene expression studies of suicide248. We are indeed treating the blood samples 
as surrogate tissue for brains, with the caveat that they are not the real target 
organ. However, with blood samples from live human subjects we have the 
advantages of in vivo accessibility,  better knowledge of the mental state at the 
time of collection, less technical artifacts,  
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Figure 4-1. Discovery 
cohort: intrasubject 
and intersubject 
analyses. Phchp### is 
study ID for each 
subject. V# after it 
denotes visit number 
(1, 2 or 3). (a) Design 
and (b) suicidal 
ideation (SI) scoring. 
(c) Overlapping 
probesets and genes. 
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and especially of being able to do powerful intra-subject analyses from visit to 
visit. We considered and differentially scored only the very top 0.1% and 5% of 
the gene expression probesets distributions, and also required overlap between 
the intra-subject  and inter-subject analyses of gene expression changes. Such a 
restrictive approach was used as a way of minimizing false positives, even at the 
risk of having false negatives (Figure 4-1C). For example, there were genes on 
each of the two lists, from intra- and inter-subject analyses, that had clear prior 
evidence for involvement in suicidality, such as MT1E248, respectively GSK3B263, 
but were not included in our subsequent analyses because they were not in the 
overlap.        
We then used a Convergent Functional Genomics approach (CFG) (Figure 4-2) to 
cross-match the list of 246 overlapping top differentially expressed genes from the 
blood samples with other key lines of evidence (human postmortem brain data, 
human genetic data) implicating them in suicidality, as a way of identifying and 
prioritizing disease-relevant genomic biomarkers, extracting generalizable signal 
out of potential cohort-specific residual noise and genetic heterogeneity. We have 
built in our lab manually curated databases of the psychiatric genomic and 
proteomic literature to date, for use in CFG analyses21,264-266. The CFG approach is 
thus a de facto field-wide collaboration. We use in essence, in a Bayesian fashion, 
the whole body of knowledge in the field to leverage findings from our discovery 
datasets. Unlike our use of CFG in previous studies, for the current one we did not 
use any human peripheral tissue evidence from the literature, as there was none 
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directly matching our genes, reflecting perhaps the dearth of peripheral gene 
expression work done so far on suicides, and the need for a study like ours. We 
also did not use animal model evidence, as there are to date no clear studies in 
animal models of self-harm or suicidality. SAT1 (spermidine/spermine N1- 
acetyltransferase 1) was the top scoring blood biomarker, with the most extensive 
convergent evidence, increased in suicidal states identified by our work (i.e. the 
top risk marker). CD24 (CD24 molecule/ small cell lung carcinoma cluster 4 
antigen) was the top blood biomarker decreased in suicidal states (i.e. the top 
protective marker) (Figure 4-2 and Table 4-2).    
Testing in suicide completers 
       In order to know whether our findings relate to actual completed 
suicide, we then tested SAT1 levels in blood samples from a heterogeneous cohort 
of 9 consecutive male suicide completers obtained from the coroner’s office, with 
the following characteristics: we required that the cases included in our analysis 
had a postmortem interval from last observed alive under 24 hours, and that they 
had committed suicide by means other than overdoses, which could alter gene 
expression. Remarkably, we found SAT1 gene expression levels to be elevated in 
9 out of 9 (100%) of subjects who committed suicide that we tested. In each of 
the suicide completers, the increase in SAT1 was at least three standard deviations 
above the average levels in high suicidal ideation subjects, which constitutes a 
very stringent threshold for use as a predictive biomarker (Figure 4-3).   
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Figure 4-2. Convergent Functional Genomics approach for identification and 
prioritization of genomic biomarkers for suicidality. 
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We also examined other top candidate biomarkers for suicidality (Figure 4-3 and 
Figure S4-3). Remarkably, 13 out of the 41 CFG top scoring biomarkers from Figure 
4-2A   (32%) showed step-wise significant change from No SI to High SI to the 
test Suicide Completers group.  6 out of them (15%) remained significant after 
strict Bonferroni correction for multiple comparisons (Figure 4-3). The top CFG 
scoring biomarker SAT1 remained the top biomarker after validation.  Thirteen out 
of the 41 CFG top-scoring biomarkers from Figure 4-2b (32%) showed step-wise 
significant change from no SI to high SI, to the validation suicide completers group. 
Six out of them (15%) remained significant after strict Bonferroni correction for 
multiple comparisons. The top CFG scoring biomarker SAT1 remained the top 
biomarker after validation. 
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Figure 4-3. Testing of biomarkers in suicide completers. (a) Upper: SAT1 
(spermidine/spermine N1–acetyltransferase 1) expression is significantly increased 
(P ¼ 0.0057) in our discovery work between subjects with high suicidal ideation 
(SI) (mean ¼ 3413.37) and those reporting no SI (mean ¼ 2642.97). Our test 
cohort of suicide completers (mean ¼ 7171.51) showed significantly greater 
expression of SAT1 than both high SI (P ¼ 7.27e-07) and no SI (P ¼ 1.51e-07) 
groups from the discovery cohort. Lower: a suicide risk score was calculated by 
scoring the s.d. band a subject fell within as derived from the high SI discovery 
cohort, starting from the mean of the high-SI discovery cohort. A score of 0 
indicates the subject falling between the means of the high SI and no SI subjects 
in the discovery cohort. A score of 1 means between the mean of the high SI and 
the first s.d. above it, score of 2 between the first and second s.d., score of 3 
between the second and third s.d., and so on. Red line marks where the average 
SAT1 gene expression in high SI subjects would fall. (b) Upper: CD24 (CD24 
molecule/small cell lung carcinoma cluster 4 antigen) expression was significantly 
decreased (P ¼ 0.0044) within the discovery cohort between subjects reporting 
high SI (mean ¼ 73.01) and no SI (mean ¼ 108.634). The test cohort of suicide 
completers (mean ¼ 71.61) was also significantly decreased (P ¼ 0.0031) when 
compared with subjects reporting no SI. Lower: suicide risk score defined as the 
s.d. band in which the subject expression fell below the mean of the high-SI 
discovery cohort. Red line marks where the average CD24 gene expression in high 
SI subjects would fall. (c) Testing of top candidate biomarkers for suicidality.   
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Mechanistic understanding 
       Pathway analyses of our suicidality biomarker data identified among the top 
pathways the omega-3 docosahexaenoic acid (DHA) signaling pathway. Low 
omega-3 levels have been correlated with increased suicidality in human 
epidemiological studies 167 168.     Several of the biomarkers from our current study 
(SAT1, S100A8, IL1B and 16 others) were changed in expression by omega-3 
treatment  in the blood of the circadian clock gene DBP (D-box binding protein) 
knock-out mouse model in opposite direction to our human suicidality data (Table 
S4-6). DBP is also one of the biomarkers identified to be decreased in high suicidal 
states in the current analysis. Serendipitously, previous work by our group has 
implicated DBP  in mood disorders267, psychosis28, alcoholism238, and  anxiety 
disorders239. Mice engineered to lack DBP were stress-reactive and displayed a 
behavioral phenotype similar to bipolar disorder and co-morbid alcoholism268. In 
addition to bipolar disorder, alcoholism increases risk for suicide 269. PTEN, a 
biomarker increased in suicidality in the current study in the blood, as well as in 
the brain of suicide completers259, was also increased in the amygdala and 
decreased in the pre-frontal cortex of DBP knock-out mice subjected to stress269. 
S100A8, another biomarker increased in suicidality in the current study, was also 
increased in the blood of DBP stressed mice. Treatment with omega-3 fatty acids 
normalized the phenotype of those mice270.    
       Other circadian clock-modulated genes identified by our analysis as 
biomarkers for suicidality were PIK3R5, MARCKS, IL1B, CASC1, CCRN4L, H3F3B, 
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RBCK1, TNK2, and UBE2B. Circadian genes are involved in sleep-wake cycles, as 
well as mood regulation235,236,267,271,272.  Abnormal sleep (insomnia) has been 
identified as a risk factor for suicide273 . IL1B is also an inflammatory marker, and 
has previously been implicated by us in anxiety disorders239.    
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     Table 4-3. Underlying Biology.  A. Pathways. B. Disease and Disorders. 
A. INGENUITY Pathways KEGG Pathways 
CF
G 
sco
re>
=6.
0 
N=
21 
gen
es 
# 
Top Canonical 
Pathways 
P-
Va
lu
e 
Rati
o 
Pathway 
Name 
Enric
hmen
t 
Score 
Enrich
ment 
p-
value 
1 
Role of Tissue Factor in 
Cancer 
2.
63
E-
04 
3/11
5 
(0.0
26) 
Apoptosis 
6.691
02 
0.0012
42 
2 Dendritic Cell Maturation 
9.
83
E-
04 
3/20
7 
(0.0
14) 
Measles 
6.063
69 
0.0023
26 
3 Melanoma Signaling 
1.
13
E-
03 
2/46 
(0.0
43) 
Endometrial 
cancer 
4.967
87 
0.0069
58 
4 
Docosahexaenoic Acid 
(DHA) Signaling 
1.
18
2/49 
(0.0
41) 
Influenza A 
4.902
23 
0.0074
3 
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E-
03 
5 
Endometrial Cancer 
Signaling 
1.
69
E-
03 
2/57 
(0.0
35) 
Phosphatidy
linositol 
signaling 
system 
4.854
48 
0.0077
93 
 # 
Top Canonical 
Pathways 
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o 
Pathway 
Name 
Enric
hmen
t 
Score 
Enrich
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CF
G 
sco
re>
=4.
0 
N=
41 
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1 NF-kB Signaling 
4.
42
E-
04 
4/17
5 
(0.0
23) 
Measles 
8.766
7 
0.0001
56 
2 Dendritic Cell Maturation 
5.
38
E-
04 
4/20
7 
(0.0
19) 
Influenza A 
6.873
08 
0.0010
35 
3 PDGF Signaling 
7.
5E
-
04 
3/85 
(0.0
35) 
mTOR 
signaling 
pathway 
6.349
86 
0.0017
47 
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4 
Role of Pattern 
Recognition Receptors in 
Recognition of Bacteria 
and Viruses 
1.
14
E-
03 
3/10
6 
(0.0
28) 
Apoptosis 
4.756
87 
0.0085
92 
5 
Role of Tissue Factor in 
Cancer 
1.
78
E-
03 
3/11
5 
(0.0
26) 
Toll-like 
receptor 
signaling 
pathway 
4.372
69 
0.0126
17 
 
B.  INGENUITY  
CFG 
score>=
6.0  
N=21 
genes 
# 
Diseases and 
Disorders 
P-Value 
Number of 
Molecules 
1 Cancer 
1.22E-06 - 
4.54E-03 
14 
2 
Connective Tissue 
Disorders 
2.19E-04 - 
3.41E-03 
8 
3 
Inflammatory 
Disease 
2.19E-04 - 
4.54E-03 
8 
4 
Skeletal and Muscular 
Disorders 
2.19E-04 - 
4.42E-03 
9 
5 Gastrointestinal Disease 
2.22E-04 - 
4.54E-03 
12 
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CFG 
score>=
4.0 
N=41 
genes 
 
# 
Diseases and 
Disorders 
P-Value 
Number of 
Molecules 
1 Cancer 
4.51E-06 - 
6.45E-03 
20 
2 
Inflammatory 
Response 
2.70E-05 - 
6.45E-03 
12 
3 Antimicrobial Response 
9.95E-05 - 
6.45E-03 
4 
4 Infectious Disease 
1.25E-04 - 
5.52E-03 
6 
5 
Connective Tissue 
Disorders 
1.53E-04 - 
6.45E-03 
11 
 
Additionally, S100A8, MBNL2 and 3 other biomarkers had evidence for 
modulation by clozapine in blood in opposite direction to our human suicidality 
data in previous independent animal model pharmacogenomics studies conducted 
by us 28,233 (Table S4-6). Clozapine is the only FDA approved treatment for 
suicidality274.  
       Thus, the convergent evidence for our biomarkers is strong in translational 
ways beyond those used for their discovery and selection.  S100A8 may be a key 
biomarker to monitor in terms of response to treatment with classic (clozapine) 
236 
 
 
and complementary (omega-3) agents. Other potential drugs to be studied for 
modulating suicidality were revealed by our analyses (Tables S4-5 and S4-6).  
       SAT1, FOXN3, DISC1, MBNL2 and RHEB had genetic association evidence 
for suicidality, suggesting that they are not only state biomarkers but also trait 
factors influencing suicidal risk. DISC1 is also one of the top candidate genes for 
schizophrenia based on a large scale CFG analysis of schizophrenia GWAS we 
recently conducted240, while DISC1 and MBNL2 are also among of the top 
candidate genes for bipolar disorder based on a large scale CFG analysis of bipolar 
disorder GWAS we previously conducted236. Additionally, DISC1 has clear animal 
model data for the role of its interaction with environmental stress in the 
pathophysiology of psychotic depression275. DISC1 and MBNL2 may thus be key 
state and trait factors for suicidality risk in psychotic mood disorder subjects, and 
an indication for clozapine treatment in such subjects.  
We also looked at the overlap of our suicide biomarkers with our previous 
mood biomarker232 and psychosis biomarker233 work (Table S4-7), as well as with 
the human postmortem brain literature for other psychiatric disorders (Table S4-
8). DOCK5 and 4 other biomarkers were changed in high suicidal states in opposite 
direction to their change in high mood states, and DOCK5 and 6 other biomarkers 
were changed in the same direction as their change in high psychosis states, 
suggesting that suicidality could be viewed as a psychotic dysphoric state, and that 
DOCK5 may be an additional key biomarker reflecting that state. This molecularly-
informed view is consistent  with the emerging clinical evidence in the field276.  The 
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convergence of evidence then suggests that, at least in the population we studied, 
suicidality may be associated with dysphoric mood, as well as increased psychosis, 
anxiety and stress. In our own data, SAT1 blood gene expression levels showed a 
trend towards increase in low mood, high psychosis, high anxiety, and high stress 
in our bipolar subjects (Figure 4-4). 
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Figure 4-4. SAT1 (spermidine/spermine N1–acetyltransferase 1) expression in 
the bipolar discovery cohort: relationship with suicidal ideation (SI), mood, 
psychosis, anxiety and stress. (a) SAT1 expression and SI item from Hamilton 
Rating Scale for Depression (HAMD) (scores of 0–4). (b) SAT1 expression and 
visual-analog scale for mood (0–100). High mood is to the left on the x-axis, low 
mood is to the right. (c) SAT1 expression and Hallucinations item from Positive 
and Negative Symptoms Scale (PANSS; scores of 1–7). Higher score indicates 
higher symptoms.   
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Prospective Validation  
       To further validate SAT1, our top marker, we also looked at subsequent 
hospitalizations with and without suicidality (Table 4-1 and Table S4-9), and 
previous hospitalizations with and without suicidality (Table S10-3), in two live 
cohorts, one bipolar (n=42) and one psychosis (schizophrenia/schizoaffective) 
(n=46). Higher SAT1 levels compared to lower SAT1 levels at time of testing 
differentiated future as well as past hospitalizations due to suicidality in the bipolar 
disorder subjects (Figure 4-5). A similar but weaker pattern was exhibited in the 
psychosis (schizophrenia/schizoaffective) subjects (Figure S4-2).  Remarkably, 
besides SAT1, three other (PTEN, MARCKS and MAP3K3)  of the six biomarkers 
that survived Bonferroni correction in the suicide completers cohort validation step 
also showed similar but weaker results (Table S4-11 and Figure S4-3). Taken 
together, the prospective and retrospective hospitalization data suggests SAT1, 
PTEN, MARCKS and MAP3K3 might be not only state markers but perhaps trait 
markers as well. 
       We also examined whether using a multi-dimensional approach enhanced 
our ability to predict future hospitalizations, by adding data about mood, anxiety, 
and psychosis to the data about SAT1 expression levels (Figure 4-6). We found 
that the ROC curve improved in a step-wise fashion, from an AUC of .640 with 
SAT1 alone, to and AUC of .798 with SAT1 and anxiety, AUC of .813 with SAT1, 
anxiety and mood, and AUC of .835 with SAT1, anxiety, mood and psychosis. From 
our preliminary work, we identified levels of SAT1 that provide different levels of 
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sensitivity and specificity (Table S4-12). The anxiety and mood information was 
obtained from simple visual analog scales, previously described by us277. The 
psychosis information is based on the combining of the scores on the hallucinations 
and delusions in the PANSS (Figure S4-5). Of note, this simple clinical-genomic 
approach does not directly ask about suicidal ideation, which some individuals may 
deny or choose not to share with clinicians. Similar data were obtained for the 
panel of six top markers (Figure S4-6). 
Discussion 
       Using discovery in live subjects and validation in suicide completers, we 
found possible biomarkers for suicidality. Our top biomarker finding, SAT1, as well 
as PTEN, MARCKS and MAP3K3, were additionally validated by prospective and 
retrospective analyses in live subjects, looking at ability to predict and differentiate 
future and past hospitalizations due to suicidality in bipolar disorder and psychosis 
(schizophrenia/schizoaffective) (Table S4-11). 
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Figure 4-5. Prospective validation of SAT1 (spermidine/spermine N1– 
acetyltransferase 1): follow-up of future psychiatric hospitalizations due to 
suicidality. We analyzed in 42 bipolar subjects whether their SAT1 levels at the 
time of initial testing differentiated those who had subsequent hospitalizations due 
to suicidality in the years since the testing occurred. Range was 0.33–5.92 years 
of follow-up, average 2.48 years. (a) Upper half of SAT1 scores versus lower half 
of SAT1 scores. Twenty-one subjects in each group. There were six psychiatric 
hospitalizations not due to suicidality, and eight psychiatric hospitalizations due to 
suicidality. (b) Upper tertile of SAT1 scores versus lower tertile of SAT1 scores. 
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Fourteen subjects in each group. There were three psychiatric hospitalizations not 
due to suicidality, and four psychiatric hospitalizations due to suicidality.  
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Apoptosis 
       Beyond predictions, as a window into the biology of suicidality, the current 
work shows overlap at a gene and pathway level with apoptosis (Table 4-3, Table 
S4-3, Table S4-4). SAT1, for example, is a key catabolic enzyme for polyamines. 
Polyamine levels within cells control cell viability, and significant decreases in 
polyamine levels can result in apoptosis278. They seem to reflect an endowment 
for cellular and organismal activity and growth, key characteristics of mood84,232,236. 
SAT1, which is increased in live suicidal ideation subjects and in suicide completers 
in our studies, is highly inducible by a variety of stimuli, including toxins, cytokines, 
heat shock, ischemia, and other stresses. SAT1 overexpressing mice had 
alterations in their polyamine pool, hair loss, infertility and weight loss279,280. 
Turecki and colleagues have provided compelling evidence for changes in the 
polyamine system in the brain of suicide completers281. CD24, our top biomarker 
decreased in suicidal subjects, also has roles in apoptosis. Mice lacking CD24 show 
an increased rate of apoptosis282. It could be that simpler mechanisms related to 
cellular survival and programed cell-death decision have been recruited by 
evolution for higher mental functions such as feelings, thoughts, actions and 
behaviors leading to suicidality.  
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Figure 4-6. Multi-dimensional prediction of future psychiatric hospitalizations due 
to suicidality. We analyzed in 42 bipolar subjects whether their SAT1 
(spermidine/spermine N1–acetyltransferase 1), anxiety, mood and psychosis levels 
at the time of initial testing differentiated from those who had subsequent 
hospitalizations due to suicidality in the years since the testing occurred. Data in 
each dimension was normalized to a 0–100 scale (with the mood visual-analog 
scale (VAS) inverted, as the assumption was made that depressed mood states 
would more closely correlate with suicidality). The angle between dimensions was 
assumed to be 901, and a simple Pythagorean distance from origin score was 
calculated. The distribution of this score in the test cohort was used to generate a 
receiver-operating characteristic curve for hospitalizations due to suicidality. (a) 
ROC curve. (b) Detailed results. (c) Three-dimensional visualization. 
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In that sense, suicidality could be viewed as whole-organism self-poptosis. 
Apoptosis mechanisms have previously been implicated in mood disorders and 
their inhibition in affective resilience283. Interestingly, lithium, a medication with 
clinical evidence for preventing suicidality in bipolar disorder284, has anti-apoptotic 
effects at a cellular level285. Imaging studies have shown reduced gray matter 
volume in the brain of individuals with bipolar disorder and history of suicide 
attempts. Long-term lithium treatment was associated with increased gray matter 
volumes in the same areas where suicide was associated with decreased gray 
matter286. 
Conclusions and future directions 
Taken together, our results have implications for the understanding of 
suicide, as well as for the development of objective laboratory tests and tools to 
track suicidal risk and response to treatment. First, our results open empirical 
avenues for future field trials, clinical testing and validation in various at-risk 
populations, including studies in individuals with major depressive disorder. The 
current work was based on subjects with bipolar disorder, psychosis 
(schizophrenia/ schizoaffective disorder), and coroner’s office cases, which may 
represent a more externalizing or impulsive population and type of suicidality. 
Other types are likely to exist. Second, more work also needs to be done to 
examine potential gender and ethnicity differences. Our current work is based on 
male Caucasian subjects. Third, predicting suicidal feelings and thoughts (ideation) 
may be different than predicting suicidal actions and behaviors. Our current work 
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has focused on suicide completers and hospitalizations, admittedly a more 
emergent concern.  Fourth, state vs. trait issues, and sensitivity vs. specificity for 
suicidality, for the individual markers identified by us, as well as for panels of 
markers and multi-modal approaches, need to be studied more extensively in 
different populations. Fifth, past individual and family history, as well as 
environmental context, may help improve predictive approaches. Our approach 
was very focused and reductionist, albeit with good results.  
Given the fact that approximately one million people die of suicide 
worldwide each year, and this is a potentially preventable cause of death, the need 
for, urgency and importance of efforts such as ours cannot be overstated.  
 
  
  
248 
 
 
Chapter 5:  An INTRA n-of-1 approach to biomarker discovery 
The next study represents an evolution in approach to the challenge of 
biomarker discovery.  While the previous study used a discovery cohort design 
consisting of individuals who had a change in suicidal ideation over time, this was 
done so at a group level, comparing group means based on the SI phenotype.  
This is certainly not a wrong approach, but it may not be the best way to get at 
relative changes that are happening within an individual.  287 
We have designed an algorithm that scores assigns simple differential 
expression scores that tracks gene expression over time as it relates to each 
individual persons phenotype.  This methodology is described in greater detail 
below.  Briefly, each successive clinic visit by a participant is scored for change or 
stability in phenotype.  At the same time gene expression is scored in the same 
way.  The score is tabulated for each succession of visits for each individual and 
then summed across all individuals to provide a simple score that indicates how 
well gene expression tracks changes in phenotype.  Methods of this type may be 
more powerful for discovering biomarkers as it helps to minimize noise artifact 
differences between individuals while magnifying true signal differences within 
individuals.   
Because of this innovation we felt confident in our ability to identify 
reproducible signal beyond the singular diagnosis of bipolar disorder used 
previously to also include major depressive disorder, schizophrenia, schizoaffective 
disorder, post traumatic stress disorder, and mood disorder NOS.  This more than 
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quadrupled our n from 9 participants to 37 for discovery and more than doubled 
the size of the independent testing cohorts.  This also enabled us to look at 
diagnostic differences in biomarker performance. 
While there is emerging evidence for biological risk factors for suicidal 
behavior, it is likely that clinical risk assessments and a clinicians judgement will 
remain vital in identifying and preventing suicides, now and in the future.  Gene 
expression or metabolites may lack the specificity to illness without the context of 
clinical assessments and patient history.  Implicated neurotransmitter systems are 
an especially good example.  Dysregulation in the serotonin system has been 
reproducibly indicated in suicide, but this has been found for a multitude of 
psychiatric conditions.  Serotonin dysregulation without the context of patient 
history and clinical data, like other purely biological markers, may never be 
sufficient to assess a patient’s suicidal risk.  The last major evolution in 
methodology was the incorporation of contextual phenotypic data in the form of 
visual analog scales for mood and anxiety, along with the suicide risk assessment 
checklist, the CFI-S.   Integration of clinical information into a universal predictive 
measure (UP-Suicide) showed greatly enhanced predictive ability to identify 
present state suicidal ideation and future hospitalizations due to suicidal behavior.  
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Understanding and predicting suicidality using a combined genomic and 
clinical risk assessment approach 
Introduction 
Predicting suicidal behavior in individuals is one of the hard problems in 
psychiatry, and in society at large. Improved, objective, and quantitative ways to 
do it are needed.  One cannot always ask individuals if they are suicidal, as desire 
not to be stopped or future impulsive changes of mind may make their self-report 
of feelings, thoughts and plans to be unreliable. We had previously provided proof 
of principle of how first generation blood biomarkers for suicide discovered in male 
bipolar participants, alone or in combination with clinical symptoms data for 
anxiety and mood, could have predictive ability for future hospitalizations for 
suicidality. We now present comprehensive new data for discovery, prioritization, 
validation, and testing of next generation broader-spectrum blood biomarkers for 
suicidal ideation and behavior, across psychiatric diagnoses. We also describe two 
clinical information questionnaires in the form of apps, one for affective state 
(Simplified Affective State Scale, SASS) and one for suicide risk factors 
(Convergent Functional Information for Suicide, CFI-S), and show their utility in 
predicting suicidality.  Both these instruments do not directly ask about suicidal 
ideation. Lastly, we demonstrate how our apriori primary endpoint, a 
comprehensive universal predictor for suicide (UP-Suicide), composed of the 
combination of top biomarkers (from discovery, prioritization and validation), along 
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with CFI-S, and SASS, predicts in independent test cohorts suicidal ideation and 
future psychiatric hospitalizations for suicidality. 
Methods 
Human participants  
       We present data from four cohorts: one live psychiatric participants 
discovery cohort; one postmortem coroner’s office validation cohort; and two  live 
psychiatric participants test cohorts–one for predicting  suicidal ideation  and one 
for predicting future hospitalizations for suicidality (Figure 5-1). 
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Figure 5-1. Cohorts used in study depicting flow of discovery, prioritization, 
validation and testing of biomarkers from each step. 
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The live psychiatric participants are part of a larger longitudinal cohort being 
collected and studied by us. Participants are recruited from the patient population 
at the Indianapolis VA Medical Center. The participants are recruited largely 
through referrals from care providers, the use of brochures left in plain sight in 
public places and mental health clinics, and through word of mouth. All participants 
understood and signed informed consent forms detailing the research goals, 
procedure, caveats and safeguards. Participants completed diagnostic 
assessments by an extensive structured clinical interview—Diagnostic Interview 
for Genetic Studies—at a baseline visit, followed by up to six testing visits, 3–6 
months apart or whenever a hospitalization occurred. At each testing visit, they 
received a series of psychiatric rating scales, including the Hamilton Rating Scale 
for Depression-17, which includes a suicidal ideation (SI) rating item (Figure 2), 
and the blood was drawn. Whole blood (10 ml) was collected in two RNA-stabilizing 
PAXgene tubes, labeled with an anonymized ID number, and stored at -80 degrees 
C in a locked freezer until the time of future processing. Whole-blood 
(predominantly lymphocyte) RNA was extracted for microarray gene expression 
studies from the PAXgene tubes, as detailed below. We focused this study on a 
male population because of the demographics of our catchment area (primarily 
male in a VA Medical Center), and to minimize any potential gender-related effects 
on gene expression, which would have decreased the discriminative power of our 
analysis given our relatively small sample size. 
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       Our within-participant discovery cohort, from which the biomarker data 
were derived, consisted of 37 male participants with psychiatric disorders, with 
multiple visits in our lab, who each had at least one diametric change in SI scores 
from no SI to high SI from one testing visit to another testing visit. There was 1 
participant with 6 visits, 1 participant with 5 visits, 1 participant with 4 visits, 23 
participants with 3 visits each, and 11 participants with 2 visits each, resulting in 
a total of 106 blood samples for subsequent microarray studies (Figure 5-2 and 
Table 5-1). 
       Our postmortem cohort, in which the top biomarker findings were validated, 
consisted of a demographically matched cohort of 26 male violent suicide 
completers obtained through the Marion County coroner’s office (Table 5-1 and 
Supplementary Table S5-2). We required a last observed alive postmortem interval 
of 24 h or less, and the cases selected had completed suicide by means other than 
overdose, which could affect gene expression. 15 participants completed suicide 
by gunshot to head or chest, 9 by hanging, 1 by electrocution and 1 by slit wrist. 
Next of kin signed informed consent at the coroner’s office for donation of blood 
for research. The samples were collected as part of our INBRAIN initiative (Indiana 
Center for Biomarker Research in Neuropsychiatry). 
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Figure 5-2. Discovery cohort: longitudinal within-participant analysis. Phchp### 
is study ID for each participant. V# denotes visit number (1, 2, 3, 4, 5 or 6). (a) 
Suicidal ideation (SI) scoring. (b) Participants and visits. (c) PhenoChipping: two-
way unsupervised hierarchical clustering of all participant visits in the discovery 
cohort vs 18 quantitative phenotypes measuring affective state and suicidality. A—
anxiety items (anxiety, uncertainty, fear, anger, average). M—mood items (mood, 
motivation, movement, thinking, self-esteem, interest, appetite, average). SASS, 
simplified affective state scale; STAI-STATE, state trait anxiety inventory, state 
subscale; YMRS, Young Mania Rating Scale. 
        Our independent test cohort for predicting suicidal ideation (Table 5-1) 
consisted of 108 male participants with psychiatric disorders, demographically 
matched with the discovery cohort, with one or multiple testing visits in our lab, 
with either no SI, intermediate SI, or high SI, resulting in a total of 223 blood 
samples in whom whole-genome blood gene expression data were obtained (Table 
5-1 and Table S5-1). 
       Our test cohort for predicting future hospitalizations (Table 5-1 and Table 
S5-1) consisted of male participants in whom whole-genome blood gene 
expression data were obtained by us at testing visits over the years as part of our 
longitudinal study. If the participants had multiple testing visits, the visit with the 
highest marker (or combination of markers) levels was selected for the analyses 
(so called “high watermark” or index visit). The participants’ subsequent number 
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of psychiatric hospitalizations, with or without suicidality, was tabulated from 
electronic medical records. 
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All participants had at least one year of follow-up or more at our VA Medical Center 
since the time of the testing visits in the lab. Participants were evaluated for the 
presence of future hospitalizations for suicidality, and for the frequency of such 
hospitalizations. A hospitalization was deemed to be without suicidality if suicidality 
was not listed as a reason for admission, and no SI was described in the admission 
and discharge medical notes. Conversely, a hospitalization was deemed to be 
because of suicidality if suicidal acts or intent was listed as a reason for admission, 
and/or SI was described in the admission and discharge medical notes. 
Medications 
       The participants in the discovery cohort were all diagnosed with various 
psychiatric disorders (Table 5-1). Their psychiatric medications were listed in their 
electronic medical records, and documented by us at the time of each testing visit. 
The participants were on a variety of different psychiatric medications: mood 
stabilizers, antidepressants, antipsychotics, benzodiazepines and others (data not 
shown). Medications can have a strong influence on gene expression. However, 
our discovery of differentially expressed genes was based on within- participant 
analyses, which factor out not only genetic background effects but also medication 
effects, as the participants had no major medication changes between visits. 
Moreover, there was no consistent pattern in any particular type of medication, or 
between any change in medications and SI, in the rare instances where there were 
changes in medications between visits. 
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Human blood gene expression experiments and analyses 
      RNA extraction. Whole blood (2.5–5 ml) was collected into each PaxGene 
tube by routine venipuncture. PaxGene tubes contain proprietary reagents for the 
stabilization of RNA. RNA was extracted and processed as previously described217. 
       Microarrays. Biotin-labeled aRNAs were hybridized to Affymetrix HG-U133 
Plus 2.0 GeneChips (Affymetrix; with over 40,000 genes and expressed sequence 
tags), according to the manufacturer’s protocols. Arrays were stained using 
standard Affymetrix protocols for antibody signal amplification and scanned on an 
Affymetrix GeneArray 2500 scanner with a target intensity set at 250. Quality-
control measures, including 30/50 ratios for glyceraldehyde 3-phosphate 
dehydrogenase and b-actin, scale factors, and background, were within acceptable 
limits. 
       Analysis. We have used the participant’s SI scores at the time of blood 
collection (0—no SI compared with 2 and above—high SI). We looked at gene 
expression differences between the no SI and the high SI visits, using a within-
participant design, then an across-participants summation (Figure 5-2). 
Gene expression analyses in the discovery cohort 
       We analyzed the data in two ways: an Absent-Present (AP) approach, as in 
previous work by us on mood biomarkers15 and on psychosis biomarkers24, and a 
differential expression (DE) approach, as in previous work by us on suicide 
biomarkers217.  The AP approach may capture turning on and off of genes, and 
the DE approach may capture gradual changes in expression. For the AP approach, 
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we used Affymetrix Microarray Suite Version 5.0 (MAS5) to generate Absent (A), 
Marginal (M), or Present (P) calls for each probeset on the chip (Affymetrix U133 
Plus 2.0 GeneChips) for all participants in the discovery cohort.  For the DE 
approach we imported all Affymetrix microarray data as .cel files into Partek 
Genomic Suites 6.6 software package (Partek Incorporated, St Louis, MI, USA). 
Using only the perfect match values, we ran a robust multi-array analysis (RMA), 
background corrected with quantile normalization and a median polish probeset 
summarization, to obtain the normalized expression levels of all probesets for each 
chip.  RMA was performed independently for each of the 6 diagnoses used in the 
study, to avoid potential artefacts due to different ranges of gene expression in 
different diagnoses288.  Then the participant’s normalized data was extracted from 
these RMAs and assembled for the different cohorts used in the study.  
        A/P analysis. For the longitudinal within-participant AP analysis, 
comparisons were made within-participant between sequential visits to identify 
changes in gene expression from Absent to Present that track changes in phene 
expression (suicidal ideation) from No SI to High SI.  For a comparison, if there 
was a change from A to P tracking a change from No SI to High SI, or a change 
from P to A tracking a change from High SI to No SI, that was given a score of +1 
(increased biomarker in High SI). If the change was in opposite direction in the 
gene vs the phene (SI), that was given a score of -1 (decreased biomarker in High 
SI). If there was no change in gene expression between visits despite a change of 
phene expression (suicidal ideation), or a change in gene expression between visits 
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despite no change in phene expression (suicidal ideation), that was given a score 
of 0 (not tracking as a biomarker). If there was no change in gene expression and 
no change in suicidal ideation between visits, that was given a score of +1 if there 
was concordance (P-P with High SI-High SI, or A-A with No SI-No SI), or a score 
of -1 if there was the opposite (A-A with High SI-High SI, or P-P with No SI-No 
SI). If the changes were to M (moderate) instead of P, the values used were 0.5 
or –0.5.  These values were then summed up across the comparisons in each 
participant, resulting in an overall score for each gene/probeset in each participant. 
We also used a perfection bonus. If the gene expression perfectly tracked the 
suicidal ideation in a participant that had at least two comparisons (3 visits), that 
probeset was rewarded by a doubling of its overall score.  Additionally, we used a 
non-tracking correction. If there was no change in gene expression in any of the 
comparisons for a particular participant, that overall score for that probeset in that 
participant was zero. 
       DE analysis. For the longitudinal within-participant DE analysis, fold changes 
(FC) in gene expression were calculated between sequential visits within each 
participant.  Scoring methodology was similar to that used above for AP.  Probesets 
that had a FC ≥ 1.2 were scored + 1 (increased in High SI) or -1 (decreased in 
High SI).  FC ≥ 1.1 were scored +0.5 or -0.5.  FC lower than 1.1 was considered 
no change.  The only difference between the DE and the AP analyses was when 
scoring comparisons where there was no phene expression (SI) change  between 
visits and no change in gene expression between visits (FC lower than 1.1). In that 
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case, the comparison received the same score as the nearest preceding 
comparison where there was a change in SI from visit to visit.  If no preceding 
comparison with a change in SI was available, then it was given the same score 
as the nearest subsequent comparison where there was a change in SI.  For DE 
also we used a perfection bonus and a non-tracking correction. If the gene 
expression perfectly tracked the suicidal ideation in a participant that had at least 
two comparisons (3 visits), that probeset was rewarded by a doubling of its score. 
If there was no change in gene expression in any of the comparisons for a 
particular participant, that overall score for that probeset in that participant was 
zero. 
       Internal score. Once scores within each participant were calculated, an 
algebraic sum across all participants was obtained, for each probeset. Probesets 
were then given internal points based upon these algebraic sum scores.  Probesets 
with scores  above the 33.3% of the distribution (for increased probesets and 
decreased probesets) received 1 point, those above 50%  of the distribution 
received 2 points, and those above 80% of the distribution received 4 points. For 
AP analyses, we have 23 probesets which received 4 points, 581 probesets with 2 
points, and 2077 probesets with 1 point, for a total of 2681 probesets. For DE 
analyses, we have 31 probesets which received 4 points, 1294 probesets with 2 
points, and 5839 probesets with 1 point, for a total of 7164 probesets. The overlap 
between the two discovery methods is shown in Figure 5-3. Different probesets 
may be found by the two methods due to differences in scope (DE capturing genes 
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that are present in both visits of a comparison, i.e. PP, but are changed in 
expression), thresholds (what makes the 33.3% change cutoff across participants 
varies between methods), and technical detection levels (what is considered in the 
noise range varies between the methods). 
      In total, we identified 9413 probesets with internal CFG score of 1. Gene 
names for the probesets were identified using NetAffyx (Affymetrix) and Partek for 
Affymetrix HG-U133 Plus 2.0 GeneChips, followed by GeneCards to confirm the 
primary gene symbol. In addition, for those probesets that were not assigned a 
gene name by NetAffyx or Partek, we used the UCSC Genome Browser to directly 
map them to known genes, with the following limitations:  1. in case the probeset 
fell in an intron, that particular gene was assumed to be implicated;  2. only one 
gene was assigned to each probeset. Genes were then scored using our manually 
curated CFG databases as described below (Figure 5-3). 
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Figure 5-3. Biomarker discovery, prioritization and validation. (a) Discovery—
number of probesets carried forward from the absent–present and differential 
expression analyses, with an internal score of 1 and above. Red-increased in 
expression in high suicidal ideation, blue-decreased in expression in high suicidal 
ideation. (b) Prioritization—convergent functional genomics integration of multiple 
lines of evidence to prioritize suicide-relevant genes from the discovery step. (c) 
Validation—top convergent functional genomics genes, with a total score of 4 and 
above, validated in the cohort of suicide completers. All the genes shown were 
significantly changed in analysis of variance from no suicidal ideation to high 
suicidal ideation to suicide completers. *Survived Bonferroni correction. SAT1 (x3) 
had three different probesets with the same total score of 8. 
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Convergent Functional Genomics 
       As described in Universal Methods. 
Pathway Analyses 
        IPA 9.0 (Ingenuity Systems, www.ingenuity.com, Redwood City, CA, USA), 
GeneGO MetaCore (Encinitas, CA), and Kyoto Encyclopedia of Genes and Genomes 
(KEGG) (through the Partek Genomics Suite 6.6 software package) were used to 
analyze the biological roles, including top canonical pathways, and diseases, of the 
candidate genes resulting from our work, as well as to identify genes in our dataset 
that are the target of existing drugs (Table 5-3 and S5-3). We ran the analyses 
together for all the AP and DE probesets with a total CFG score ≥ 4, then for those 
of them that showed stepwise change in the suicide completer’s validation cohort, 
then for those of them that were nominally significant, and finally for those of 
them that survived Bonferroni correction.   
Validation analyses 
       For validation of our candidate biomarker genes, we examined which of the 
top candidate genes (CFG score of 4 or above) were stepwise changed in 
expression from the No SI group to the High SI group to the suicide completers 
group. We used an empirical cutoff of 33.3% of the maximum possible CFG score 
of 12, which also permits the inclusion of potentially novel genes with maximal 
internal CFG score but no external CFG score. Statistical analyses were performed 
in SPSS using one-way ANOVA and Bonferroni corrections.   
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       For the AP analyses, we imported the Affymetrix microarray data files from 
the participants in the validation cohort of suicide completers into MAS5, alongside 
the data files from the participants in the discovery cohort 
       For the DE analyses, we imported .cel files into Partek Genomic Suites. We 
then ran a RMA, background corrected with quantile normalization, and a median 
polish probeset summarization of all the chips from the validation cohort to obtain 
the normalized expression levels of all probesets for each chip. Partek normalizes 
expression data into a log base of 2 for visualization purposes. We non-log-
transformed expression data by taking 2 to the power of the transformed 
expression value. We then used the non-log-transformed expression data to 
compare expression levels of biomarkers in the different groups (Figure S5-1).  
Clinical measures 
       The Simplified Affective State Scale (SASS) is an 11 item scale for measuring 
mood and anxiety, previously developed and described by us as TASS (Total 
Affective State Scale) 277. The SASS has a set of 11 visual analog scales (7 for 
mood, 4 for anxiety) that ends up providing a number ranging from 0 to 100 for 
mood state, and the same for anxiety state. We have now developed an Android 
app version (Figure S5-2). 
      Convergent Functional Information for Suicidality (CFI-S) (Table 5-4) is a new 
22 item scale and Android app (Figure S5-2) for suicide risk, which integrates, in 
a simple binary fashion (Yes-1, No-0), similar to a polygenic risk score, information 
about known life events, mental health, physical health, stress, addictions, and 
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cultural factors that can influence suicide risk289 290. For live psychiatric 
participants, the scale was administered at participant testing visits (n= 57), or 
scored based on retrospective electronic medical record information and 
Diagnostic Interview for Genetic Testing (DIGS) information (n=269). For suicide 
completers (n=35), the scale was based on answers provided by next of kin, and 
corroborated by coroner’s office reports and medical record information. When 
information was not available for an item, it was not scored (NA).  
Combining gene expression and clinical measures 
       The Universal Predictor for Suicide (UP-Suicide) construct was decided upon 
as part of our apriori study design to be broad- spectrum, and combine our top 
biomarkers from each step (discovery, prioritization, validation) with the phenomic 
(clinical) markers (SASS and CFI-S). That was our primary endpoint. Had we done 
it post-hoc with only the markers that showed the best predictive ability in our 
testing analyses, the results would be even better, but not independent.  
Testing analyses 
       The test cohort for suicidal ideation and the test cohort for future 
hospitalizations analyses were assembled out of data that was RMA normalized by 
diagnosis. Phenomic (clinical) and gene expression markers used for predictions 
were z scored by diagnosis, to be able to combine different markers into panels 
and to avoid potential artefacts due to different ranges of phene expression and 
gene expression in different diagnoses.  Markers were combined by computing the 
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average of the increased risk markers minus the average of the decreased risk 
markers.  Predictions were performed using R-studio.   
Predicting Suicidal Ideation. Receiver-operating characteristic (ROC) analyses 
between marker levels and suicidal ideation (SI) were performed by assigning 
participants with a HAMD-SI score of 0-1 into the no SI category, and participants 
with a HAMD-SI score of 2 and greater into the SI category.  Additionally, ANOVA 
was performed between no (HAMD-SI 0), intermediate (HAMD-SI 1), and high SI 
participants (HAMD-SI 2 and above) and Pearson R (one-tail) was calculated 
between HAMD-SI scores and marker levels (Table 5B-5 and Figure 5-5).  
Predicting Future Hospitalizations for Suicidality. We conducted analyses 
for hospitalizations in the first year following testing, on the participants for which 
we had at least a year of follow-up data. For each participant in the test cohort for 
future hospitalizations, the study visit with highest levels for the marker or 
combination of markers was selected as index visit (or with the lowest levels, in 
the case of decreased markers). ROC analyses between marker levels and future 
hospitalizations were performed based on assigning if participants had been 
hospitalized for suicidality (ideation, attempts) or not following the index testing 
visit.  Additionally, a one tailed t-test with unequal variance was performed 
between groups of participants with and without hospitalizations for suicidality.  
Pearson R (one-tail) correlation was performed between hospitalization frequency 
(number of hospitalizations for suicidality divided by duration of follow-up) and 
biomarker score. We also conducted only the correlation analyses for 
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hospitalizations frequency for all future hospitalizations due to suicidality, beyond 
one year, as this calculation, unlike the ROC and t-test, accounts for the actual 
length of follow-up, which varied beyond one year from participant to participant.  
Figures 
Each figure in this chapter was completed by Daniel Levey and Helen Le-
Niculescu.  This work has been published.  196 
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Table 5-2 Top biomarkers for suicidality from Discovery, Prioritization and 
Validation. 
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Results 
Discovery of biomarkers for suicidal ideation     
       We conducted whole-genome gene expression profiling in the blood 
samples from a longitudinally followed cohort of male participants with psychiatric 
disorders that predispose to suicidality. The samples were collected at repeated 
visits, 3–6 months apart. State information about suicidal ideation (SI) was 
collected from a questionnaire (HAMD) administered at the time of each blood 
draw (Table S5-1). Out of 217 psychiatric participants (with a total of 531 visits) 
followed longitudinally in our study, there were 37 participants that switched from 
a no SI (SI score of 0) to a high SI state (SI score of 2 and above) at different 
visits, which was our intended discovery group (Figure 5-2). We used a powerful 
within-participant design to analyze data from these 37 participants and their 106 
visits.  A within-participant design factors out genetic variability, as well as some 
medications, lifestyle, and demographic effects on gene expression, permitting 
identification of relevant signal with Ns as small as 114.  Another benefit of a within-
participant design may be accuracy/consistency of self-report of psychiatric 
symptoms (‘phene expression’), similar in rationale to the signal detection benefits 
it provides in gene expression. The number of participants that met our criteria 
and were analyzed is small, but comparable to those in human postmortem brain 
gene expression studies of suicide. We are indeed treating the blood samples as 
surrogate tissue for brains, with the caveat that they are not the real target organ. 
However, with the blood samples from live human participants we have the 
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advantages of in vivo accessibility, better knowledge of the mental state at the 
time of collection, less technical artifacts and especially of being able to do 
powerful within-participant analyses from visit to visit.  
       For discovery, we used two differential expression methodologies: 
Absent/Present (reflecting on/off of transcription), and Differential Expression 
(reflecting more subtle gradual changes in expression levels). The genes that 
tracked suicidal ideation in each participant were identified in our analyses.  We 
used three thresholds for increased in expression genes and for decreased in 
expression genes: ≥ 33.3% (low), ≥50% (medium), and ≥ 80% (high) of the 
maximum scoring increased and decreased gene across participants.  Such a 
restrictive approach was used as a way of minimizing false positives, even at the 
risk of having false negatives. For example, there were genes on each of the two 
lists, from AP and DE analyses, that had clear prior evidence for involvement in 
suicidality, such as OLR1303,248 (32%) and LEPR252, 217 (32%) for AP, and  
OPRM1304, 305 (32%) and CD24 248, 217 (33%) from DE, but were not included in 
our subsequent analyses because they did not meet our apriori set 33.3% 
threshold. 
Prioritization of biomarkers based on prior evidence in the field 
       These differentially expressed genes were then prioritized using a Bayesian-
like Convergent Functional Genomics (CFG) approach (Figure 5-3) integrating all 
the previously published human genetic evidence, postmortem brain gene 
expression evidence, and peripheral fluids evidence for suicide in the field available 
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at the time of our final analyses (September 2014).This is a way of  identifying 
and prioritizing disease relevant genomic biomarkers, extracting generalizable 
signal out of potential cohort-specific noise and genetic heterogeneity. We have 
built in our lab manually curated databases of the psychiatric genomic and 
proteomic literature to date, for use in CFG analyses. The CFG approach is thus a 
de facto field-wide collaboration. We use in essence, in a Bayesian fashion, the 
whole body of knowledge in the field to leverage findings from our discovery data 
sets. Unlike our use of CFG in many previous studies, for the current one we did 
not use any animal model evidence, as there are to date no clear  animal models 
of self-harm or suicidality published to date. 
Validation of biomarkers for behavior in suicide completers 
       For validation in suicide completers, we used 412 genes that had a CFG 
score of 4 and above, from AP and DE, reflecting either maximum internal score 
from discovery or additional external literature cross-validating evidence. Out of 
these, 208 did not show any stepwise change in suicide completers (NC- non-
concordant). As such, they may be involved primarily in ideation and not in 
behavior (Table S5-6). The remaining 204 genes ( 49.5%) had levels of expression 
that were changed stepwise from no suicidal ideation to high suicidal ideation to 
suicide completion. 143 of these genes ( 34.7%) were nominally significant, and 
76 genes (18.4%)  survived Bonferroni correction for multiple comparisons 
(Figures 5-3 and S5-1). These genes are likely involved in suicidal ideation and 
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suicidal behavior. (You can have suicidal ideation without suicidal behavior, but 
you cannot have suicidal behavior without suicidal ideation). 
Selection of biomarkers for testing of predictive ability 
       For testing, we decided apriori to select the top scoring increased and 
decreased biomarkers from each step (discovery, prioritization, validation), so as 
to avoid potential false negatives in the prioritization step due to lack of prior 
evidence in the literature, or false negatives in validation step due to possible 
postmortem artefacts. The top scoring genes after the discovery step were DTNA 
and KIF2C from AP, CADM1 and CLIP4 from DE. The top genes after the 
prioritization with CFG step were SLC4A4 and SKA2 from AP, SAT1 and SKA2 from 
DE. The top genes after the validation in suicide completers step were IL6 and 
MBP from AP, JUN and KLHDC3 from DE (Figure 5-3).  Notably, our SAT1 finding 
is a replication and expansion of our previously reported results identifying SAT1 
as a blood biomarker for suicidality in bipolars (Le-Niculescu et al. 2013), and our 
SKA2 finding is an independent replication of a previous report identifying SKA2 as 
a blood biomarker for suicidality by  Kaminsky and colleagues220. We also 
replicated in this larger cohort other top biomarkers from our previous work in 
bipolar disorder, notably MARCKS and PTEN (Table 5-2, Figure S5-4). A number 
of other genes we identified (CADM1, KIF2C, DTNA, CLIP4) are completely novel 
in terms of their involvement in suicidality.  
Biological understanding 
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       We also sought to understand the biology represented by the biomarkers 
identified by us, and derive some mechanistic and practical insights. We 
conducted: 1. unbiased biological pathway analyses and hypothesis driven 
mechanistic queries, 2. overall disease involvement and specific neuropsychiatric 
disorders queries, and 3. overall drug modulation along with targeted queries for 
omega-3, lithium and clozapine306 (Tables 5-3, S5-3, S5-4). Administration of 
omega-3s in particular may be a mass- deployable therapeutic and preventive 
strategy167. 
       The sets of biomarkers identified have biological roles in immune and 
inflammatory response, growth factor regulation, mTOR signaling, stress, and 
perhaps overall the switch between cell survival and proliferation vs. apoptosis 
(Tables 5-3 and S5-3). 14% of the candidate biomarkers in Table S5-3 have 
evidence for involvement in psychological stress response, and 19% for 
involvement in programmed cell death/ cellular suicide (apoptosis). An 
extrapolation can be made and model proposed whereas suicide is a whole body 
apoptosis (or “self-poptosis”) in response to perceived stressful life events.  
       We also examined evidence for the involvement of these biomarkers for 
suicidality in other psychiatric disorders, permitting us to address issues of context 
and specificity (Table S5-3).  SKA2, HADHA, SNORA68,  RASL11B, CXCL11, 
HOMEZ, LOC728543, AHCYL1, LDLRAP1, NEAT1 and PAFAH1B2 seem to be 
relatively specific for  
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suicide, based on the evidence to date in the field. SAT1, IL6 , FOXN3 and FKBP5 
are less specific for suicide, having equally high evidence for involvement in suicide 
and in other psychiatric disorders, possibly mediating stress response as a common 
denominator248,307. These boundaries and understanding will likely change as 
additional evidence in the field accumulates. For example, CADM1, discovered in 
this work as a top biomarker for suicide, had previous evidence for involvement in 
other psychiatric disorders, such as autism and bipolar disorder. Interestingly, it 
was identified in a previous study by us as a blood biomarker increased in 
expression in low mood states in bipolar participants, and it is increased in 
expression in the current study in high suicidal ideation states. Increased 
expression of CADM1 is associated with decreased cellular proliferation and with 
apoptosis, and this gene is decreased in expression or silenced in certain types of 
cancers. 
       A number of other genes besides CADM1 are changed in opposite direction 
in suicide in this study vs. high mood in our previous mood biomarker study-CHD2, 
MBP, LPAR1, IGHG1, TEX261 (Table S5-3), suggesting that suicidal participants 
are in a low mood state.   Also, some of the top suicide biomarkers are changed 
in expression in the same direction as in high psychosis participants in a previous 
psychosis biomarker study of ours -PIK3C2A, GPM6B, PCBD2, DAB2, IQCH, LAMB1, 
TEX261 (Table S5-3), suggesting that suicidal participants may be in a psychosis-
like state. TEX261 in particular appears in all three studies, decreased in expression 
in suicide and high hallucinations, and increased in expression in high mood. This 
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protective marker may be an interesting target for future biological studies and 
drug development. Taken together, the data indicates that suicidality could be 
viewed as a psychotic dysphoric state, and that TEX261 may be a key biomarker 
reflecting that state. This molecularly informed view is consistent with the 
emerging clinical evidence in the field308.  
      Lastly, we conducted biological pathway analyses on the genes that, after 
discovery and prioritization, were stepwise changed in suicide completers (n=204) 
and may be involved in ideation and behavior, vs. those that were not stepwise 
changed (n=208), and that may only be involved in ideation (Table S5-6). The 
genes involved in ideation map to pathways related to neuronal connectivity 
(cytoskeleton rearrangement, axonal guidance) and schizophrenia. The genes 
involved in behavior map to pathways related to neuronal activity (WNT, growth 
factors) and mood disorders. This is consistent with ideation being related to 
psychosis, and behavior being related to mood. Of note, clinically, the risk for 
suicide behavior/completion is higher in mood disorders than in psychotic 
disorders.  
Clinical information 
       We also developed a simple new 22 item scale and app for suicide risk, 
Convergent Functional Information for Suicidality (CFI-S), which scores in a simple 
binary fashion and integrates,  information about known life events, mental health, 
physical health, stress, addictions, and cultural factors that can influence suicide 
risk289 290. Clinical risk predictors and scales are of high interest in the military309  
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and in the general population at large310.  Our scale builds on those excellent prior 
achievements, while aiming for comprehensiveness, simplicity and quantification 
similar to a polygenic risk score. CFI-S is able to distinguish between individuals 
who committed suicide (coroner’s cases n=35, information obtained from the next 
of kin) and those high risk participants who did not but had experienced changes 
in suicidal ideation (our discovery cohort of psychiatric participants) (Figure 5-4). 
We analyzed which items of the CFI-S scale were the most significantly different 
between high suicidal ideation live participants and suicide completers. We 
identified 7 items that were significantly different, 5 of which survived Bonferroni 
correction: lack of coping skills when faced with stress (p= 3.35E-11), 
dissatisfaction with current life (p=2.77E-06), lack of hope for the future (4.58E-
05), current substance abuse (p=1.25E-04), and acute loss/grief (p= 9.45E-5). It 
is highly interesting that the top item was inability to cope with stress, which is 
independently consistent with our biological marker results.  
      We also simplified the wording (and developed a new app for) an 11 item 
scale for measuring mood and anxiety, the Simplified Affective State Scale (SASS), 
previously developed and described by us as TASS (Total Affective State Scale) 
277. The SASS is a set of 11 visual analog scales (7 for mood, 4 for anxiety) that 
ends up providing a number ranging from 0 to 100 for mood state, and the same 
for anxiety state. 
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Figure 5-4. Convergent Functional Information for Suicide (CFI-S) Scale. (a) 
Validation of scale. Convergent Functional Information for Suicide levels in the 
discovery cohort and suicide completers. (b) Validation of items. Convergent 
Functional Information for Suicide was developed independently of any data from 
this study, by compiling known sociodemographic and clinical risk factors for 
suicide. It is composed of 22 items that assess the influence of mental health 
factors, as well as of life satisfaction, physical health, environmental stress, 
addictions, cultural factors known to influence suicidal behavior, and two 
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demographic factors, age and gender. These 22 items are shown here validated 
in the discovery cohort and suicide completers in a manner similar to that for 
biomarkers. Additionally, a student’s t-test was used to evaluate items that were 
increased in suicide completers when compared to living participants with high 
suicidal ideation. (c) Predictions. Convergent Functional Information for Suicide 
predicting SI in the independent test cohort, and predicting future hospitalizations 
due to suicidality. 
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Testing for predictive ability  
       The best single biomarker predictor for suicidal ideation state across all 
diagnostic groups is SLC4A4 (ROC AUC 0.72, p-value 2.41E-05), the top increased 
biomarker from our prioritization with CFG of discovery data from AP (Table 5-5). 
Within diagnostic groups, the accuracy is even higher. SLC4A4 has very good 
accuracy at predicting future high suicidal ideation in bipolar participants (AUC 
0.93, p-value 9.45E-06) and good accuracy in schizophrenia participants (AUC 
0.76, p-value 0.030). SLC4A4 is a sodium-bicarbonate co-transporter that 
regulates intracellular pH, and possibly apoptosis. Very little is known to date about 
its roles in the brain, thus representing a completely novel finding. Brain pH has 
been reported by Wemmie and colleagues to play a role in pain, fear and panic 
attacks311, which clinically share features with acute suicidal ideation states. 
       SKA2, the top decreased  biomarker from prioritization with CFG of 
discovery data from  AP and DE,  has good accuracy at predicting suicidal ideation 
across all diagnostic groups ( AUC 0.69, p-value 0.00018), and  even better  
accuracy in bipolar participants (AUC 0.76, p-value 0.0045) and schizophrenia 
participants (AUC 0.82, p-value 0.011).  
       The best single biomarker predictor for future hospitalizations for suicidal 
behavior in the first year across all diagnostic groups was SAT1, the top increased 
biomarker from the prioritization with CFG of discovery data from DE (AUC 0.55, 
p-value 0.28). The results across all diagnoses are modest, likely due to the 
significant variation of markers by diagnostic group (Table 5-5 and Figure S5-4). 
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This seems to be even more of an issue for trait than for state predictions. Within 
diagnostic groups, in bipolar disorder, the SAT1 prediction accuracy for future 
hospitalizations is higher (AUC 0.63, p-value 0.18), consistent with our previous 
work217. CADM1 (AUC 0.72, p-value 0.076), SKA2 (AUC 0.71, p-value 0.056), and 
SLC4A4 (AUC 0.70, p-value 0.08) are even better predictors than SAT1 in bipolar 
disorder.  
       CFI-S has very good accuracy (AUC 0.89, p-value 3.53E-13) at predicting 
suicidal ideation in psychiatric participants across diagnostic groups (Figure 4C-5). 
Within diagnostic groups, in affective disorders, the accuracy is even higher. CFI-
S has excellent accuracy at predicting high suicidal ideation in bipolar participants 
(AUC 0.97, p-value 1.75E-06) and in depression participants (AUC 0.95, p-value 
7.98E-06).    CFI-S has good accuracy (AUC 0.71, p-value 0.006) at predicting 
future hospitalizations for suicidality in the first year, across diagnostic groups. 
       SASS has very good accuracy (AUC 0.85, 9.96E-11) at predicting suicidal 
ideation in psychiatric participants across diagnostic groups. Within diagnostic 
groups, in bipolar disorder, the accuracy is even higher (AUC 0.87, p-value 
0.00011).  SASS also has good accuracy (AUC 0.71, p-value 0.008) at predicting 
future hospitalizations for suicidality in the first year following testing. 
       Our apriori primary endpoint was a combined universal predictor for suicide 
(UP-Suicide), composed of the top increased and decreased biomarkers (n=11) 
from the discovery for ideation (CADM1, CLIP4, DTNA, KIF2C), prioritization with 
CFG for prior evidence (SAT1, SKA2, SLC4A4), and validation for behavior in 
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suicide completers (IL6, MBP, JUN, KLHDC3) steps, along with CFI-S, and SASS. 
UP-Suicide is an excellent predictor of suicidal ideation across all disorders in the 
independent cohort of psychiatric  
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participants (AUC 0.92, p-value 7.94E-15) (Figure 5-6). UP-Suicide also has good 
predictive ability for future psychiatric hospitalizations for suicidality in the first 
year of follow-up (AUC 0.71, p-value 0.0094). The predictive ability of UP-Suicide 
is notably higher in affective disorder participants (bipolar, depression) (Table 5-5 
and Figure 5-5). 
Discussion 
       We carried out systematic studies to identify clinically useful predictors for 
suicide.  Our work focuses on identifying markers involved in suicidal ideation and 
suicidal behavior, including suicide completion. Markers involved in behavior may 
be on a continuum with some of the markers involved in ideation, varying in the 
degree of expression changes from less severe (ideation) to more severe 
(behavior). One cannot have suicidal behavior without suicidal ideation, but it may 
be possible to have suicidal ideation without suicidal behavior. 
        As a first step, we sought to use a powerful but difficult to conduct within-
participant design for discovery of blood biomarkers. Such a design is more 
informative than case-control, case-case, or even identical twins designs. The 
power of a within-participants longitudinal design for multi-omic discovery was first 
illustrated by Snyder and colleagues14 in a landmark paper with an n=1.  We 
studied a cohort of male participants with major psychiatric disorders (n=217 
participants) followed longitudinally (2 to 6 testing visits, at 3 to 6 months interval). 
In a smaller (n=37) but very valuable subset of these participants, we captured 
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one or more major  switches from a no suicidal ideation state to a high suicidal 
ideation state at the time of the different testing visits (Figure 5-1 and 5-2). 
       Second, we conducted whole-genome gene expression discovery studies in 
the participants that exhibited the switches, using a longitudinal within-participant 
design, which factors out genetic variability and reduces environmental variability 
as well. We have demonstrated the power of such a design in our previous work 
on suicide biomarkers with an n=9217. Our current n=37 was four-fold higher, and 
consequently our power to detect signal was commensurately increased (Figure 5-
2). Genes whose levels of expression tracked suicidal ideation within each 
participant were identified.   
       Third, the lists of top candidate biomarkers for suicidal ideation from the 
discovery and prioritization step (genes with a CFG score of 4 and above, reflecting 
genes that have maximal experimental internal evidence from this study and/or 
additional external literature cross-validating evidence), were additionally validated 
for involvement in suicidal behavior in a cohort of demographically matched suicide 
completers from the coroner’s office (n=26) (Figure 5-3).  
       Given that we used two methods (AP, DE), three steps (discovery for 
ideation, prioritization based on literature evidence, validation for behavior in 
completers), and two types of markers (increased, decreased), we anticipated 
having 2 x 3 x 2 =12 top markers. We ended up with 11 due to overlap (Table 5-
2). Of note, 8 of these 11 markers ( SAT1, SKA2, SLC4A4, KIF2C, MBP, IL6, JUN, 
KLHDC3), were significant in validation for behavior in terms of being changed 
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even more in suicide completers, and 5 of them survived Bonferroni correction 
(SAT1, SLC4A4, MBP, IL6, KLHDC3). The 3 out of 11 markers that were not 
validated for behavior   (DTNA, CLIP4 and CADM1) seemed indeed better in the 
independent test cohorts at predicting suicidal ideation than at predicting suicidal 
behavior (hospitalizations) (Table 5-5B).  
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Figure 5-5. Testing of universal predictor for suicide (UP-Suicide). UP-Suicide is 
a combination of our best gene expression biomarkers (top increased and 
decreased biomarkers from discovery, prioritization by CFG, and validation in 
suicide completers steps), and phenomic data (CFI-S and SASS). (a) Area Under 
the Curve (AUC) for the UP-Suicide predicting suicidal ideation and hospitalizations 
within the first year in all participants, as well as separately in bipolar (BP), major 
depressive disorder (MDD), schizophrenia (SZ), and schizoaffective (SZA) 
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participants. **Indicates the comparison survived Bonferroni correction for 
multiple comparisons. *Indicates nominal significance of Po0.05. Bold outline 
indicates that the UP-Suicide was synergistic to its components, i.e., performed 
better than the gene expression biomarkers or phenomic data individually. (b) 
Table containing descriptive statistics for all participants together, as well as 
separately in BP, MDD, SZ, and SZA. Bold indicates the measure survived 
Bonferroni correction for 200 comparisons (20 genomic and phenomic 
markers/combinations × 2 testing cohorts for SI and future hospitalizations in the 
first year × 5 diagnostic categories–all, BP, MDD, SZA, SZ). We also show Pearson 
correlation data in the suicidal ideation test cohort for HAMD-SI vs. UP-Suicide, as 
well as Pearson correlation data in the hospitalization test cohort for frequency of 
hospitalizations for suicidality in the first year, and for frequency of hospitalizations 
for suicidality in all future available follow-up interval (which varies among 
participants, from 1 year to 8.5 years).    
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Fourth, we describe a novel, simple and comprehensive phenomic (clinical) 
risk assessment scale, the Convergent Functional Phenomics for Suicidality (CFI-
S) scale, as well as a companion app to it for use by clinicians and individuals 
(Figure S5-2). CFI-S was developed independently of any data from this study, by 
integrating known risk factors for suicide from the clinical literature. It has a total 
of 20 items (scored in a binary fashion- 1 for present, 0 for absent, NA for 
information not available) that assess the influence of mental health factors, as 
well as of  life satisfaction, physical health, environmental stress, addictions, and 
cultural factors known to influence suicidal behavior. It also has 2 demographics 
risk factors items: age and gender. The result is a simple polyphenic risk score 
with  an absolute range of 0 to 22, normalized by the number of items on which 
we had available information, resulting in a score in the range from  0 to 1 (Table 
5-4). We present data validating the CFI-S in our discovery cohort of live 
psychiatric participants and in suicide completers from the coroner’s office (Figure 
5-4). We acknowledge the possibility of a potential upward bias in next-of-kin 
reporting post-suicide completion, although each item of the scale was scored 
factually by a trained rater on its own merits. We believe it is still illustrative and 
informative to compare the CFI-S in live participants with ideation vs. suicide 
completers, and identify which items are most different (such as inability to cope 
with stress, which is consistent with biological data from the biomarker side of our 
study).  
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       Fifth, we have also assessed anxiety and mood, using a visual analog 
Simplified Affective State Scale (SASS), previously described by us (Niculescu et 
al. 2006), for which we now have developed an app version (Figure S5-2). Using 
a PhenoChipping approach277 in our discovery cohort of psychiatric participants, 
we show that anxiety measures cluster with suicidal ideation and CFI-S, and mood 
measures are in the opposite cluster, suggesting that our participants have high 
suicidal ideation when they have high anxiety and low mood (Figure 5-2). We 
would also like to include in the future measures of psychosis, and of stress, to be 
more comprehensive. 
       Sixth, we examined how the biomarkers identified by us are able to predict 
state (suicidal ideation) in a larger independent cohort of psychiatric participants 
(n= 108 participants). 
Seventh, we examined whether the biomarkers are able to predict trait 
(future hospitalizations for suicidal behavior) in psychiatric participants (n=157) in 
the short term (first year of follow-up) as well as overall (all data for future 
hospitalizations available for each patient). 
       Last but not least, we demonstrate how our apriori primary endpoint, a 
comprehensive universal predictor for suicide (UP-Suicide), composed of the 
combination of the top increased and decreased biomarkers (n=11) from the 
discovery, prioritization and validation steps, along with CFI-S, and SASS, predicts 
state (suicidal ideation) and trait (future psychiatric hospitalizations for suicidality). 
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Figure 5-6. Prediction of suicidal ideation by universal predictive measure-suicide. 
(a) (top left) Receiver-operating curve identifying participants with suicidal ideation 
against participants with no suicidal ideation or intermediate SI. (top right) Y axis 
contains the average UP-Suicide scores with standard error of mean for no suicidal 
ideation, intermediate suicidal ideation and high suicidal ideation. (bottom right) 
Scatter plot depicting HAMDSI score on the Y axis and universal predictive 
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measure-suicide score on the X axis with linear trend line. (bottom) Table 
summarizing descriptive statistics. Analysis of variance was performed between 
groups with no suicidal ideation, intermediate suicidal ideation and high suicidal 
ideation. (b) Predictions in test cohort based on thresholds in the discovery cohort 
- average UP-Suicide scores with standard deviation. (c) Number of participants 
correctly identified in the test cohort by categories based on thresholds in the 
discovery cohort. Category 1 means within 1 s.d. above the average of high 
suicidal ideation participants in the discovery cohort, category 2 means between 1 
and 2 s.d. above, and so on. Category 1 means within 1 s.d. below the average of 
the no suicidal ideation participants in the discovery cohort, category 2 means 
between 1 and 2 s.d. below and so on. 
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       The rationale for identifying blood biomarkers as opposed to brain 
biomarkers is a pragmatic one- the brain cannot be readily accessed in live 
individuals. Other peripheral fluids, such as CSF, require more invasive and painful 
procedures. Nevertheless, it is likely that many of the peripheral blood 
transcriptomic changes are not necessarily mirroring what is happening in the 
brain, and vice-versa. The keys to finding peripheral biomarkers288 are, first,  to 
have a powerful discovery approach, such as our within-participant design, that 
closely tracks the phenotype you are trying to measure and reduces noise.  
Second, cross-validating and prioritizing the results with other lines of evidence, 
such as brain gene expression and genetic data, are important in order to establish 
relevance and generalizability of findings. Third, it is important to validate for 
behavior in an independent cohort with a robust and relevant phenotype, in this 
case suicide completers. Fourth,   testing for predictive ability in 
independent/prospective cohorts is a must. 
       Biomarkers that survive such a rigorous step-wise discovery, prioritization, 
validation and testing process are likely directly relevant to the disorder studied. 
As such, we endeavored to study their biology, whether they are involved in other 
psychiatric disorders or are relatively specific for suicide, and whether they are the 
modulated by existing drugs in general, and drugs known to treat suicidality in 
particular. We have identified a series of biomarkers that seem to be changed in 
opposite direction in suicide vs. in treatments with omega-3 fatty acids, lithium, 
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clozapine, or MAOIs. These biomarkers could potentially be used to stratify 
patients to different treatment approaches, and monitor their response 
(Supplementary Table S5-4). 
       We also conducted predictive studies, across all participants and by 
diagnosis, as a way of assessing how generalizable and how particular to a 
diagnosis biomarkers are. Different diagnostic groups have different disease 
biology and are on different medications, which may modify the levels of the 
biomarkers. We observe a significant variation in the predictive ability of 
biomarkers by diagnosis, which has important practical applications for future work 
on diagnostic-specific predictors (Table 5-5).  Of note, a number of biomarkers 
from the current larger study reproduce our previous work in a smaller, bipolar 
cohort (SAT1, MARCKS, PTEN, as well as FOXN3, GCOM1, RECK, IL1B, LHFP, 
ATP6V0E1, and KLHDC3) (Table S5-2). In the current datasets, we have also post-
hoc carried out biomarker discovery within each diagnosis, which revealed a 
diversity of top markers, but should be interpreted with caution given the smaller 
N within each diagnostic group (Table S5-5). 
       Prior to any testing, we planned to use a comprehensive combination of 
genomic data (specifically, the top increased and decreased biomarkers from 
discovery, prioritization, and validation) and phenomic data (specifically, the CFI-
S and the SASS) as the primary endpoint measure, a broad-spectrum universal 
predictor (UP-Suicide) for state suicidal ideation and trait future hospitalizations. 
It has not escaped our attention that certain single biomarkers, particular 
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phenotypic items, or combinations thereof seem to perform better than the UP-
Suicide in one or another type of prediction or diagnostic group (see Table 5-5). 
However, since such markers and combinations were not chosen by us apriori and 
such insights derive from testing, we cannot exclude a fit to cohort effect for them 
and reserve judgement as to their robustness as predictors until further testing in 
additional independent cohorts, by us and others. What we can put forward for 
now based on the current work is the UP-Suicide, which seems to be a robust 
predictor across different scenarios and diagnostic groups.  
       Overall, our predictive ability for trait future hospitalizations is somewhat 
less than for state suicidal ideation (Figure 5-5, Tables 5-5). However, clinically, 
events may indeed be driven by state, and the immediate concern is preventing 
immediate or short term adverse outcomes.  
       Our study has a number of limitations. All this work was carried out in 
psychiatric patients, a high risk group, and it remains to be seen how such 
predictors apply to non-psychiatric participants. Additionally, the current studies 
were carried out exclusively in males. Similar work is needed in females, with and 
without psychiatric disorders. Such work is ongoing in our group. Lastly, for the 
UP-Suicide testing, the prevalence rate for high suicidal ideation in our 
independent test cohort was a relatively low 21% (23 out of 108), and the 
incidence of future hospitalizations for suicidality was even lower:  7.6% in the 
first year (12 out of 157), and 21.0% overall (33 out of 157) (Figure 5-5). While 
this is fortunate for the participants enrolled and may reflect the excellence of 
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clinical care they were receiving in our hospital independent of this study, it may 
bias the predictions. Studies with larger numbers and longer follow-up, currently 
ongoing, as well as studies in different clinical settings, may provide more 
generalizability. It is to be noted, however, that the incidence of suicidality in the 
general population is lower, for example at 1.5% in adolescents in an European 
cohort312 and estimates of 0.2 to 2% in the US231, which underlines the rationale 
of using a very high risk group like we did for magnifying and enabling signal 
detection with a relatively small N.  
       In conclusion, we have advanced the biological understanding of suicidality, 
highlighting behavioral and biological mechanisms related to inflammation, mTOR 
signaling, growth factors, stress response and apoptosis. mTOR signaling has been 
identified as necessary for the rapid antidepressant response of ketamine313. The 
fact that this biological pathway was identified in an unbiased fashion by our work 
as the top pathway changed in suicide in the validated biomarkers from our 
analyses (Table 5-3 and Figure S5-3) is scientifically interesting, and provides a 
biological rationale for studying ketamine as a potential treatment in acutely 
suicidal individuals314.   Of equal importance, we developed  instruments  
(biomarkers and apps) for predicting suicidality, that  do not require asking the 
person assessed if they have suicidal thoughts, as individuals who are truly suicidal 
often do not share that information with people close to them or with clinicians. 
We propose that the widespread use of such risk prediction tests as part of routine 
or targeted healthcare assessments will lead to early disease interception followed 
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by preventive lifestyle modifications or treatment. Given the magnitude and 
urgency of the problem, the importance of efforts to implement such tools cannot 
be overstated. 
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Chapter 6:  The Gender Paradox in Suicidal Behavior 
The gender paradox in suicide alludes to the fact that while women have 
higher rates of suicidal ideation and behavior, men have significantly higher rates 
of mortality from suicide.  In the United States, males are 3.5 times more likely to 
die by suicide.  Despite the gender disparities in suicide completion rates, women 
actually attempt suicide at three times the rate of men194.  
This finding has been fairly stable across most countries where data is 
readily available, and has been consistently observed for more than a decade.  315  
The most recent data from the WHO Global Heath Observatory data repository 
from 2012 shows that men commit suicide with greater frequency than women in 
166 out of 171 countries with data available when standardized for age.  A 
common thread across these different nations may be found in reduced social role 
opportunities, culturally accepted codes of expressiveness, and reluctance for men 
to seek help.  316  In addition to social factors, men tend to use more violent 
methods, such as firearms.  Given the disparity in suicide outcomes by gender, it 
may prove worthwhile to consider gender differences in pathophysiology as well.  
196 197 
Previous work had focused entirely on male study participants.  This was 
partially a pragmatic decision, as the catchment at Indianapolis VA Medical Center 
skews more male, and we didn’t have a sufficient sample size for the analysis.  
Another approach could have been to pool male and female samples.  Given the 
striking epidemiological differences in suicidal behavior, however, the decision was 
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made to instead use a segregated approach within each gender and continue to 
collect more female participants.  We have carried out a pilot study in women, 
finding some similarities but also novel differences between the genders.  
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Towards understanding and predicting suicidality in women: biomarkers 
and clinical risk assessment 
Predicting suicidality (suicidal ideation, suicide attempts, and suicide 
completion) in individuals is a difficult task, which is even more challenging in an 
understudied population like women. Although women have a lower rate of suicide 
completion than men, due in part to the less-violent methods used, they have a 
higher rate of suicide attempts317. It is reasonable to assume that genetic and 
biological differences may exist in suicidality between men and women. Studies by 
gender are a first step towards individualized medicine. We have previously shown 
in men with psychiatric disorders how blood biomarkers for suicide, alone or in 
combination with quantitative phenomic data for anxiety and mood, the Simplified 
Affective State Scale (SASS), and with a risk profile scale we have developed, 
Convergent Functional Information for Suicide (CFI-S), collected in the form of 
apps, could have predictive ability for suicidal ideation, and for future 
hospitalizations for suicidality196. We now present data for discovery, prioritization, 
validation, and testing of blood biomarkers for suicidality in women, across 
psychiatric diagnoses.  We also show the utility of SASS and CFI–S in predicting 
suicidality in women.  Both these type of tools, biomarkers and phenomic data 
apps, do not directly ask about suicidal ideation. We demonstrate how our apriori 
primary endpoint, a comprehensive universal predictor for suicide (UP-Suicide), 
composed of the combination of 50 top Bonferroni validated biomarkers, along 
with SASS, and CFI-S, predicts in independent test cohorts suicidal ideation and 
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future psychiatric hospitalizations for suicidality. Lastly, we uncover biological 
pathways involved in suicide in women, and potential therapeutics. 
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Methods 
Human participants  
We derived our data from four cohorts: one live psychiatric participants 
discovery cohort; one postmortem coroner’s office validation cohort; and two live 
psychiatric participants test cohorts–one for predicting suicidal ideation, and one 
for predicting future hospitalizations for suicidality (Figure 6-1). 
    
  
Figure 6-1. Cohorts used in study depicting, flow of discovery, 
prioritization, validation and testing of biomarkers from each step. 
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Our within participant discovery cohort, from which the biomarker data 
were derived, consisted of 12 female participants with psychiatric disorders and 
multiple visits in our lab, who each had at least one diametric change in SI scores 
from no SI to high SI from one testing visit to another. There were 7 participants 
with 3 visits each, and 5 participants with 2 visits each, resulting in a total of 31 
blood samples for subsequent microarray studies (Figure 6-2 and Table S6-1). 
      Our postmortem cohort, in which the top biomarker findings were 
validated for behavior, consisted of a demographically matched cohort of 6 female 
violent suicide completers obtained through the Marion County coroner’s office 
(Table 6-1 and Supplementary Table S6-1). We required a last observed alive 
postmortem interval of 24 h or less, and the cases selected had completed suicide 
by means other than overdose, which could affect gene expression. 5 participants 
completed suicide by gunshot to head or chest, and 1 by asphyxiation. Next of kin 
signed informed consent at the coroner’s office for donation of blood for research. 
The samples were collected as part of our INBRAIN initiative (Indiana Center for 
Biomarker Research in Neuropsychiatry).  
       Our independent test cohort for predicting suicidal ideation (Table 6-
1) consisted of 33 female participants with psychiatric disorders, demographically 
matched with the discovery cohort, with one or multiple testing visits in our lab, 
with either no SI, intermediate SI, or high SI, resulting in a total of 74 blood 
samples in whom whole-genome blood gene expression data were obtained (Table 
6-1 and Table S6-1). 
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      Our test cohort for predicting future hospitalizations (Table 6-1 and 
Table S6-1) consisted of 24 female participants in whom whole-genome blood 
gene expression data were obtained by us at testing visits over the years as part 
of our longitudinal study. If  
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the participants had multiple testing visits, the visit with the highest marker (or 
combination of markers) levels was selected for the analyses (so called “high 
watermark” or index visit). The participants’ subsequent number of psychiatric 
hospitalizations, with or without suicidality (ideation or attempt), was tabulated 
from electronic medical records. Participants were evaluated for the presence of 
future hospitalizations for suicidality, and for the frequency of such 
hospitalizations. A hospitalization was deemed to be without suicidality if suicidality 
was not listed as a reason for admission, and no SI was described in the admission 
and discharge medical notes. Conversely, a hospitalization was deemed to be 
because of suicidality if suicidal acts or intent was listed as a reason for admission, 
and/or SI was described in the admission and discharge medical notes. 
Medications 
The participants in the discovery cohort were all diagnosed with various 
psychiatric disorders (Table 6-1). Their psychiatric medications were listed in their 
electronic medical records, and documented by us at the time of each testing visit. 
The participants were on a variety of different psychiatric medications: mood 
stabilizers, antidepressants, antipsychotics, benzodiazepines and others (data not 
shown). Medications can have a strong influence on gene expression. However, 
our discovery of differentially expressed genes was based on within- participant 
analyses, which factor out not only genetic background effects but also medication 
effects, as the participants had no major medication changes between visits. 
Moreover, there was no consistent pattern in any particular type of medication, or 
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between any change in medications and SI, in the rare instances where there were 
changes in medications between visits. 
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Figure 6-2. Biomarker discovery, prioritization and validation. Discovery cohort: 
longitudinal within-participant analysis. Phchp### is study ID for each participant. 
V# denotes visit number (1, 2 or 3). (a) Suicidal ideation (SI) scoring. (b) 
Participants and visits. (c) PhenoChipping: two-way unsupervised hierarchical 
clustering of all participant visits in the discovery cohort vs 18 quantitative 
phenotypes measuring affective state and suicidality. SASS, Simplified Affective 
State Scale. A—Anxiety items (Anxiety, Uncertainty, Fear, Anger, Average). M—
Mood items (Mood, Motivation, Movement, Thinking, Self-esteem, Interest, 
Appetite, Average). STAI-STATE is State Trait Anxiety Inventory, State Subscale. 
YMRS is Young Mania Rating Scale. (d) Discovery—number of probesets carried 
forward from the Absent-Present (AP) and differential expression (DE) analyses, 
328 
 
 
with an internal score of 1 and above. Red—increased in expression in high SI and 
blue—decreased in expression in high SI; (e) Prioritization—CFG integration of 
multiple lines of evidence to prioritize suicide—relevant genes from the discovery 
step. (f) Validation—Top CFG genes, with a total score of 4 and above, validated 
in the cohort of suicide completers. All the genes shown were significantly changed 
and survived Bonferroni correction in ANOVA from no SI to high SI to suicide 
completers. 
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Clock Gene Database 
We compiled a database of genes associated with circadian function, by 
using a combination of review papers (Zhang et al. 2009, McCarthy and Welsh 
2012318,319) and searches of existing databases CircaDB 
(http://circadb.hogeneschlab.org), GeneCards (http://www.genecards.org), and 
GenAtlas (http://genatlas.medecine.univ-paris5.fr). Using the data we compiled 
from these sources we identified a total of 1468 genes that show circadian 
functioning. We further classified genes into “core” clock genes, i.e. those genes 
that are the main engine driving circadian function (n=18), “immediate” clock 
genes, i.e.  the genes that directly input or output to the core clock (n=331), and  
“distant” clock genes, i.e. genes that directly input or output to the immediate 
clock genes (n=1,119).    
Clinical measures 
The Simplified Affective State Scale (SASS) is an 11 item scale for measuring 
mood and anxiety, previously developed and described by us 277,320. The SASS has 
a set of 11 visual analog scales (7 for mood, 4 for anxiety) that ends up providing 
a number ranging from 0 to 100 for mood state, and the same for anxiety state. 
We have developed an Android app version. 
Convergent Functional Information for Suicidality (CFI-S) (Figures  6-3 and 
S6-2) is a 22 item scale and Android app for suicide risk320, which integrates, in a 
simple binary fashion (Yes-1, No-0), similar to a polygenic risk score, information 
about known life events, mental health, physical health, stress, addictions, and 
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cultural factors that can influence suicide risk289 290. The scale was administered at 
participant testing visits (n= 39), or scored based on retrospective electronic 
medical record information and Diagnostic Interview for Genetic Testing (DIGS) 
information (n=48). When information was not available for an item, it was not 
scored (NA).  
Combining gene expression biomarkers and clinical measures 
The Universal Predictor for Suicide (UP-Suicide) construct, our primary 
endpoint,  was decided upon as part of our apriori study design to be broad- 
spectrum, and combine our top Bonferroni validated biomarkers with the phenomic 
(clinical) markers (SASS and CFI-S).  It is calculated as the average of three 
increased markers (BioM-18 averaged increased Bonferroni biomarkers, Anxiety, 
CFI-S), minus the average of two decreased markers (BioM-32 averaged 
decreased Bonferroni biomarkers, Mood).  All individual markers are Z-scored by 
diagnosis, to account for different ranges and be able to combine them into a 
composite predictor.  
Testing analyses 
The test cohort for suicidal ideation and the test cohort for future 
hospitalizations analyses were assembled out of data that was RMA normalized by 
diagnosis. Phenomic (clinical) and gene expression markers used for predictions 
were z scored by diagnosis, to be able to combine different markers into panels 
and to avoid potential artefacts due to different ranges of phene expression and 
gene expression in different diagnoses.  Markers were combined by computing the 
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average of the increased risk markers minus the average of the decreased risk 
markers.  Predictions were performed using R-studio.    
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Figure 6-3. Convergent Functional Information for Suicide (CFI-S) scale testing 
in women. Prediction of high suicidal ideation in women in a larger cohort that 
combines the discovery and test cohorts used for biomarker work. CFI-S was 
developed independently of any data from this study, by compiling known socio-
demographic and clinical risk factors for suicide. It is composed of 22 items that 
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assess the influence of mental health factors, as well as of life satisfaction, physical 
health, environmental stress, addictions, cultural factors known to influence 
suicidal behavior, and two demographic factors, age and gender. Table depicts 
individual items and their ability to differentiate between no SI and high SI. 
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Predicting Suicidal Ideation. Receiver-operating characteristic (ROC) 
analyses between genomic and phenomic marker levels and suicidal ideation (SI) 
were performed by assigning participants with a HAMD-SI score of 2 and greater 
into the high SI category.  We used the pROC function of the R studio. We used 
the z-scored biomarker and app scores, running them in this ROC generating 
program against the “diagnostic” groups in the independent test cohort (high SI 
vs. the rest of subjects).  
Additionally, ANOVA was performed between no SI (HAMD-SI 0), 
intermediate (HAMD-SI 1), and high SI participants (HAMD-SI 2 and above) and 
Pearson R (one-tail) was calculated between HAMD-SI scores and marker levels 
(Table 6-4 and Figure 6-4).  
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Figure 6-4. UP-Suicide predicting suicidal ideation in the independent test cohort, 
and predicting future hospitalizations due to suicidality. UP-Suicide is composed of 
the 50 Bonferroni validated biomarkers along with CFI-S scores and SASS (Mood 
and Anxiety scores). n= number of testing visits. (a) Top left: Receiver operating 
curve identifying participants with suicidal ideation against participants with no SI 
or intermediate SI. Top right: Y axis contains the average UP-Suicide scores with 
standard error of mean for no SI, intermediate SI and high SI. Bottom right: 
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Scatter plot depicting HAMD-SI score on the Y axis and UP-Suicide score on the X 
axis with linear trend line. Bottom: Table summarizing descriptive statistics. (b) 
Top left: Receiver operating curve identifying participants with future 
hospitalizations due to suicidality against participants without future 
hospitalizations due to suicidality. Top right: Y axis contains the average UP-
Suicide scores with standard error of mean for no future hospitalizations due to 
suicidality and participants with future hospitalizations due to suicidality. Bottom 
right: Scatter plot depicting frequency of future hospitalizations due to suicidality 
on the Y axis and UP-Suicide score on the X axis with linear trend line. Bottom: 
Table summarizing descriptive statistics. 
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Predicting Future Hospitalizations for Suicidality.  
We conducted analyses for hospitalizations in the years following testing 
(on average 2.75 years, range 0.3 to 7.5 years; see Table S6-1). For each 
participant in the test cohort for future hospitalizations, the study visit with highest 
levels for the marker or combination of markers was selected as index visit (or 
with the lowest levels, in the case of decreased markers). ROC analyses between 
genomic and phenomic marker levels and future hospitalizations were performed 
as described above, based on assigning if participants had been hospitalized for 
suicidality (ideation, attempts) or not following the index testing visit.  Additionally, 
a one tailed t-test with unequal variance was performed between groups of 
participants with and without hospitalizations for suicidality.  Pearson R (one-tail) 
correlation was performed between hospitalization frequency (number of 
hospitalizations for suicidality divided by duration of follow-up) and marker scores. 
We conducted correlation analyses for hospitalizations frequency for all future 
hospitalizations due to suicidality as this calculation, unlike the ROC and t-test, 
accounts for the actual length of follow-up at our VA, which varied from participant 
to participant. The ROC and t-test might in fact, if anything, under-represent the 
power of the markers to predict, as the more severe psychiatric patients are more 
likely to move geographically and/or be lost to follow-up. 
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Figures 
Each figure in this chapter was completed by Daniel Levey and Helen Le-
Niculescu.  This work has been published.  197 
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BCL2 
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Results 
Discovery of biomarkers for suicidal ideation     
We conducted whole-genome gene expression profiling in the blood 
samples from a longitudinally followed cohort of female participants with 
psychiatric disorders that predispose to suicidality. The samples were collected at 
repeated visits, 3–6 months apart. State information about suicidal ideation (SI) 
was collected from a questionnaire (HAMD) administered at the time of each blood 
draw (Table S6-1). Out of 51 female psychiatric participants (with a total of 123 
visits) followed longitudinally in our study, with a diagnosis of BP, MDD, SZ and 
SZA, there were 12 participants that switched from a no SI (SI score of 0) to a 
high SI state (SI score of 2 and above) at different visits, which was our intended 
discovery group (Figure 6-2). We used a powerful within-participant design to 
analyze data from these 12 participants and their 31 visits.  A within-participant 
design factors out genetic variability, as well as some medications, lifestyle, and 
demographic effects on gene expression, permitting identification of relevant 
signal with Ns as small as 114.  Another benefit of a within-participant design may 
be accuracy/consistency of self-report of psychiatric symptoms (‘phene 
expression’), similar in rationale to the signal detection benefits it provides in gene 
expression.  
For discovery, we used two methodologies: Absent/Present (reflecting 
on/off of transcription), and Differential Expression (reflecting more subtle gradual 
changes in expression levels). The genes that tracked suicidal ideation in each 
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participant were identified in our analyses.  We used three thresholds for increased 
in expression genes and for decreased in expression genes: ≥ 33.3% (low), ≥50% 
(medium), and ≥ 80% (high) of the maximum scoring increased and decreased 
gene across participants.  Such a restrictive approach was used as a way of 
minimizing false positives, even at the risk of having false negatives. For example, 
there were genes on each of the two lists, from AP and DE analyses, that had clear 
prior evidence for involvement in suicidality, such as AKAP10 (248) (31.7%) and 
MED28 248 ( 31.8%) from AP, and S100B248,324 (31.7%) and SKA2220 (31.4%) for 
DE, but were not included in our subsequent analyses because they did not meet 
our apriori set 33.3% threshold. Notably, SKA2 reproduces our results in males 
(Niculescu et al. 2015), as well as the work from Kaminsky and colleagues219,220. 
Prioritization of biomarkers based on prior evidence in the field 
These differentially expressed genes were then prioritized using a Bayesian-
like Convergent Functional Genomics (CFG) approach (Figure 6-2) integrating all 
the previously published human genetic evidence, postmortem brain gene 
expression evidence, and peripheral fluids evidence for suicide in the field available 
at the time of our analyses (September 2015).This is a way of  identifying and 
prioritizing disease relevant genomic biomarkers, extracting generalizable signal 
out of potential cohort-specific noise and genetic heterogeneity. We have built in 
our lab manually curated databases of the psychiatric genomic and proteomic 
literature to date, for use in CFG analyses. The CFG approach is thus a de facto 
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field-wide collaboration. We use in essence, in a Bayesian fashion, the whole body 
of knowledge in the field to leverage findings from our discovery data sets.  
Validation of biomarkers for behavior in suicide completers 
For validation in suicide completers, we used 1471 genes that had a CFG 
score of 4 and above, from AP and DE, reflecting either maximum internal score 
from discovery or additional external literature cross-validating evidence. Out of 
these, 882 did not show any stepwise change in suicide completers (NC- non-
concordant). As such, they may be involved primarily in ideation and not in 
behavior (Table S6-5). The remaining 589 genes ( 40.0%) had levels of expression 
that were changed stepwise from no suicidal ideation to high suicidal ideation to 
suicide completion. 396 of these genes ( 26.9%) were nominally significant, and 
49 genes (50 probesets- two for JUN) (3.33%)  survived Bonferroni correction for 
multiple comparisons (Figure 6-2f). These genes are likely involved in suicidal 
ideation and suicidal behavior. (A person can have suicidal ideation without suicidal 
behavior, but cannot have suicidal behavior without suicidal ideation). 
Selection of biomarkers for testing of predictive ability  
For testing, we decided apriori to focus on the Bonferroni validated 
biomarkers (49 genes, 50 probesets). We also examined in a secondary analysis 
the top scoring biomarkers from both discovery and prioritization (65 genes), so 
as to avoid potential false negatives in the validation step  due to possible 
postmortem artefacts or extreme stringency of statistical cutoff (Figure S6-1). The 
top CFG scoring genes after the Bonferroni validation step were BCL2 and GSK3B.  
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The top CFG scoring genes from the discovery and prioritization steps were 
FAM214A, CLTA, HSPD1, and ZMYND8. Notably, all have co-directional gene 
expression changes evidence in brains of suicide completers in studies from other 
groups (Figure 6-2, Tables 6-2 and S6-2).  
Biological understanding 
We also sought to understand the biology represented by the biomarkers 
identified by us, and derive some mechanistic and practical insights. We 
conducted: 1. unbiased biological pathway analyses and hypothesis driven 
mechanistic queries, 2. overall disease involvement and specific neuropsychiatric 
disorders queries, and 3. overall drug modulation along with targeted queries for 
omega-3, lithium and clozapine306 (Tables 6-3, S6-3, S6-4). Administration of 
omega-3s in particular may be a mass- deployable therapeutic and preventive 
strategy167,207. 
352 
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E
-
0
4 
3 
Role of 
Osteobla
sts, 
Osteocla
sts and 
Chondroc
ytes in 
Rheumat
oid 
Arthritis 
8.71
E-05 
2.
2 
% 
5/
22
5 
Colore
ctal 
cancer 
3/2
93 
0.00
1214 
Immune 
response_
Th17-
derived 
cytokines 
4/9
8 
4
.
5
8
9
E
-
0
4 
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B. Ingenuity GeneGO 
4 
Docosah
exaenoic 
Acid 
(DHA) 
Signaling 
1.02
E-04 
6.
7 
% 
3/
45 
Trypto
phan 
metab
olism 
2/1
32 
0.00
4229 
Inflammati
on_IL-2 
signaling 
4/1
04 
5
.
7
5
2
E
-
0
4 
5 
Ovarian 
Cancer 
Signaling 
1.48
E-04 
3.
0 
% 
4/
13
3 
Neurot
rophin 
signali
ng 
pathw
ay 
3/5
71 
0.00
7844 
Cell 
cycle_G1-
S Growth 
factor 
regulation 
5/1
95 
7
.
1
2
7
E
-
0
4 
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Priori
tizati
on 
CFG 
score 
≥4 
(n= 
1904 
prob
esets
/ 
1471 
gene
s) 
# 
Diseases and 
Disorders 
P-
Value 
# 
Mole
cule
s 
Diseases 
Rat
io 
P-
Val
ue 
1 Cancer 
2.25E-
06 - 
2.21E-
45 
1242 Mental Disorders  
256
/16
10 
1.8
90E
-35 
2 
Organismal 
Injury and 
Abnormalities 
2.25E-
06 - 
2.21E-
45 
1242 
Psychiatry and 
Psychology 
284
/19
04 
2.1
94E
-34 
3 
Gastrointestinal 
Disease 
1.02E-
06 - 
5.07E-
31 
905 
Depressive 
Disorder, Major  
120
/54
3 
2.6
60E
-29 
4 
Reproductive 
System Disease 
1.43E-
06 - 
2.31E-
24 
617 
Central Nervous 
System Diseases 
379
/30
60 
8.7
70E
-29 
363 
 
 
5 
Infectious 
Diseases 
8.30E-
07 - 
1.15E-
17 
246 
Depressive 
Disorder 
120
/55
7 
3.1
25E
-28 
 # 
Diseases and 
Disorders 
P-
Value 
# 
Mole
cule
s 
Diseases 
Rat
io 
P-
Val
ue 
 
Valid
ation 
Step
wise 
in 
Suici
de 
Com
plete
rs 
1 Cancer 
6.57E-
04 - 
6.34E-
17 
487 Breast Neoplasms  
356
/88
94 
3.7
27E
-15 
2 
Organismal 
Injury and 
Abnormalities 
6.57E-
04 - 
6.34E-
17 
492 Breast Diseases 
356
/88
95 
3.7
98E
-15 
3 
Gastrointestinal 
Disease 
6.23E-
04 - 
2.76E-
10 
355 
Psychiatry and 
Psychology 
115
/19
04 
2.2
68E
-14 
364 
 
 
(n=5
89 
gene
s) 
 
4 
Reproductive 
System Disease 
6.50E-
04 - 
8.34E-
09 
240 
Pathological 
Conditions, Signs 
and Symptoms  
207
/44
33 
1.0
78E
-13 
5 
Infectious 
Diseases 
6.57E-
04 - 
6.95E-
08 
104 Mental Disorders  
101
/16
10 
1.1
46E
-13 
 # 
Diseases and 
Disorders 
P-
Value 
# 
Mole
cule
s 
Diseases 
Rat
io 
P-
Val
ue 
 
Valid
ation 
Nomi
nally  
signi
fican
t 
1 Cancer 
2.36E-
03 - 
1.87E-
10 
325 
Depressive 
Disorder, Major 
40/
543 
1.0
45E
-12 
2 
Organismal 
Injury and 
Abnormalities 
2.47E-
03 - 
1.87E-
10 
330 
Pathological 
Conditions, Signs 
and Symptoms 
150
/44
33 
2.0
02E
-12 
365 
 
 
In 
Suici
de 
Com
plete
rs 
(n= 
396 
gene
s) 
 
 
3 
Tumor 
Morphology 
2.29E-
03 - 
1.17E-
07 
36 
Depressive 
Disorder 
40/
557 
2.3
33E
-12 
4 
Developmental 
Disorder 
2.47E-
03 - 
1.40E-
06 
69 Breast Neoplasms 
245
/88
94 
2.7
70E
-11 
5 
Gastrointestinal 
Disease 
2.44E-
03 - 
2.43E-
06 
230 Breast Diseases 
245
/88
95 
2.8
06E
-11 
 # 
Diseases and 
Disorders 
P-
Value 
# 
Mole
cule
s 
Diseases 
Rat
io 
P-
Val
ue 
Valid
ation 
Bonf
erron
1 
 
Immunological 
Disease 
4.03E-
03 - 
1.27E-
06 
14 
Lymphoma, 
Mantle-Cell 
8/1
96 
3.4
30E
-08 
366 
 
 
i 
signi
fican
t in 
Suici
de 
Com
plete
rs 
(n= 
49 
gene
s) 
 
 
2 Cancer 
4.15E-
03 - 
3.97E-
06 
42 
Psychiatry and 
Psychology 
19/
190
4 
1.2
09E
-07 
3 
Dermatological 
Diseases and 
Conditions 
4.03E-
03 - 
3.97E-
06 
10 
Lymphoma, Non-
Hodgkin 
12/
726 
2.3
23E
-07 
4 
Hematological 
Disease 
4.03E-
03 - 
3.97E-
06 
5 Mental Disorders  
17/
161
0 
3.0
79E
-07 
5 
Organismal 
Injury and 
Abnormalities 
4.15E-
03 - 
3.97E-
06 
42 Leukemia, Myeloid 
16/
143
6 
3.6
67E
-07 
 
 
The sets of biomarkers identified have biological roles in inflammation, 
neurotrophins, inositol signaling, stress response, and perhaps overall the switch 
between cell survival and proliferation vs. apoptosis (Tables 6-3 and S6-5).  
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We also examined evidence for the involvement of these biomarkers for 
suicidality in other psychiatric disorders, permitting us to address issues of context 
and specificity (Table S6-3).  FAM214A, MOB3B, ZNF548, and ARHGAP35 seem to 
be relatively specific for suicide, based on the evidence to date in the field.  BCL2, 
GSK3B, HSPD1, and PER1 are less specific for suicide, having equally high evidence 
for involvement in suicide and in other psychiatric disorders.  
These boundaries and understanding will likely change as additional 
evidence in the field accumulates. For example, HSPD1,   discovered in this work 
as a top biomarker increased in expression in suicidality, is also increased in 
expression in the blood following anti-depressant treatment325,326 , and thus might 
be a useful biomarker for treatment-emergent suicidal ideation (TESI).   
A number of the genes are changed in expression in opposite direction in 
suicide in this study vs. high mood in our previous mood biomarker study15- SSBP2, 
ZNF596   (Table S6-3), suggesting that suicidal participants are in a low mood 
state.   Also, some of the top suicide biomarkers are changed in expression in the 
same direction as in high psychosis participants in a previous psychosis biomarker 
study of ours24 – HERC4, PIP5K1B, SLC35B3, SNX27,  KIR2DL4,   NUDT10   (Table 
S6-3), suggesting that suicidal participants may be in a psychosis-like state. Taken 
together, the data indicates that suicidality could be viewed as a psychotic 
dysphoric state. This molecularly informed view is consistent with the emerging 
clinical evidence in the field308.  
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A number of top biomarkers identified by us have biological roles that are 
related to the core circadian clock (such as PER1), or modulate the circadian clock 
(such as CSNK1A1), or show at least some circadian pattern (such as HTRA1). To 
be able to ascertain all the genes in our dataset that were circadian and do 
estimates for enrichment, we compiled from the literature a database of all the 
known genes that fall into these three categories, numbering a total of 1468 genes. 
Using an estimate of about 21,000 genes in the human genome, that gives about 
7% of genes having some circadian pattern. Out of our 49 Bonferroni validated 
biomarker genes, 7 had circadian evidence (14.3%) (Table S6-3), suggesting a 
two-fold enrichment for circadian genes.  Circadian clock abnormalities are related 
to mood disorders268,319, and sleep abnormalities have been implicated in 
suicide327. 
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Table 6-4. Predictions. UP-Suicide is composed of 50 validated biomarkers (18 
increased in expression, 32 decreased in expression), along with clinical measures 
app scores (CFI-S, SASS).  SASS is composed of Mood scale and Anxiety scale. 
  Marker 
    
Partic
ipant
s 
with  
Suici
dality
/ 
Partic
ipant
s 
Total 
ROC 
AUC/p-
value 
Pearson'
s 
Correlati
on R/p-
value 
Stud
ent's 
t-
test  
p-
valu
e 
  
Suicid
al 
Ideati
on 
Cohor
t 
     Best 
Blood 
Biomar
kers 
Best Validated Biomarkers (Bonferroni) 
(49 genes, 50 probesets) 
EPB41L
5 
7 | 33 
0.68/0.0
62 
0.22/0.
028 
0.09
1 
 
HAVCR
2 
7 | 33 
0.62/0.1
5 
0.17/0.0
69 
0.18 
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n=33 
Partic
ipants 
ARHGA
P15 
7 | 33 
0.55/0.3
4 
0.12/0.1
5 
0.22 
PIK3C3 7 | 33 
0.65/0.0
98 
-
0.21/0.
037 
0.08
4 
GTF3C2 7 | 33 
0.64/0.1
1 
-
0.11/0.1
8 
0.07
2 
ALDH3
A2 
7 | 33 
0.62/0.1
4 
-
0.21/0.
036 
0.14 
Best Discovery and Prioritization 
Biomarkers(Non Bonferroni Validated) 
DPCD 7 | 33 
0.67/0.0
67 
0.21/0.
040 
0.12 
GTF3C3 7 | 33 
0.67/0.0
75 
0.23/0.
024 
0.11 
ASPH 7 | 33 
0.65/0.0
98 
0.073/0.
27 
0.13 
ACTR3 7 | 33 
0.62/0.1
5 
-
0.19/0.
054 
0.13 
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NUDT6 7 | 33 
0.62/0.1
5 
-
0.072/0.
27 
0.19 
LRRC8B 7 | 33 
0.60/0.1
9 
-
0.15/0.
11 
0.13 
Panels of  Validated Biomarkers 
(Increased, Decreased, Combined) 
BioM-
18 
7 | 33 
0.37/0.8
7 
0.032/0.
39 
0.59 
BioM-
32 
7 | 33 
0.43/0.7
2 
-
0.0031/0
.49 
0.68 
BioM-
50 
7 | 33 
0.50/0.5
1 
0.021/0.
43 
0.47 
Clinical 
measur
es 
Anxiety 7 | 33 
0.72/0.
029 
0.26/0.
011 
0.0
083 
Mood 7 | 33 
0.78/0.
0078 
-
0.37/0.
00062 
0.0
020 
372 
 
 
SASS 7 | 33 
0.81/0.
0035 
0.38/0.
00049 
5.0
4E-
05 
CFI-S 7 | 29 
0.84/0.
0020 
0.39/0.
0013 
0.0
031 
CFI-S + 
SASS 
7 | 29 
0.87/0.
00088 
0.48/5.
22E-05 
0.0
002
7 
 
Combin
ed 
UP-
Suicide 
7 | 29 
0.82/0.
0034 
0.43/0.
00029 
0.0
015 
Futur
e 
Hospi
talizat
ions 
for 
Suicid
ality 
n=24 
Partic
ipants 
Best  
Blood 
Biomar
kers 
Marker 
    
Partic
ipant
s 
Hospi
talize
d for  
Suici
dality
/ 
Partic
ipant
ROC 
AUC/p-
value 
Pearson'
s 
Correlati
on R/p-
value 
Stud
ent's 
t-
test  
p-
valu
e 
Cox 
Regr
essio
n 
Haza
rd 
Ratio 
Cox 
Regr
essio
n p-
valu
e 
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s 
Hospi
talize
d 
Total 
Best Validated Biomarkers (Bonferroni) (49 genes, 50 
probesets) 
HTRA1 5 | 24 
0.84/0.
0096 
0.62/0.
00058 
0.0
24 
4.6 
0.01
2 
PER1 4 | 24 
0.84/0.
018 
0.39/0.
029 
0.1
3 
1.5 0.16 
PDXDC
1 
5 | 24 
0.81/0.
018 
0.64/0.
00043 
0.0
42 
2.4 
0.01
5 
PIK3C3 3 | 24 
0.90/0.
011 
-
0.25/0.1
2 
0.0
26 
6.0 0.12 
BCL2 4 | 24 
0.89/0.
0067 
-
0.35/0.
047 
0.0
54 
3.1 
0.01
2 
MOB3B 4 | 24 
0.85/0.
015 
-
0.34/0.
053 
0.0
004
6 
9.6 
0.08
9 
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Best Discovery and Prioritization Biomarkers(Non 
Bonferroni Validated) 
KLHL28 5 | 24 
0.91/0.
0020 
0.51/0.
0051 
0.0
026 
7.3 
0.03
6 
UIMC1 5 | 24 
0.86/0.
0060 
0.40/0.0
25 
0.0
37 
2.3 
0.02
8 
SNX27 4 | 24 
0.85/0.
015 
0.74/1.8
3E-05 
0.0
52 
4.5 
0.01
5 
CSNK1
A1 
4 | 24 
0.96/0.
00066 
-
0.27/0.1
0 
0.0
006
6 
620.
5 
0.02
2 
LARP4 4 | 24 
0.90/0.
0050 
-
0.30/0.0
77 
6.3
0E-
05 
37.0 0.11 
ZNF548 5 | 24 
0.83/0.
012 
-
0.31/0.0
71 
0.0
077 
15.9 
0.01
9 
Panels of  Validated Biomarkers (Increased, 
Decreased, Combined) 
BioM-
18 
4 | 24 
0.88/0.
0088 
0.46/0.
011 
0.0
33 
27.6 
0.02
1 
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BioM-
32 
4 | 24 
0.71/0.
11 
-
0.34/0.
053 
0.1
6 
10.6 0.23 
BioM-
50 
5 | 24 
0.94/0.
0017 
0.54/0.
0033 
0.0
058 
89.5 
0.02
3 
Clinical 
measur
es 
Anxiety 4 | 24 
0.86/0.
014 
0.43/0.
017 
0.0
039 
16.0 
0.05
4 
Mood 3 | 24 
0.68/0.1
8 
-
0.21/0.1
6 
0.22 33.4 0.10 
SASS 4 | 24 
0.83/0.
023 
0.40/0.
027 
0.0
34 
4.0 
0.06
2 
CFI-S 3 | 24 
0.50/0.5
2 
0.25/0.1
2 
0.38 1.2 0.79 
CFI-S + 
SASS 
4 | 24 
0.74/0.0
79 
0.40/0.
026 
0.08
3 
4.9 
0.05
4 
 
Combin
ed 
UP-
Suicide 
5 | 24 
0.78/0.
032 
0.51/0.
0057 
0.0
37 
9.6 
0.01
0 
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Lastly, we conducted biological pathway analyses on the genes that, after 
discovery and prioritization, were stepwise changed in suicide completers (n=882) 
and may be involved in ideation and behavior, vs. those that were not stepwise 
changed (n=589), and that may only be involved in ideation (Table S5-6). The 
genes involved in ideation map to pathways related to PI3K signaling. The genes 
involved in behavior map to pathways related to glucocorticoid receptor signaling. 
This is consistent with ideation without behavior being related to neurotrophic 
factors, and ideation with behavior being related to stress.  
Clinical information 
We used a  simple new 22 item scale and app for suicide risk, Convergent 
Functional Information for Suicidality (CFI-S), which scores in a simple binary 
fashion and integrates  information about known life events, mental health, 
physical health, stress, addictions, and cultural factors that can influence suicide 
risk289 290,320. Clinical risk predictors and scales are of high interest in the military309  
and in the general population at large310. Our scale aims for comprehensiveness, 
simplicity and quantification similar to a polygenic risk score, and may provide 
context to the blood biomarker signals. We analyzed which items of the CFI-S scale 
were the most significantly different between no and high suicidal ideation live 
participants (Figure 6-3).  We identified 7 items that were significantly different:  
lack of positive relationships/social isolation (p=0.004), substance abuse 
(p=0.0071), history of impulsive behaviors (p=0.015), lack of religious beliefs 
(p=0.018), past history of suicidal acts/gestures (p=0.025), rejection (p=0.029), 
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and history of command auditory hallucinations (p=0.045). Social isolation 
increases vulnerability to stress, which is independently consistent with our 
biological marker results.  
We also used an 11 item scale for measuring mood and anxiety, the 
Simplified Affective State Scale (SASS)320. The SASS is a set of 11 visual analog 
scales (7 for mood, 4 for anxiety) that ends up providing a number ranging from 
0 to 100 for mood state, and the same for anxiety state. 
Testing for predictive ability  
The best single increased (risk) biomarker predictor for suicidal ideation 
state is EPB41L5 (ROC AUC 0.68, p-value 0.06; Pearson Correlation 0.22, p-value 
0.03), an increased in expression, Bonferroni validated biomarker (Tables 6-2 and 
6-4). This biomarker was also identified co-directionally in our previous male 
work320, and has no evidence for involvement in other psychiatric disorders. The 
best single decreased (protective) biomarker predictor for suicidal ideation is 
PIK3C3 (ROC AUC 0.65, p-value 0.1; Pearson Correlation -0.21, p-value 0.037), a 
decreased in expression, Bonferroni validated biomarker (Tables 6-2 and 6-4). 
PIK3C3 is also decreased in expression in postmortem brains in depression 328. 
The best single increased (risk) biomarker predictor for future hospitalizations for 
suicidality is HTRA1 (ROC AUC 0.84, p-value 0.01; Cox Regression Hazard Ratio 
4.55, p- value 0.01), an increased in expression, Bonferroni validated biomarker 
(Tables 6-2 and 6-4). HTRA1 is also increased in expression in the blood of 
schizophrenics329. The best single decreased (protective) biomarker predictor for 
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future hospitalizations for suicidality is CSNK1A1 (ROC AUC 0.96, p-value 0.0007; 
Cox Regression Hazard Ratio 620.5, p-value 0.02), a top discovery and 
prioritization, non-Bonferroni validated biomarker (Tables 6-2 and 6-4). This 
biomarker was also identified co-directionally in our previous male work320. 
CSNK1A1 (casein kinase 1, alpha 1) is a circadian clock gene, part of the input into 
the core clock.    It is decreased in expression in suicidality in our work, and 
decreased in postmortem brains of alcoholics330. Interestingly, it is increased in 
expression by mood stabilizers  331 and by omega-3 fatty acids 65.  PIK3C3 is also 
a good predictor for future hospitalizations for suicidality (ROC AUC 0.9, p-value 
0.011). 
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Gene 
symbol
/ 
Gene 
Name 
 
Prob
esets 
Mal
es 
Disc
over
y 
(Dire
ction 
of 
Chan
ge) 
Meth
od/ 
Inter
nal 
Scor
e 
(%) 
Males 
Partic
ipant
s 
Teste
d 
With 
Suicid
ality / 
Total 
Male
s 
Predi
ction
s 
ROC/ 
p-
value 
 
Female
s 
Discove
ry 
(Directio
n of 
Change) 
Method/ 
Internal 
Score 
 
Fema
les 
Partic
ipant
s 
Teste
d 
With 
Suicid
ality / 
Total 
Femal
es 
Predic
tions 
ROC/ 
p-value 
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Top Biomarkers from Males 
that were co-directional in Females 
SLC4A4 
solute 
carrier 
family 4 
(sodium 
bicarbon
ate 
cotransp
orter), 
member 
4 
2107
39_x
_at 
(I) 
AP/2 
(71
%) 
SI: 33 
| 108 
Hosp: 
32 | 
157 
 
SI: 
0.72/
2.41E
-05 
Hosp: 
0.44/
0.87 
 
(I) 
DE/0 
(20%) 
SI: 7 | 
33 
Hosp: 
3 | 24 
 
SI: 
0.62/0.
15 
Hosp: 
0.86/
0.03 
SKA2 
spindle 
and 
kinetoch
ore 
associate
d 
2256
86_a
t 
(D) 
DE/1 
(34
%) 
AP/1 
(42
%) 
SI:  33 
| 108 
Hosp: 
32 | 
157 
 
SI: 
0.69/
0.00
02 
Hosp: 
0.46/
0.75 
 
(D) 
DE/0 
(6%) 
SI:  7 | 
33 
Hosp: 
3 | 24 
 
SI: 
0.50/0.
51 
Hosp: 
0.78/0.
07 
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Table 6-5. Cross-prediction in the other gender. Examples of top predictive 
biomarkers from men (Niculescu et al. 2015)196 and from women (current study) 
that were changed in expression in the same direction in both genders. The 
complex 
subunit 2 
Top Biomarkers from Females 
that were co-directional in Males 
PIK3C3 
 
phosphat
idylinosit
ol 3-
kinase, 
catalytic 
subunit 
type 3 
2320
86_a
t 
 
(D) 
DE/0 
(14
%) 
SI: 33 
| 108 
Hosp: 
32 | 
157 
 
SI: 
0.62/
0.01 
Hosp: 
0.5/0.
49 
 
(D) 
DE/1 
(49%) 
 
SI: 7 | 
33 
Hosp: 
3 | 24 
 
SI: 
0.65/0.
098 
Hosp: 
0.9/0.
011 
CSNK1
A1 
 casein 
kinase 1, 
alpha 1 
2354
64_a
t 
 
(D) 
AP/0 
(21
%) 
SI: 33 
| 108 
Hosp: 
31 | 
157 
 
SI: 
0.63/
0.01 
Hosp: 
0.5/0.
53 
 
(D) 
DE/4 
(86%) 
AP/1 
(36%) 
SI: 7 | 
33 
Hosp: 
3 | 24 
 
SI: 
0.56/0.
316 
Hosp: 
0.96/
0.001 
382 
 
 
markers were discovered in just one gender, as they were below the apriori set 
threshold for discovery (33.3%) in the other gender. Yet they show some ability 
to predict in the other gender as well. SI- predicting suicidal ideation. Hosp- 
predicting future hospitalizations for suicidality. Bold -p-value is significant.  
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BCL2, the top CFG scoring biomarker from validation, has good accuracy at 
predicting future hospitalizations for suicidality (ROC AUC 0.89, p-value 0.007; Cox 
Regression Hazard Ratio 3.08, p-value 0.01). The panel of 50 validated 
biomarkers, BioM-50, had even better accuracy at predicting future 
hospitalizations for suicidality (ROC AUC 0.94, p-value 0.002; Cox Regression 
Hazard Ratio 89.46, p-value 0.02). Overall, in women, blood biomarkers seemed 
to perform better for predicting future hospitalizations for suicidality (trait) than 
for predicting suicidal ideation (state). This is different than the trend we saw in 
men320, where blood biomarkers were somewhat better predictors of state than of 
trait. This gender differences are interesting, and merit exploration in additional 
future comparative studies.  
CFI-S has very good accuracy (ROC AUC 0.84, p-value 0.002; Pearson 
Correlation 0.39, p-value 0.001) at predicting suicidal ideation in psychiatric 
participants across diagnostic groups. The other app, SASS, also has very good 
accuracy (ROC AUC 0.81, p-value 0.003; Pearson Correlation 0.38, p-value 0.0005) 
at predicting suicidal ideation in women psychiatric participants. The combination 
of the apps is synergistic (ROC AUC 0.87, p-value 0.0009; Pearson Correlation 
0.48, p-value 0.0001). Thus, even without the benefit of potentially more costly, 
invasive and labor intensive blood biomarker testing, clinically useful predictions 
could be made with the apps. 
Our apriori primary endpoint was a combined universal predictor for suicide 
(UP-Suicide), composed of the scores in CFI-S and in SASS (Mood, Anxiety), along 
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with the Bonferroni validated biomarkers (n=50) resulting from the sequential 
discovery for ideation, prioritization with CFG , and validation for behavior  in 
suicide completers steps. UP-Suicide is a good predictor of suicidal ideation (ROC 
AUC 0.82, p-value 0.003; Pearson Correlation 0.43, p-value 0.0003) (Table 6-4 
and Figure 6-4). UP-Suicide also has good predictive ability for future psychiatric 
hospitalizations for suicidality (ROC AUC 0.78, p-value 0.032; Cox Regression 
Hazard Ratio 9.61, p-value 0.01). Overall, while there may post-hoc appear to be 
better individual predictors for suicidal ideation and for future hospitalizations 
(Table 6-4), our apriori primary broad spectrum endpoint (UP-Suicide) has been 
successful, may be more robust to effects of fit to cohort, and might be more 
generalizable to other populations. 
Discussion 
We carried out systematic studies to identify clinically useful predictors for 
suicide in women, an understudied population to date.  Our work focuses on 
identifying markers involved in suicidal ideation and suicidal behavior, including 
suicide completion. Markers involved in behavior may be on a continuum with 
some of the markers involved in ideation, varying in the degree of expression 
changes from less severe (ideation) to more severe (behavior). One cannot have 
suicidal behavior without suicidal ideation, but it may be possible to have suicidal 
ideation without suicidal behavior. 
As a first step, we sought to use a powerful but difficult to conduct within-
participant design for discovery of blood biomarkers. Such a design is more 
385 
 
 
informative than case-control, case-case, or even identical twins designs. The 
power of a within-participants longitudinal design for multi-omic discovery was first 
illustrated by Snyder and colleagues14 in a landmark paper with an n=1.  We also 
have previously demonstrated its power in an initial pilot study in male bipolar 
participants (n=9 out of 75 showed a switch from a no suicidal ideation to a high 
suicidal ideation state)217, and then a larger studies in males with major psychiatric 
disorders (n=37 out of 217) 320. In this small (n= 12 out of 51) but very valuable 
pilot study in women, we followed a similar path. 
Second, we conducted whole-genome gene expression discovery studies in 
the participants that exhibited the switches, using a longitudinal within-participant 
design, which factors out genetic variability and reduces environmental variability 
as well. We have demonstrated the power of such a design in our earlier successful 
pilot work on suicide biomarkers in men with an n=9217. Our current n=12 is 
comparable (Figure 6-2). Genes whose levels of expression tracked suicidal 
ideation within each participant were identified.   
Third, the lists of top candidate biomarkers for suicidal ideation from the 
discovery and prioritization step (genes with a CFG score of 4 and above, reflecting 
genes that have maximal experimental internal evidence from this study and/or 
additional external literature cross-validating evidence), were additionally validated 
for involvement in suicidal behavior in a cohort of demographically matched suicide 
completers from the coroner’s office (n=6) (Figure 6-2).  
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We ended up with 50 biomarkers that survived Bonferroni correction (49 
genes; one gene, JUN, had two different probesets that validated). Additionally, 
we tested 65 other biomarkers that were non Bonferroni validated but  had 
maximum internal score of 4 in discovery and  a CFG score of 6 and above, which 
means that in addition to strong evidence in this study they also had prior 
independent evidence of involvement in suicide from other studies.  These 
additional biomarkers are likely involved in suicide but did not make our Bonferroni 
validation cutoff due to its stringency or potential technical/postmortem artefact 
reasons (Table 6-2 and S6-2).  
Fourth, we describe the use in a female population of the simple and 
comprehensive phenomic (clinical) risk assessment scale, Convergent Functional 
Phenomics for Suicidality (CFI-S) scale320, as well as of the companion app to it for 
use by clinicians and individuals (Figure S6-2). CFI-S was developed independently 
of any data from this study, by integrating known risk factors for suicide from the 
clinical literature. It has a total of 20 items (scored in a binary fashion- 1 for 
present, 0 for absent, NA for information not available) that assess the influence 
of mental health factors, as well as of  life satisfaction, physical health, 
environmental stress, addictions, and cultural factors known to influence suicidal 
behavior. It also has 2 demographics risk factors items: age and gender. The result 
is a simple polyphenic risk score with  an absolute range of 0 to 22, normalized by 
the number of items on which we had available information, resulting in a score in 
the range from  0 to 1 (Figures 6-3 and S6-2). We present data validating the CFI-
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S in women, in the combined discovery and test cohort of live psychiatric 
participants (Figure 6-3). We identified the chronic stress of lack of positive 
relationships/social isolation as the top differential item between no and high SI in 
women, which is consistent with biological data from the biomarker side of our 
study.  
Fifth, we also assessed anxiety and mood, using a visual analog Simplified 
Affective State Scale (SASS), previously described by us320 (Niculescu et al. 2006), 
for which we now have developed an app version (Figure S6-2). Using a 
PhenoChipping approach277 in our discovery cohort of psychiatric participants, we 
show that anxiety measures cluster with suicidal ideation and CFI-S, and mood 
measures are in the opposite cluster, suggesting that our participants have high 
suicidal ideation when they have high anxiety and low mood (Figure 6-2). We 
would also like to include in the future measures of psychosis, and of stress, to be 
more comprehensive. 
Sixth, we examined how the biomarkers identified by us are able to predict 
state (suicidal ideation) in a larger independent cohort of women psychiatric 
participants (n= 33 participants). 
Seventh, we examined whether the biomarkers are able to predict trait 
(future hospitalizations for suicidal behavior) in women psychiatric participants 
(n=24). 
Last but not least, we demonstrate how our apriori primary endpoint, a 
comprehensive universal predictor for suicide (UP-Suicide), composed of the 
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combination of the Bonferroni validated biomarkers (n=50), along with the scores 
from CFI-S and SASS, predicts state (suicidal ideation) and trait (future psychiatric 
hospitalizations for suicidality). 
The rationale for identifying blood biomarkers as opposed to brain 
biomarkers is a pragmatic one- the brain cannot be readily accessed in live 
individuals. Other peripheral fluids, such as cerebrospinal fluid, require more 
invasive and painful procedures. Nevertheless, it is likely that many of the 
peripheral blood transcriptomic changes are not necessarily mirroring what is 
happening in the brain, and vice-versa. The keys to finding peripheral 
biomarkers288 are, first,  to have a powerful discovery approach, such as our 
within-participant design, that closely tracks the phenotype you are trying to 
measure and reduces noise.  Second, cross-validating and prioritizing the results 
with other lines of evidence, such as brain gene expression and genetic data, are 
important in order to establish relevance to disease and generalizability of findings. 
Third, it is important to validate for behavior in an independent cohort with a 
robust and relevant phenotype, in this case suicide completers. Fourth,   testing 
for predictive ability in independent/prospective cohorts is a must (Figure S6-1). 
Biomarkers that survive such a rigorous step-wise discovery, prioritization, 
validation and testing process are likely directly relevant to the disorder studied. 
As such, we endeavored to study their biology, whether they are involved in other 
psychiatric disorders or are relatively specific for suicide, and whether they are 
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modulated by existing drugs in general, and drugs known to treat suicidality in 
particular.  
We have identified a series of biomarkers that seem to be changed in 
opposite direction in suicide vs. in treatments with omega-3 fatty acids, lithium, 
clozapine (Table S6-4). These biomarkers could potentially be used to stratify 
patients to different treatment approaches, and monitor their response. BCL2, 
JUN, GHA1, ENTPD1, ITIH5, MBNL1, and SSBP2 are changed in expression by two 
of these three treatments, suggesting they may be core to the anti-suicidal 
mechanism of these drugs.  Interestingly, MBNL1 which is decreased in expression 
in suicidality, was identified as increased in expression in longevity/ healthy 
aging332 . BCL2, CAT, and JUN may be useful blood pharmacogenomic markers of 
response to lithium. CD84, MBNL1, and RAB22A may be useful blood 
pharmacogenomic markers of response to clozapine. NDRG1, FOXP1, AFF3, 
ATXN1, CSNK1A1, ENTPD1, ITIH5, PRDX3, and SSBP2 may be useful blood 
pharmacogenomic markers of response to omega-3 fatty acids. Three existing 
drugs used for other indications have been identified as targeting the top suicide 
biomarkers identified by us (Table S6-4), and could potentially be re-purposed for 
testing in treatment of acute suicidality: anakinra (inhibiting ILR1), enzastaurin 
(inhibiting AKT3), and tesevatinib (inhibiting EPHB4). Additionally, Connectivity 
Map333 analyses (Table S6-6) identified novel compounds that induce gene 
expression signatures that are the opposite of those present in suicide, and might  
generate leads and/or be tested for use to treat/prevent suicidality, including 
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mifepristone, LY294002,  acetylsalicylic acid, estradiol, buspirone, corticosterone, 
metformin, diphenhydramine, haloperidol, and fluoxetine (Table S6-6).  
Of note, a number of biomarkers from the current study in women 
reproduce and are co-directional with our previous findings in men (Table 6-5, 
Table 6-2 and Table S6-2), whereas others had changes in opposite directions 
(Table 6-2 and Table S6-2), underlying the issue of biological context and 
differences in suicidality between the two genders. This avenue merits attention 
in the field, and detailed future comparative studies, as do studies by diagnostic 
groups. 
Prior to any testing, we planned to use a comprehensive combination of 
genomic data (specifically, the top validated biomarkers) and phenomic data 
(specifically, the CFI-S and the SASS) as the primary endpoint measure, a broad-
spectrum universal predictor (UP-Suicide) for state suicidal ideation and trait future 
hospitalizations. It has not escaped our attention that certain single biomarkers, 
particular phenotypic items, or combinations thereof seem to perform better than 
the UP-Suicide in one or another type of prediction (see Table 4-6). However, since 
such markers and combinations were not chosen by us apriori and such insights 
derive from testing, we cannot exclude a fit to cohort effect for them and reserve 
judgement as to their robustness as predictors until further testing in additional 
independent cohorts, by us and others. What we can put forward for now based 
on the current work is the UP-Suicide, which seems to be a robust predictor across 
different scenarios and diagnostic groups.  
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Our study has a number of limitations. All this work was carried out in 
psychiatric patients, a high risk group, and it remains to be seen how such 
predictors apply to non-psychiatric participants. For the UP-Suicide testing, the 
prevalence rate for suicidality in our test cohorts was 21% (7 out of 33 for suicidal 
ideation, 5 out of 24 for future hospitalizations) (Table 4-6). Of note, this rate was 
remarkably similar to our previous work in men320. It is to be noted that the 
incidence of suicidality in the general population is lower, for example at 1.5% in 
adolescents in an European cohort312 and estimates of 0.2 to 2% in the US231, 
which underlines the rationale of using a very high risk group like we did for 
magnifying and enabling signal detection with a relatively small N. Over 40% of 
the live participants from the discovery cohort (5 out of 12) and independent test 
cohort ( 14 out of 33) are non-VA, and all the suicide completers used for validation 
are  from the general population, not VA, so we believe our results have broader 
relevance. Studies with larger numbers and longer follow-up, currently ongoing, 
as well as studies in different clinical settings, may provide more generalizability.   
The current studies were carried out exclusively in females. Similar work is needed 
in larger meta-analyses across gender, in participants with and without psychiatric 
disorders, to find generalizable predictors. Conversely, a narrow focus by gender, 
diagnosis (or lack of), and perhaps age, may be needed to find more individualized 
predictors. Such work is ongoing in our group.  
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Figure 6-5. Study participant who committed suicide. Subject phchp328 was a 
38-year-old divorced Caucasian female with a long history of MDD, PTSD, BP and 
polysubstance abuse/dependence. She had multiple psychiatric hospitalizations 
due to suicidal ideation (n =21) and due to suicidal attempts (n=3), in the 5 years 
before her suicide. She committed suicide by overdose with pills, leaving behind a 
suicide note addressed to her mother. (a) Percentile for scores on top predictors 
in all the female subjects in this study (n=105 for biomarkers and n =88 for apps 
and UP-Suicide). Her panel of Bonferroni validated biomarkers (BioM50) score, 
apps score (CFI-S+SASS), and UP-Suicide predictor score at a study visit (Visit 1) 
were at the 100% of the scores of all the psychiatric participant visits tested in this 
current study. Of note, that testing was conducted during an inpatient 
hospitalization due to suicidal ideation. While her scores did improve at subsequent 
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outpatient testing visits (Visits 2 and 3), this high watermark score indicated her 
high risk. After the last testing visit in our study, she had four subsequent 
psychiatric hospitalizations: three due to suicidal ideation, one for opioid 
withdrawal/detox (the last one), ending 2 weeks before date of committing suicide 
(T). For decreased biomarkers, a higher percentile corresponds to lower 
expression values. Only 5 of the 32 predictors (biomarkers, clinical, combined) 
were discordant between the highest and lowest SI visit (italicized). In all, 17 of 
the 32 predictors (bold) were stepwise decreased corresponding to her SI scores. 
One of the biomarkers (HTRA1) was in the 100% of the subjects tested, as was 
the panel of 50 validated markers (BioM-50), the combination of the clinical 
measures/apps (CFI-S+SASS), and the combined biomarker panels and clinical/ 
apps predictor (UP-Suicide). (b) Tri-dimensional representation of the percentilized 
scores of the combination of the two apps, CFI-S and SASS (Anxiety and Mood) of 
all the female participant visits tested in the current study (n= 87) and all the male 
participant visits in our previous work (n=317). A tri-dimensional scatter plot was 
created using Partek. Tri-dimensional 95% confidence intervals were inserted as 
ellipsoids, color coded blue, yellow and red for No SI, Intermediate SI and High 
SI, respectively. Subject phchp328visit1 had the highest Euclidian D (distance from 
origin), as indicated by the arrow. This is the only subject that completed suicide 
as far as we know, as of the end of this study in November 2015. BP, bipolar 
disorder; MDD, major depressive disorder; PTSD, post-traumatic stress disorder. 
394 
 
 
In conclusion, we have advanced the biological understanding of suicidality 
in women, highlighting behavioral and biological mechanisms related to 
inflammation, neurotrophic factors, circadian clock, stress response, and 
apoptosis. Biomarkers that may track treatment response to lithium and 
intriguingly, omega-3 fatty acids, have been identified.   Of equal importance, we 
developed  instruments  (biomarkers and apps) for predicting suicidality, that  do 
not require asking the person assessed if they have suicidal thoughts, as 
individuals who are truly suicidal often do not share that information with people 
close to them or with clinicians. We propose that the widespread use of such risk 
prediction tests as part of routine or targeted healthcare assessments will lead to 
early disease interception followed by preventive lifestyle modifications or 
treatment. Given the magnitude and urgency of the problem, the importance of 
efforts to implement such tools cannot be overstated. We note that we have sadly 
lost one study participant to suicide (Figure 6-5), which in retrospect was 
highlighted by UP-Suicide as being the highest participant risk in our cohort.  
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Chapter 7: Conclusions 
These works indicate how the field may move forward by integrating data 
from genomics, transcriptomics, and phenomics, which could yield a more 
precision approach to psychiatric medicine.  While evidence from any one approach 
will provide information on an individual patients risk for disease, a single line of 
evidence is often insufficient.  In the cases of the genetic studies of schizophrenia 
and alcoholism discussed above in chapter 1 and chapter 2, respectively, we find 
convincing evidence for a panel of SNPs, when combined into a polygenic GRP 
score, are involved in the genetic risk for each disease.  Further, we are able to 
use the discovered panel of SNPs and replicate in completely independent cohorts 
and demonstrate a statistical separation between groups.  Despite the strength of 
these findings, this panel alone still had insufficient sensitivity and specificity to 
discriminate individual subjects.  Genetic polymorphisms clearly play an important 
role but more information from an individual is necessary to improve predictive 
accuracy and provide more precise and targeted treatment to patients. 
CFG 
Using a Bayesian integration of evidence from studies in human patients 
and multiple animal models in the form of Convergent Functional Genomics, as 
discussed in previous chapters, is one way to prioritize disease-relevant genes.  
Following our initial experiments, CFG cross-validates experimental findings across 
approaches and tissue types.  Animal studies provide the sensitivity to detect 
mechanistic changes in developed models of disease.  Human studies provide the 
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specificity of the target disease.  We used this approach to prioritize our own 
experimental findings.   
In the schizophrenia study, thirteen SNPs in proximity to DISC1 were 
identified as significantly changed in schizophrenia, but they were otherwise 
unremarkable compared to the other 45,972 SNPs identified as ‘significant’.  CFG 
allowed us to integrate numerous hypothesis driven findings such as prior 
knowledge that DISC1 expression has been shown to be elevated during acute 
psychotic episodes and to be reduced by treatment44.  In the suicide work SLC4A4 
tracked suicidal ideation in our longitudinal discovery cohort and it was also shown 
to be increased in suicide completers, but it was not the ‘strongest’ finding in these 
discovery analyses.  When prioritized with what is already known in the field by 
using CFG we find that a SNP associated with SLC4A4 has previously been 
associated with suicide222, and that expression is altered in the prefrontal cortex 
of schizophrenia patients who committed suicide when compated to schizophrenia 
patients who died of other causes297.  SLC4A4 had strong evidence from our own 
experiments for tracking suicidal ideation, was found to be concordantly increased 
in our cohort of suicide completers, but it was the addition of CFG that made 
SLC4A4 our top prioritized marker.  In follow up testing it was our strongest 
predictor of suicidal ideation, with a 93% AUC for bipolar patients.  Prior evidence 
in the published literature is underleveraged.  This work provides additional 
pragmatic proof of principle as to how this rich and abundant resource could be 
better used by the field.    
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Within subject longitudinal design 
Another powerful approach that improves power and precision is the use of 
within subject design of a longitudinal cohort of participants who provided a wealth 
of dimensional quantitative phenotypes in addition to gene expression.  This allows 
us to focus on how genes track and change along with an individuals phenotype, 
filtering out artifacts produced by inter individual differences.  It’s true that a large 
focus of this work used CFG to prioritize findings, but where we utilized a within 
subject analysis in the suicide project we also sought to test the novel markers 
that were the best at tracking suicidal ideation in the discovery cohort.  In the 
male suicide work, reported in Chapter 5, CLIP4 was the most significantly 
decreased biomarker in tracking suicidal ideation within individuals.  In an 
independent cohort of male bipolar patients this marker was able to distinguish no 
SI from high SI with an AUC of 0.76.  Even without the filtering power derived 
from CFG, this approach is able to identify biomarkers with potential clinical utility. 
It could be that previous findings in the literature and under developed 
drugs could see new utility within certain subsets of individuals, and this data may 
be lost without a more precise approach.  Several papers in recent years have 
highlighted the power of carefully designed trials within even a single individual14 
334.  This is an approach and design which should see wider implementation in the 
field. 
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Dimensionality 
 Perhaps the most important message that should be taken from this work 
is the dimensionality of an individual patient and how this influences suicide risk.  
The genes identified to be associated with suicidal ideation may not be specific to 
suicide per se, but may be related to impulsive, stressed, or agitated states that 
influence suicidal ideation.  Providing additional contextual precision is essential to 
improving diagnostic and predictive accuracy. 
We have in our lab quantitative scales, developed by Dr. Niculescu, for 
assessing mood and anxiety state.  Dr. Niculescu has also developed a 22-item 
scale and Android app for assessing suicide risk called the CFI-S.  These scales 
alone have shown the ability to discriminate between no and high SI states.  When 
combined so that we are using an individual’s mood, anxiety, and suicidal risk 
factors together in the same model with the biomarkers we get a much more 
powerful ability to distinguish those with and without suicidal ideation.   
This approach should be applied broadly.  It is the rare exception that a 
single gene or biomarker is sufficiently sensitive or specific to define an illness or 
behavior.  The fields of psychiatry and psychology are ripening with increasing 
information and knowledge from areas such as genetics, transcriptomics, and 
imaging.  Harvesting this information through dynamic integrations at an individual 
level will enable personalized precision medicine, improving our understanding of 
psychiatric disease and improving patient treatment and outcomes.  
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Limitations 
 While these studies represent a comprehensive approach to integrating 
genetics, functional genomics and phenomics, there are several limitations which 
should be addressed by future studies.  Firstly, the criteria for assigning of SNPs 
or probes to genes is a decision that could have profound impact on the analysis 
bioinformatics analyses that occur downstream.  For GWAS study we followed the 
assumption that the most proximal gene should be assigned to a given SNP.  This 
may not be true in all cases, particularly for intergenic SNPs.  This could open up 
the possibility of false positive or negative findings in the initial discovery analysis.  
Using the convergent approach employed in the preceding chapters reduces the 
risk of false positives through the use of prior peer reviewed evidence.  This is also 
addressed by using outside cohorts to test the initial findings, showing 
reproducibility.   
The issue of false negatives is a more difficult one.  A more expansive 
selection criteria could be employed.  One popular method has been to select 
genes which fall within a set distance from the identified SNP (often measured in 
base pairs). This method doesn’t necessarily eliminate the problem of false 
negatives, as the ‘true positive’ gene impacted by a SNP could still fall outside of 
the selected range.  The methodology we selected is a trade-off which might 
increase the rate of false negatives. 
Secondly, while the weighting of the CFG follows a logical and a priori locked 
algorithm, it is true that altering the weighting of the different lines of evidence 
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could alter the prioritization of top genes.  While this would have absolutely no 
impact on the list of genes discovered in initial experiments it is still not a trivial 
matter.  The method employed is simple and straight forward and consist of 
assuming that evidence in human studies is more specific to human illness (and 
therefore is weighed twice) and evidence found in the target tissue, the brain, to 
be weighed twice as much as evidence found in the periphery or by genetics.  This 
decision to weight the CFG was made following the schizophrenia work, and the 
algorithm was locked for all of the work which followed.   
A danger in not using a locked algorithm is an increase in the possibility of 
overfitting findings to the cohorts being studied and losing generalizability.   All 
experiments, of course, require fitting of data derived from the cohort being 
studied.  The challenge is optimizing how much of the fit is due to the variable 
being studied (suicidal ideation) and how much is due to uncontrolled confounding 
variables in the cohort.  The former provides the signal of gene expression that 
tracks suicidal ideation, the latter creates noise that reduces generalizability and 
confounds findings.  The goal of this work has been to identify genes which may 
serve as biomarkers for psychiatry. Altering the algorithm with goal of developing 
more empirically derived weights introduces an additional variable, and it might 
become difficult to discern whether an improvement in predictive accuracy is due 
to better fitting the signal or the noise in the data.  Available additional outside 
independent cohorts were used for the purpose of testing those findings and 
providing evidence for the generalizability of biomarkers.  Future meta analyses 
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seeking to refine the algorithm across multiple independent data sets could be an 
important step to improving biomarker discovery.  Future work should examine 
the utility of more empirical methods of assigning weight to the different lines of 
evidence.   
Future Directions 
 Moving forward the exponential increase in available data provides great 
opportunity for enabling precision medicine in psychiatry.  This massive increase 
in data also presents a great challenge in how to best integrate that information 
and how to screen it for quality.  Convergent Functional Genomics is a tool with 
great potential to separate high quality information from the vast quantity that is 
being produced on a daily basis.  This work highlights how it can be used to 
prioritize reproducible biomarkers for disease states and traits.  Room for 
improvement exists, however, as discussed in the limitations section.  More 
empirical algorithmic means for weighting the individual lines of evidence should 
improve the predictive ability of identified biomarkers, but great care will need to 
be taken to ensure that the new weighting reflects high quality signal in the data 
and not just a fit to noise in the individual cohorts used to create the weighting. 
 Another challenge that must be addressed is the relative non-specificity of 
any one individual biomarker.  Implications of glutamate, serotonin, polyamines, 
and SKA2 among others are a common theme identified not only by us but by 
many other labs to associate with suicidal behavior.  The reproducibility of these 
findings is not necessarily evidence of a role in suicide specifically but of other 
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associated states and conditions which are tied to risk for suicidal behavior.  Future 
work should continue to try to place these findings into a greater dimensional 
context with recognition that these risk factors alone are neither necessary nor are 
they sufficient to predict suicidal outcomes.    
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